ID   INSR_MOUSE              Reviewed;        1372 AA.
AC   P15208; F8VPU4;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 2.
DT   07-SEP-2016, entry version 186.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=Insr;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2557333;
RA   Flores-Riveros J.R., Sibley E., Kastelic T., Lane M.D.;
RT   "Substrate phosphorylation catalyzed by the insulin receptor tyrosine
RT   kinase. Kinetic correlation to autophosphorylation of specific sites
RT   in the beta subunit.";
RL   J. Biol. Chem. 264:21557-21572(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33.
RX   PubMed=2602374; DOI=10.1073/pnas.86.24.9732;
RA   Sibley E., Kastelic T., Kelly T.J., Lane M.D.;
RT   "Characterization of the mouse insulin receptor gene promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9732-9736(1989).
RN   [4]
RP   INTERACTION WITH IRS1 AND IRS2, AND MUTAGENESIS OF TYR-989.
RX   PubMed=8626379; DOI=10.1074/jbc.271.11.5980;
RA   Sawka-Verhelle D., Tartare-Deckert S., White M.F., Van Obberghen E.;
RT   "Insulin receptor substrate-2 binds to the insulin receptor through
RT   its phosphotyrosine-binding domain and through a newly identified
RT   domain comprising amino acids 591-786.";
RL   J. Biol. Chem. 271:5980-5983(1996).
RN   [5]
RP   INTERACTION WITH SORBS1.
RX   PubMed=9447983;
RA   Ribon V., Printen J.A., Hoffman N.G., Kay B.K., Saltiel A.R.;
RT   "A novel, multifunctional c-Cbl binding protein in insulin receptor
RT   signaling in 3T3-L1 adipocytes.";
RL   Mol. Cell. Biol. 18:872-879(1998).
RN   [6]
RP   MUTAGENESIS OF TYR-989.
RX   PubMed=10207032; DOI=10.1074/jbc.274.17.12075;
RA   Chaika O.V., Chaika N., Volle D.J., Hayashi H., Ebina Y., Wang L.M.,
RA   Pierce J.H., Lewis R.E.;
RT   "Mutation of tyrosine 960 within the insulin receptor juxtamembrane
RT   domain impairs glucose transport but does not inhibit ligand-mediated
RT   phosphorylation of insulin receptor substrate-2 in 3T3-L1
RT   adipocytes.";
RL   J. Biol. Chem. 274:12075-12080(1999).
RN   [7]
RP   INTERACTION WITH SOCS3.
RX   PubMed=10821852; DOI=10.1074/jbc.275.21.15985;
RA   Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D.,
RA   Van Obberghen E.;
RT   "SOCS-3 is an insulin-induced negative regulator of insulin
RT   signaling.";
RL   J. Biol. Chem. 275:15985-15991(2000).
RN   [8]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12612081; DOI=10.1128/MCB.23.6.2096-2108.2003;
RA   Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A.,
RA   Meng T.C., Tonks N.K., Tiganis T.;
RT   "Regulation of insulin receptor signaling by the protein tyrosine
RT   phosphatase TCPTP.";
RL   Mol. Cell. Biol. 23:2096-2108(2003).
RN   [9]
RP   INTERACTION WITH SOCS1 AND SOCS3.
RX   PubMed=15169905; DOI=10.1128/MCB.24.12.5434-5446.2004;
RA   Ueki K., Kondo T., Kahn C.R.;
RT   "Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin
RT   resistance through inhibition of tyrosine phosphorylation of insulin
RT   receptor substrate proteins by discrete mechanisms.";
RL   Mol. Cell. Biol. 24:5434-5446(2004).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [12]
RP   INTERACTION WITH ARRB2.
RX   PubMed=19122674; DOI=10.1038/nature07617;
RA   Luan B., Zhao J., Wu H., Duan B., Shu G., Wang X., Li D., Jia W.,
RA   Kang J., Pei G.;
RT   "Deficiency of a beta-arrestin-2 signal complex contributes to insulin
RT   resistance.";
RL   Nature 457:1146-1149(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, and
RC   Pancreas;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic
CC       actions of insulin. Binding of insulin leads to phosphorylation of
CC       several intracellular substrates, including, insulin receptor
CC       substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling
CC       intermediates. Each of these phosphorylated proteins serve as
CC       docking proteins for other signaling proteins that contain Src-
CC       homology-2 domains (SH2 domain) that specifically recognize
CC       different phosphotyrosines residues, including the p85 regulatory
CC       subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to
CC       the activation of two main signaling pathways: the PI3K-AKT/PKB
CC       pathway, which is responsible for most of the metabolic actions of
CC       insulin, and the Ras-MAPK pathway, which regulates expression of
CC       some genes and cooperates with the PI3K pathway to control cell
CC       growth and differentiation. Binding of the SH2 domains of PI3K to
CC       phosphotyrosines on IRS1 leads to the activation of PI3K and the
CC       generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3),
CC       a lipid second messenger, which activates several PIP3-dependent
CC       serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB.
CC       The net effect of this pathway is to produce a translocation of
CC       the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to
CC       the cell membrane to facilitate glucose transport. Moreover, upon
CC       insulin stimulation, activated AKT/PKB is responsible for: anti-
CC       apoptotic effect of insulin by inducing phosphorylation of BAD;
CC       regulates the expression of gluconeogenic and lipogenic enzymes by
CC       controlling the activity of the winged helix or forkhead (FOX)
CC       class of transcription factors. Another pathway regulated by PI3K-
CC       AKT/PKB activation is mTORC1 signaling pathway which regulates
CC       cell growth and metabolism and integrates signals from insulin.
CC       AKT mediates insulin-stimulated protein synthesis by
CC       phosphorylating TSC2 thereby activating mTORC1 pathway. The
CC       Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell
CC       growth, survival and cellular differentiation of insulin.
CC       Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the
CC       activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to
CC       binding insulin, the insulin receptor can bind insulin-like growth
CC       factors (IGFI and IGFII). When present in a hybrid receptor with
CC       IGF1R, binds IGF1 (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated in response to insulin.
CC       Autophosphorylation activates the kinase activity. PTPN1, PTPRE
CC       and PTPRF dephosphorylate important tyrosine residues, thereby
CC       reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14
CC       inhibit the catalytic activity of the INSR, they block access of
CC       substrates to the activated receptor. SOCS1 and SOCS3 act as
CC       negative regulators of INSR activity, they bind to the activated
CC       INRS and interfere with the phosphorylation of INSR substrates (By
CC       similarity). Interacts with PTPRF (By similarity). Interacts with
CC       ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is
CC       proposed to be part of a signaling netwok regulating INSR
CC       autophosphorylation and endocytosis (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P15127}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains carry the insulin-binding regions, while
CC       the beta chains carry the kinase domain. Forms a hybrid receptor
CC       with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain
CC       and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of
CC       IGF1R. Interacts with SORBS1 but dissociates from it following
CC       insulin stimulation. Binds SH2B2 (By similarity). Activated form
CC       of INSR interacts (via Tyr-989) with the PTB/PID domains of IRS1
CC       and SHC1. The sequences surrounding the phosphorylated NPXY motif
CC       contribute differentially to either IRS1 or SHC1 recognition.
CC       Interacts (via tyrosines in the C-terminus) with IRS2 (via PTB
CC       domain and 591-786 AA); the 591-786 would be the primary anchor of
CC       IRS2 to INSR while the PTB domain would have a stabilizing action
CC       on the interaction with INSR. Interacts with the SH2 domains of
CC       the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when
CC       autophosphorylated on tyrosine residues. Interacts with SOCS7 (By
CC       similarity). Interacts (via the phosphorylated Tyr-989), with
CC       SOCS3. Interacts (via the phosphorylated Tyr-1175, Tyr-1179, Tyr-
CC       1180) with SOCS1. Interacts with CAV2 (tyrosine-phosphorylated
CC       form); the interaction is increased with 'Tyr-27'phosphorylation
CC       of CAV2 (By similarity). Interacts with ARRB2. Interacts with
CC       GRB10; this interaction blocks the association between IRS1/IRS2
CC       and INSR, significantly reduces insulin-stimulated tyrosine
CC       phosphorylation of IRS1 and IRS2 and thus decreases insulin
CC       signaling (By similarity). Interacts with GRB7 (By similarity).
CC       Interacts with PDPK1 (By similarity). Interacts (via Tyr-1180)
CC       with GRB14 (via BPS domain); this interaction protects the
CC       tyrosines in the activation loop from dephosphorylation, but
CC       promotes dephosphorylation of Tyr-989, this results in decreased
CC       interaction with, and phosphorylation of, IRS1 (By similarity).
CC       Interacts (via subunit alpha) with ENPP1 (via 485-599 AA); this
CC       interaction blocks autophosphorylation (By similarity). Interacts
CC       with PTPRE; this interaction is dependent of Tyr-1175, Tyr-1179
CC       and Tyr-1180 of the INSR (By similarity). Interacts with STAT5B
CC       (via SH2 domain) (By similarity). Interacts with PTPRF (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q60760:Grb10; NbExp=6; IntAct=EBI-6999015, EBI-861810;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-
CC       identical regions from two alpha chains, primarily via the C-
CC       terminal region of the first INSR alpha chain. Residues from the
CC       leucine-rich N-terminus of the other INSR alpha chain also
CC       contribute to this insulin binding site. A secondary insulin-
CC       binding site is formed by residues at the junction of fibronectin
CC       type-III domain 1 and 2 (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin (By similarity). Phosphorylation of Tyr-989 is required
CC       for IRS1-, SHC1-, and STAT5B-binding (By similarity).
CC       Dephosphorylated by PTPRE on Tyr-989, Tyr-1175, Tyr-1179 and Tyr-
CC       1180 residues (By similarity). Dephosphorylated by PTPRF and PTPN1
CC       (By similarity). Dephosphorylated by PTPN2; down-regulates
CC       insulin-induced signaling. {ECO:0000250,
CC       ECO:0000269|PubMed:12612081}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05149; AAA39318.1; -; mRNA.
DR   EMBL; AC168068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M28869; AAA39319.1; -; Genomic_DNA.
DR   CCDS; CCDS22059.1; -.
DR   PIR; A34157; A34157.
DR   RefSeq; NP_034698.2; NM_010568.2.
DR   UniGene; Mm.268003; -.
DR   PDB; 1LK2; X-ray; 1.35 A; P=423-430.
DR   PDBsum; 1LK2; -.
DR   ProteinModelPortal; P15208; -.
DR   SMR; P15208; 31-978, 998-1300.
DR   BioGrid; 200774; 22.
DR   DIP; DIP-41452N; -.
DR   IntAct; P15208; 13.
DR   MINT; MINT-1516207; -.
DR   STRING; 10090.ENSMUSP00000088837; -.
DR   BindingDB; P15208; -.
DR   ChEMBL; CHEMBL3187; -.
DR   iPTMnet; P15208; -.
DR   PhosphoSite; P15208; -.
DR   MaxQB; P15208; -.
DR   PaxDb; P15208; -.
DR   PeptideAtlas; P15208; -.
DR   PRIDE; P15208; -.
DR   Ensembl; ENSMUST00000091291; ENSMUSP00000088837; ENSMUSG00000005534.
DR   GeneID; 16337; -.
DR   KEGG; mmu:16337; -.
DR   UCSC; uc009krc.2; mouse.
DR   CTD; 3643; -.
DR   MGI; MGI:96575; Insr.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P15208; -.
DR   KO; K04527; -.
DR   OMA; GAAGHLY; -.
DR   OrthoDB; EOG091G00GE; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   Reactome; R-MMU-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-MMU-74713; IRS activation.
DR   Reactome; R-MMU-74749; Signal attenuation.
DR   Reactome; R-MMU-74751; Insulin receptor signalling cascade.
DR   Reactome; R-MMU-74752; Signaling by Insulin receptor.
DR   Reactome; R-MMU-77387; Insulin receptor recycling.
DR   ChiTaRS; Insr; mouse.
DR   EvolutionaryTrace; P15208; -.
DR   PRO; PR:P15208; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; ENSMUSG00000005534; -.
DR   CleanEx; MM_INSR; -.
DR   ExpressionAtlas; P15208; baseline and differential.
DR   Genevisible; P15208; MM.
DR   GO; GO:0005901; C:caveola; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005899; C:insulin receptor complex; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISO:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; ISO:MGI.
DR   GO; GO:0005525; F:GTP binding; ISO:MGI.
DR   GO; GO:0043559; F:insulin binding; ISS:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; ISO:MGI.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; ISO:MGI.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; ISO:MGI.
DR   GO; GO:0031405; F:lipoic acid binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0051425; F:PTB domain binding; ISS:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0000187; P:activation of MAPK activity; ISO:MGI.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISO:MGI.
DR   GO; GO:0032148; P:activation of protein kinase B activity; ISO:MGI.
DR   GO; GO:0030325; P:adrenal gland development; IGI:CACAO.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:MGI.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:MGI.
DR   GO; GO:0008544; P:epidermis development; IMP:MGI.
DR   GO; GO:0031017; P:exocrine pancreas development; IMP:MGI.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; ISO:MGI.
DR   GO; GO:0042593; P:glucose homeostasis; ISO:MGI.
DR   GO; GO:0003007; P:heart morphogenesis; ISO:MGI.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:MGI.
DR   GO; GO:0008584; P:male gonad development; IGI:CACAO.
DR   GO; GO:0030238; P:male sex determination; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IEA:Ensembl.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0048639; P:positive regulation of developmental growth; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISO:MGI.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISO:MGI.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0051446; P:positive regulation of meiotic cell cycle; IGI:CACAO.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IGI:CACAO.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; ISS:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; ISO:MGI.
DR   GO; GO:2000194; P:regulation of female gonad development; IGI:CACAO.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0010042; P:response to manganese ion; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0019087; P:transformation of host cell by virus; ISO:MGI.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     27
FT   CHAIN        28    748       Insulin receptor subunit alpha.
FT                                /FTId=PRO_0000016693.
FT   CHAIN       753   1372       Insulin receptor subunit beta.
FT                                /FTId=PRO_0000016695.
FT   TOPO_DOM     28    748       Extracellular. {ECO:0000305}.
FT   TOPO_DOM    753    946       Extracellular. {ECO:0000305}.
FT   TRANSMEM    947    967       Helical. {ECO:0000255}.
FT   TOPO_DOM    968   1372       Cytoplasmic. {ECO:0000305}.
FT   DOMAIN      626    728       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      744    838       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      843    937       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1013   1288       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1094   1100       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1153   1154       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      735    743       Insulin-binding. {ECO:0000250}.
FT   REGION      986    989       Important for interaction with IRS1, SHC1
FT                                and STAT5B. {ECO:0000250}.
FT   REGION     1351   1354       PIK3R1 binding. {ECO:0000250}.
FT   COMPBIAS     28    174       Leu-rich.
FT   ACT_SITE   1149   1149       Proton donor/acceptor. {ECO:0000250}.
FT   BINDING    1023   1023       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    1047   1047       ATP.
FT   BINDING    1167   1167       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         66     66       Insulin-binding. {ECO:0000250}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES     401    401       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES     989    989       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1175   1175       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1179   1179       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1180   1180       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1345   1345       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1351   1351       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     52     52       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    105    105       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    242    242       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    282    282       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    364    364       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    424    424       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973,
FT                                ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    541    541       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    635    635       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    653    653       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    700    700       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    759    759       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    772    772       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    910    910       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    923    923       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     35     53       {ECO:0000250}.
FT   DISULFID    153    182       {ECO:0000250}.
FT   DISULFID    186    209       {ECO:0000250}.
FT   DISULFID    196    215       {ECO:0000250}.
FT   DISULFID    219    228       {ECO:0000250}.
FT   DISULFID    223    234       {ECO:0000250}.
FT   DISULFID    235    243       {ECO:0000250}.
FT   DISULFID    239    252       {ECO:0000250}.
FT   DISULFID    255    264       {ECO:0000250}.
FT   DISULFID    268    280       {ECO:0000250}.
FT   DISULFID    286    311       {ECO:0000250}.
FT   DISULFID    293    301       {ECO:0000250}.
FT   DISULFID    315    328       {ECO:0000250}.
FT   DISULFID    331    335       {ECO:0000250}.
FT   DISULFID    339    360       {ECO:0000250}.
FT   DISULFID    462    495       {ECO:0000250}.
FT   DISULFID    551    551       Interchain. {ECO:0000250}.
FT   DISULFID    676    889       {ECO:0000250}.
FT   DISULFID    815    824       {ECO:0000250}.
FT   MUTAGEN     989    989       Y->F: Abolishes interaction with IRS1 but
FT                                not with IRS2.
FT                                {ECO:0000269|PubMed:10207032,
FT                                ECO:0000269|PubMed:8626379}.
FT   CONFLICT   1089   1089       T -> M (in Ref. 1; AAA39318).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1372 AA;  155610 MW;  B0FA7DBD2AD4646A CRC64;
     MGFGRGCETT AVPLLVAVAA LLVGTAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL
     QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL
     VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE
     ECGDVCPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHKECL
     GNCSEPDDPT KCVACRNFYL DGQCVETCPP PYYHFQDWRC VNFSFCQDLH FKCRNSRKPG
     CHQYVIHNNK CIPECPSGYT MNSSNLMCTP CLGPCPKVCQ ILEGEKTIDS VTSAQELRGC
     TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGFLKIRRS YALVSLSFFR KLHLIRGETL
     EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE
     RNDIALKTNG DQASCENELL KFSFIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ
     NVTEFDGQDA CGSNSWTVVD IDPPQRSNDP KSQTPSHPGW LMRGLKPWTQ YAIFVKTLVT
     FSDERRTYGA KSDIIYVQTD ATNPSVPLDP ISVSNSSSQI ILKWKPPSDP NGNITHYLVY
     WERQAEDSEL FELDYCLKGL KLPSRTWSPP FESDDSQKHN QSEYDDSASE CCSCPKTDSQ
     ILKELEESSF RKTFEDYLHN VVFVPRPSRK RRSLEEVGNV TATTLTLPDF PNVSSTIVPT
     SQEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDSP DERCSVAAYV SARTMPEAKA
     DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG
     CRLRGLSPGN YSVRVRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV
     VIGSIYLFLR KRQPDGPMGP LYASSNPEYL SASDVFPSSV YVPDEWEVPR EKITLLRELG
     QGSFGMVYEG NAKDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL
     GVVSKGQPTL VVMELMAHGD LKSHLRSLRP DAENNPGRPP PTLQEMIQMT AEIADGMAYL
     NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMSPESLKD
     GVFTASSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDPPDN CPERLTDLMR
     MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFYSEENK APESEELEME FEDMENVPLD
     RSSHCQREEA GGREGGSSLS IKRTYDEHIP YTHMNGGKKN GRVLTLPRSN PS
//
ID   INSR_RAT                Reviewed;        1383 AA.
AC   P15127; P97681;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   06-JUL-2016, entry version 168.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=Insr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND ALTERNATIVE SPLICING
RP   (ISOFORM SHORT).
RX   PubMed=2330003; DOI=10.1210/mend-4-2-235;
RA   Goldstein B.J., Dudley A.L.;
RT   "The rat insulin receptor: primary structure and conservation of
RT   tissue-specific alternative messenger RNA splicing.";
RL   Mol. Endocrinol. 4:235-244(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 731-756; 758-819; 969-994 AND
RP   1119-1177.
RC   STRAIN=Sprague-Dawley;
RA   Liu Y., Tam J.W.O.;
RL   Submitted (MAY-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION WITH GRB7.
RX   PubMed=10803466; DOI=10.1038/sj.onc.1203469;
RA   Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.;
RT   "Evidence for an interaction between the insulin receptor and Grb7. A
RT   role for two of its binding domains, PIR and SH2.";
RL   Oncogene 19:2052-2059(2000).
RN   [4]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=16803852; DOI=10.1152/ajpendo.00565.2005;
RA   Johansson G.S., Arnqvist H.J.;
RT   "Insulin and IGF-I action on insulin receptors, IGF-I receptors, and
RT   hybrid insulin/IGF-I receptors in vascular smooth muscle cells.";
RL   Am. J. Physiol. 291:E1124-E1130(2006).
RN   [5]
RP   INTERACTION WITH CAV2.
RX   PubMed=19778377; DOI=10.1111/j.1582-4934.2009.00391.x;
RA   Kwon H., Jeong K., Pak Y.;
RT   "Identification of pY19-caveolin-2 as a positive regulator of insulin-
RT   stimulated actin cytoskeleton-dependent mitogenesis.";
RL   J. Cell. Mol. Med. 13:1549-1564(2009).
RN   [6]
RP   INTERACTION WITH ATIC.
RX   PubMed=25687571; DOI=10.1074/mcp.M114.047159;
RA   Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S.,
RA   Kelly I., Landry C.R., Faure R.L.;
RT   "The last enzyme of the de novo purine synthesis pathway 5-
RT   aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP
RT   cyclohydrolase (ATIC) plays a central role in insulin signaling and
RT   the Golgi/endosomes protein network.";
RL   Mol. Cell. Proteomics 14:1079-1092(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic
CC       actions of insulin. Binding of insulin leads to phosphorylation of
CC       several intracellular substrates, including, insulin receptor
CC       substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling
CC       intermediates. Each of these phosphorylated proteins serve as
CC       docking proteins for other signaling proteins that contain Src-
CC       homology-2 domains (SH2 domain) that specifically recognize
CC       different phosphotyrosines residues, including the p85 regulatory
CC       subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to
CC       the activation of two main signaling pathways: the PI3K-AKT/PKB
CC       pathway, which is responsible for most of the metabolic actions of
CC       insulin, and the Ras-MAPK pathway, which regulates expression of
CC       some genes and cooperates with the PI3K pathway to control cell
CC       growth and differentiation. Binding of the SH2 domains of PI3K to
CC       phosphotyrosines on IRS1 leads to the activation of PI3K and the
CC       generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3),
CC       a lipid second messenger, which activates several PIP3-dependent
CC       serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB.
CC       The net effect of this pathway is to produce a translocation of
CC       the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to
CC       the cell membrane to facilitate glucose transport. Moreover, upon
CC       insulin stimulation, activated AKT/PKB is responsible for: anti-
CC       apoptotic effect of insulin by inducing phosphorylation of BAD;
CC       regulates the expression of gluconeogenic and lipogenic enzymes by
CC       controlling the activity of the winged helix or forkhead (FOX)
CC       class of transcription factors. Another pathway regulated by PI3K-
CC       AKT/PKB activation is mTORC1 signaling pathway which regulates
CC       cell growth and metabolism and integrates signals from insulin.
CC       AKT mediates insulin-stimulated protein synthesis by
CC       phosphorylating TSC2 thereby activating mTORC1 pathway. The
CC       Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell
CC       growth, survival and cellular differentiation of insulin.
CC       Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the
CC       activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to
CC       binding insulin, the insulin receptor can bind insulin-like growth
CC       factors (IGFI and IGFII). When present in a hybrid receptor with
CC       IGF1R, binds IGF1 (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16803852}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated in response to insulin.
CC       Autophosphorylation activates the kinase activity. PTPN1, PTPRE
CC       and PTPRF dephosphorylate important tyrosine residues, thereby
CC       reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14
CC       inhibit the catalytic activity of the INSR, they block access of
CC       substrates to the activated receptor. SOCS1 and SOCS3 act as
CC       negative regulators of INSR activity, they bind to the activated
CC       INRS and interfere with the phosphorylation of INSR substrates (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains carry the insulin-binding regions, while
CC       the beta chains carry the kinase domain. Forms a hybrid receptor
CC       with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain
CC       and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of
CC       IGF1R. Interacts with SORBS1 but dissociates from it following
CC       insulin stimulation. Binds SH2B2. Activated form of INSR interacts
CC       (via Tyr-1000) with the PTB/PID domains of IRS1 and SHC1. The
CC       sequences surrounding the phosphorylated NPXY motif contribute
CC       differentially to either IRS1 or SHC1 recognition. Interacts (via
CC       tyrosines in the C-terminus) with IRS2 (via PTB domain and 591-786
CC       AA); the 591-786 would be the primary anchor of IRS2 to INSR while
CC       the PTB domain would have a stabilizing action on the interaction
CC       with INSR. Interacts with the SH2 domains of the 85 kDa regulatory
CC       subunit of PI3K (PIK3R1) in vitro, when autophosphorylated on
CC       tyrosine residues. Interacts with SOCS7. Interacts (via the
CC       phosphorylated Tyr-1000), with SOCS3. Interacts (via the
CC       phosphorylated Tyr-1186, Tyr-1190, Tyr-1191) with SOCS1. Interacts
CC       with ARRB2 (By similarity). Interacts with GRB10; this interaction
CC       blocks the association between IRS1/IRS2 and INSR, significantly
CC       reduces insulin-stimulated tyrosine phosphorylation of IRS1 and
CC       IRS2 and thus decreases insulin signaling. Interacts with PDPK1.
CC       Interacts (via Tyr-1191) with GRB14 (via BPS domain); this
CC       interaction protects the tyrosines in the activation loop from
CC       dephosphorylation, but promotes dephosphorylation of Tyr-1000,
CC       this results in decreased interaction with, and phosphorylation
CC       of, IRS1. Interacts (via subunit alpha) with ENPP1 (via 485-599
CC       AA); this interaction blocks autophosphorylation. Interacts with
CC       PTPRE; this interaction is dependent of Tyr-1186, Tyr-1190 and
CC       Tyr-1191 of the INSR. Interacts with STAT5B (via SH2 domain).
CC       Interacts with PTPRF (By similarity). Interacts with GRB7.
CC       Interacts with CAV2 (tyrosine-phosphorylated form); the
CC       interaction is increased with 'Tyr-27'phosphorylation of CAV2.
CC       Interacts with ATIC; ATIC together with PRKAA2/AMPK2 and
CC       HACD3/PTPLAD1 is proposed to be part of a signaling netwok
CC       regulating INSR autophosphorylation and endocytosis
CC       (PubMed:25687571). {ECO:0000250, ECO:0000269|PubMed:10803466,
CC       ECO:0000269|PubMed:19778377, ECO:0000269|PubMed:25687571}.
CC   -!- INTERACTION:
CC       O35567:Atic; NbExp=3; IntAct=EBI-10768746, EBI-10768817;
CC       Q62689:Jak2; NbExp=2; IntAct=EBI-7472166, EBI-8656708;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=RIR-B;
CC         IsoId=P15127-1; Sequence=Displayed;
CC       Name=Short; Synonyms=RIR-A;
CC         IsoId=P15127-2; Sequence=VSP_036680;
CC   -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-
CC       identical regions from two alpha chains, primarily via the C-
CC       terminal region of the first INSR alpha chain. Residues from the
CC       leucine-rich N-terminus of the other INSR alpha chain also
CC       contribute to this insulin binding site. A secondary insulin-
CC       binding site is formed by residues at the junction of fibronectin
CC       type-III domain 1 and 2 (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin. Phosphorylation of Tyr-1000 is required for binding to
CC       IRS1, SHC1, and STAT5B. Dephosphorylated by PTPRE on Tyr-1000,
CC       Tyr-1186, Tyr-1190 and Tyr-1191 residues. Dephosphorylated by
CC       PTPRF and PTPN1. Dephosphorylated by PTPN2; down-regulates
CC       insulin-induced signaling. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29014; AAA41441.1; -; mRNA.
DR   EMBL; AF005776; AAB61414.1; -; Genomic_DNA.
DR   EMBL; AF005777; AAB61415.1; -; Genomic_DNA.
DR   EMBL; AH004882; AAB38967.1; -; Genomic_DNA.
DR   EMBL; AH004883; AAB38968.1; -; Genomic_DNA.
DR   EMBL; U80633; AAB38746.1; -; Genomic_DNA.
DR   PIR; A36080; A36080.
DR   UniGene; Rn.9876; -.
DR   PDB; 4XST; X-ray; 3.00 A; F=726-748.
DR   PDBsum; 4XST; -.
DR   ProteinModelPortal; P15127; -.
DR   SMR; P15127; 30-949, 1009-1311.
DR   DIP; DIP-42209N; -.
DR   IntAct; P15127; 11.
DR   MINT; MINT-1348005; -.
DR   STRING; 10116.ENSRNOP00000060141; -.
DR   BindingDB; P15127; -.
DR   ChEMBL; CHEMBL5486; -.
DR   iPTMnet; P15127; -.
DR   PhosphoSite; P15127; -.
DR   UniCarbKB; P15127; -.
DR   PaxDb; P15127; -.
DR   PeptideAtlas; P15127; -.
DR   PRIDE; P15127; -.
DR   UCSC; RGD:2917; rat. [P15127-1]
DR   RGD; 2917; Insr.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P15127; -.
DR   PhylomeDB; P15127; -.
DR   BRENDA; 2.7.10.1; 5301.
DR   PRO; PR:P15127; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0005768; C:endosome; IDA:RGD.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IDA:RGD.
DR   GO; GO:0043423; F:3-phosphoinositide-dependent protein kinase binding; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043559; F:insulin binding; IDA:RGD.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IMP:RGD.
DR   GO; GO:0005009; F:insulin-activated receptor activity; IDA:RGD.
DR   GO; GO:0031405; F:lipoic acid binding; IPI:RGD.
DR   GO; GO:0032403; F:protein complex binding; IDA:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0004672; F:protein kinase activity; IDA:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0019903; F:protein phosphatase binding; IMP:RGD.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:RGD.
DR   GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR   GO; GO:0045444; P:fat cell differentiation; IEP:RGD.
DR   GO; GO:0042593; P:glucose homeostasis; IDA:RGD.
DR   GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:RGD.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IMP:RGD.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:RGD.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; IMP:RGD.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:RGD.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:RGD.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:RGD.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; IDA:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:BHF-UCL.
DR   GO; GO:0009725; P:response to hormone; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:BHF-UCL.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IMP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     26
FT   CHAIN        27    759       Insulin receptor subunit alpha.
FT                                /FTId=PRO_0000016696.
FT   CHAIN       764   1383       Insulin receptor subunit beta.
FT                                /FTId=PRO_0000016698.
FT   TOPO_DOM     27    759       Extracellular. {ECO:0000305}.
FT   TOPO_DOM    764    957       Extracellular. {ECO:0000305}.
FT   TRANSMEM    958    978       Helical. {ECO:0000255}.
FT   TOPO_DOM    979   1383       Cytoplasmic. {ECO:0000305}.
FT   DOMAIN      625    727       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      754    848       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      854    948       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1024   1299       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1105   1111       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1164   1165       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      734    742       Insulin-binding. {ECO:0000250}.
FT   REGION      997   1000       Important for interaction with IRS1, SHC1
FT                                and STAT5B.
FT   REGION     1362   1365       PIK3R1 binding. {ECO:0000250}.
FT   COMPBIAS     27    173       Leu-rich.
FT   ACT_SITE   1160   1160       Proton donor/acceptor. {ECO:0000250}.
FT   BINDING    1034   1034       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    1058   1058       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    1178   1178       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         65     65       Insulin-binding. {ECO:0000250}.
FT   MOD_RES     399    399       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES     400    400       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES     406    406       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   MOD_RES    1000   1000       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1186   1186       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1190   1190       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1191   1191       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1356   1356       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1362   1362       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    104    104       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    137    137       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    321    321       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    363    363       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    423    423       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    540    540       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    652    652       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    699    699       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    770    770       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    783    783       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    921    921       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    934    934       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     52       {ECO:0000250}.
FT   DISULFID    152    181       {ECO:0000250}.
FT   DISULFID    185    208       {ECO:0000250}.
FT   DISULFID    195    214       {ECO:0000250}.
FT   DISULFID    218    227       {ECO:0000250}.
FT   DISULFID    222    233       {ECO:0000250}.
FT   DISULFID    234    242       {ECO:0000250}.
FT   DISULFID    238    251       {ECO:0000250}.
FT   DISULFID    254    263       {ECO:0000250}.
FT   DISULFID    267    279       {ECO:0000250}.
FT   DISULFID    285    310       {ECO:0000250}.
FT   DISULFID    292    300       {ECO:0000250}.
FT   DISULFID    314    327       {ECO:0000250}.
FT   DISULFID    330    334       {ECO:0000250}.
FT   DISULFID    338    359       {ECO:0000250}.
FT   DISULFID    461    494       {ECO:0000250}.
FT   DISULFID    550    550       Interchain. {ECO:0000250}.
FT   DISULFID    675    900       {ECO:0000250}.
FT   VAR_SEQ     746    757       Missing (in isoform Short).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_036680.
FT   HELIX       727    736       {ECO:0000244|PDB:4XST}.
SQ   SEQUENCE   1383 AA;  156757 MW;  4B919566902A944A CRC64;
     MGSGRGCETT AVPLLMAVAV AGGTAGHLYP GEVCPGMDIR NNLTRLHELE NCSVIEGHLQ
     ILLMFKTRPE DFRDLSFPKL IMITDYLLLF RVYGLESLKD LFPNLTVIRG SRLFFNYALV
     IFEMVHLKEL GLYNLMNITR GSVRIEKNNE LCYLATIDWS RILDYVEDNY IVLNKDDNEE
     CGDVCPGTAK GKTNCPATVI NGQFVERCWT HSHCQKVCPT ICKSHGCTAE GLCCHKECLG
     NCSEPDDPTK CVACRNFYLD GQCVETCPPP YYHFQDWRCV NFSFCQDLHY KCRNSRKPGC
     HQYVIHNNKC IPECPSGYTM NSSNLMCTPC LGPCPKVCQI LEGEKTIDSV TSAQELRGCT
     VINGSLIINI RGGNNLAAEL EANLGLIEEI SGFLKIRRSY ALVSLSFFRK LHLIRGETLE
     IGNYSFYALD NQNLRQLWDW NKHNLTITQG KLFFHYNPKL CLSEIHKMEE VSGTKGRQER
     NDIALKTNGD QASCENELLK FSFIRTSFDK ILLRWEPYWP PDFRDLLGFM LFYKEAPYQN
     VTEFDGQDAC GSNSWTVVDI DPPQRSNDPK SQTPSHPGWL MRGLKPWTQY AIFVKTLVTF
     SDERRTYGAK SDIIYVQTDA TNPSVPLDPI SVSNSSSQII LKWKPPSDPN GNITHYLVYW
     ERQAEDSELF ELDYCLKGLK LPSRTWSPPF ESDDSQKHNQ SEYDDSASEC CSCPKTDSQI
     LKELEESSFR KTFEDYLHNV VFVPRKTSSG NGAEDTRPSR KRRSLEEVGN VTATTPTLPD
     FPNISSTIAP TSHEEHRPFE KVVNKESLVI SGLRHFTGYR IELQACNQDS PEERSGVAAY
     VSARTMPEAK ADDIVGPVTH EIFENNVVHL MWQEPKEPNG LIVLYEVSYR RYGDEELHLC
     VSRKHFALER GCRLRGLSPG NYSVRVRATS LAGNGSWTEP TYFYVTDYLD VPSNIAKIII
     GPLIFVFLFS VVIGSIYLFL RKRQPDGPMG PLYASSNPEY LSASDVFPSS VYVPDEWEVP
     REKITLLREL GQGSFGMVYE GNAKDIIKGE VETRVAVKTV NESASLRERI EFLNEASVMK
     GFTCHHVVRL LGVVSKGQPT LVVMELMAHG DLKSHLRSLR PDAENNPGRP PPTLQEMIQM
     TAEIADGMAY LNAKKFVHRD LAARNCMVAH DFTVKIGDFG MTRDIYETDY YRKGGKGLLP
     VRWMSPESLK DGVFTASSDM WSFGVVLWEI TSLAEQPYQG LSNEQVLKFV MDGGYLDPPD
     NCPERLTDLM RMCWQFNPKM RPTFLEIVNL LKDDLHPSFP EVSFFYSEEN KAPESEELEM
     EFEDMENVPL DRSSHCQREE AGCREGGSSL SIKRTYDEHI PYTHMNGGKK NGRVLTLPRS
     NPS
//
ID   INSR_HUMAN              Reviewed;        1382 AA.
AC   P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 4.
DT   07-SEP-2016, entry version 228.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=INSR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2;
RP   HIS-171; THR-448 AND LYS-492.
RX   PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4;
RA   Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E.,
RA   Ou J.-H., Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.;
RT   "The human insulin receptor cDNA: the structural basis for hormone-
RT   activated transmembrane signalling.";
RL   Cell 40:747-758(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49
RP   AND 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2.
RX   PubMed=2983222; DOI=10.1038/313756a0;
RA   Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M.,
RA   Dull T.J., Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A.,
RA   Seeburg P.H., Grunfeld C., Rosen O.M., Ramachandran J.;
RT   "Human insulin receptor and its relationship to the tyrosine kinase
RT   family of oncogenes.";
RL   Nature 313:756-761(1985).
RN   [3]
RP   SEQUENCE REVISION TO 899-900.
RA   Chen E.Y.;
RL   Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2.
RC   TISSUE=Fetal liver;
RX   PubMed=2210055; DOI=10.2337/diacare.39.1.123;
RA   Seino S., Seino M., Bell G.I.;
RT   "Human insulin-receptor gene. Partial sequence and amplification of
RT   exons by polymerase chain reaction.";
RL   Diabetes 39:123-128(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT
RP   GLY-2.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=3680248;
RA   Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene. Evidence for promoter activity.";
RL   J. Biol. Chem. 262:16186-16191(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5;
RA   Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene.";
RL   Diabetes Res. Clin. Pract. 7:S31-S33(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2777789;
RA   Tewari D.S., Cook D.M., Taub R.;
RT   "Characterization of the promoter region and 3' end of the human
RT   insulin receptor gene.";
RL   J. Biol. Chem. 264:16238-16245(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RC   TISSUE=Skin fibroblast;
RX   PubMed=2280779; DOI=10.1210/mend-4-4-647;
RA   McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D.,
RA   Taylor S.I.;
RT   "Structural and functional analysis of the insulin receptor
RT   promoter.";
RL   Mol. Endocrinol. 4:647-656(1990).
RN   [11]
RP   PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780,
RP   ENZYME REGULATION, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=2211730;
RA   Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.;
RT   "Substructural analysis of the insulin receptor by microsequence
RT   analyses of limited tryptic fragments isolated by sodium dodecyl
RT   sulfate-polyacrylamide gel electrophoresis in the absence or presence
RT   of dithiothreitol.";
RL   J. Biol. Chem. 265:18673-18681(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH IGF1R.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=2538124; DOI=10.1016/0006-291X(89)92439-X;
RA   Seino S., Bell G.I.;
RT   "Alternative splicing of human insulin receptor messenger RNA.";
RL   Biochem. Biophys. Res. Commun. 159:312-316(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE
RP   SPECIFICITY, LIGAND-BINDING, AND AUTOPHOSPHORYLATION.
RX   PubMed=2369896;
RA   Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A.,
RA   McClain D.A.;
RT   "Functionally distinct insulin receptors generated by tissue-specific
RT   alternative splicing.";
RL   EMBO J. 9:2409-2413(1990).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085.
RX   PubMed=2566545; DOI=10.2337/diab.38.6.737;
RA   Elbein S.C.;
RT   "Molecular and clinical characterization of an insertional
RT   polymorphism of the insulin-receptor gene.";
RL   Diabetes 38:737-743(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND
RP   PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361.
RC   TISSUE=Placenta;
RX   PubMed=3166375; DOI=10.1042/bj2520607;
RA   Tavare J.M., Denton R.M.;
RT   "Studies on the autophosphorylation of the insulin receptor from human
RT   placenta. Analysis of the sites phosphorylated by two-dimensional
RT   peptide mapping.";
RL   Biochem. J. 252:607-615(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123.
RX   PubMed=2544997; DOI=10.1126/science.2544997;
RA   Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A.,
RA   Nakamura F., Ebina Y., Tatibana M., Makino H.;
RT   "Human diabetes associated with a deletion of the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:63-66(1989).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3447155;
RA   Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.;
RT   "Partial amino acid sequence analyses of human placental insulin
RT   receptor.";
RL   Protein Seq. Data Anal. 1:3-6(1987).
RN   [20]
RP   MUTAGENESIS OF LYS-1057.
RX   PubMed=3101064; DOI=10.1073/pnas.84.3.704;
RA   Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S.,
RA   Siddle K., Pierce S.B., Roth R.A., Rutter W.J.;
RT   "Replacement of lysine residue 1030 in the putative ATP-binding region
RT   of the insulin receptor abolishes insulin- and antibody-stimulated
RT   glucose uptake and receptor kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987).
RN   [21]
RP   MUTAGENESIS OF TYR-999.
RX   PubMed=2842060; DOI=10.1016/S0092-8674(88)80008-4;
RA   White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J.,
RA   Ullrich A., Kahn C.R.;
RT   "Mutation of the insulin receptor at tyrosine 960 inhibits signal
RT   transmission but does not affect its tyrosine kinase activity.";
RL   Cell 54:641-649(1988).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1321605; DOI=10.1016/S0006-291X(05)80799-5;
RA   Dickens M., Tavare J.M.;
RT   "Analysis of the order of autophosphorylation of human insulin
RT   receptor tyrosines 1158, 1162 and 1163.";
RL   Biochem. Biophys. Res. Commun. 186:244-250(1992).
RN   [23]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541.
RX   PubMed=1472036; DOI=10.1016/0006-291X(92)92250-2;
RA   Schaeffer L., Ljungqvist L.;
RT   "Identification of a disulfide bridge connecting the alpha-subunits of
RT   the extracellular domain of the insulin receptor.";
RL   Biochem. Biophys. Res. Commun. 189:650-653(1992).
RN   [24]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=8452530; DOI=10.1042/bj2900419;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PIK3R1.
RX   PubMed=8276809;
RA   Van Horn D.J., Myers M.G. Jr., Backer J.M.;
RT   "Direct activation of the phosphatidylinositol 3'-kinase by the
RT   insulin receptor.";
RL   J. Biol. Chem. 269:29-32(1994).
RN   [26]
RP   INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992;
RP   ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002.
RX   PubMed=7559478; DOI=10.1074/jbc.270.40.23258;
RA   He W., O'Neill T.J., Gustafson T.A.;
RT   "Distinct modes of interaction of SHC and insulin receptor substrate-1
RT   with the insulin receptor NPEY region via non-SH2 domains.";
RL   J. Biol. Chem. 270:23258-23262(1995).
RN   [27]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996;
RP   PRO-997; GLU-998; TYR-999 AND LYS-1057.
RX   PubMed=7537849;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel
RT   non-SH2 domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [28]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9355755; DOI=10.1042/bj3270209;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND
RP   INTERACTION WITH STAT5B; IRS1 AND IRS2.
RX   PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x;
RA   Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I.,
RA   Van Obberghen E.;
RT   "Identification of Stat 5B as a substrate of the insulin receptor.";
RL   Eur. J. Biochem. 250:411-417(1997).
RN   [30]
RP   INTERACTION WITH PTPRF.
RX   PubMed=8995282; DOI=10.1074/jbc.272.11.7519;
RA   Ahmad F., Goldstein B.J.;
RT   "Functional association between the insulin receptor and the
RT   transmembrane protein-tyrosine phosphatase LAR in intact cells.";
RL   J. Biol. Chem. 272:448-457(1997).
RN   [31]
RP   INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=8999839; DOI=10.1074/jbc.272.3.1639;
RA   Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J.,
RA   Gustafson T.A., Kusari J.;
RT   "Protein-tyrosine phosphatase 1B complexes with the insulin receptor
RT   in vivo and is tyrosine-phosphorylated in the presence of insulin.";
RL   J. Biol. Chem. 272:1639-1645(1997).
RN   [32]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [33]
RP   TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM
RP   SHORT).
RX   PubMed=10207053;
RA   Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A.,
RA   Goldfine I.D., Belfiore A., Vigneri R.;
RT   "Insulin receptor isoform A, a newly recognized, high-affinity
RT   insulin-like growth factor II receptor in fetal and cancer cells.";
RL   Mol. Cell. Biol. 19:3278-3288(1999).
RN   [34]
RP   INTERACTION WITH ENPP1, AND ENZYME REGULATION.
RX   PubMed=10615944; DOI=10.2337/diabetes.49.1.13;
RA   Maddux B.A., Goldfine I.D.;
RT   "Membrane glycoprotein PC-1 inhibition of insulin receptor function
RT   occurs via direct interaction with the receptor alpha-subunit.";
RL   Diabetes 49:13-19(2000).
RN   [35]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2.
RX   PubMed=10734133; DOI=10.1074/jbc.275.13.9792;
RA   Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S.,
RA   Hooft van Huijsduijnen R.;
RT   "Identification of tyrosine phosphatases that dephosphorylate the
RT   insulin receptor. A brute force approach based on 'substrate-trapping'
RT   mutants.";
RL   J. Biol. Chem. 275:9792-9796(2000).
RN   [36]
RP   INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=10803466; DOI=10.1038/sj.onc.1203469;
RA   Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.;
RT   "Evidence for an interaction between the insulin receptor and Grb7. A
RT   role for two of its binding domains, PIR and SH2.";
RL   Oncogene 19:2052-2059(2000).
RN   [37]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [38]
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ENZYME
RP   REGULATION.
RX   PubMed=11598120; DOI=10.1074/jbc.M107236200;
RA   Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.;
RT   "Multiple activation loop conformations and their regulatory
RT   properties in the insulin receptor's kinase domain.";
RL   J. Biol. Chem. 276:46933-46940(2001).
RN   [39]
RP   INTERACTION WITH GRB14, AND ENZYME REGULATION.
RX   PubMed=11726652; DOI=10.1074/jbc.M106574200;
RA   Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J.,
RA   Burnol A.F.;
RT   "Inhibition of insulin receptor catalytic activity by the molecular
RT   adapter Grb14.";
RL   J. Biol. Chem. 277:4845-4852(2002).
RN   [40]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [41]
RP   INTERACTION WITH GRB10, AND ENZYME REGULATION.
RX   PubMed=12493740; DOI=10.1074/jbc.M208518200;
RA   Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q.,
RA   Shoelson S.E., Liu F.;
RT   "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-
RT   phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the
RT   association of IRS-1/IRS-2 with the insulin receptor.";
RL   J. Biol. Chem. 278:8460-8467(2003).
RN   [42]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12612081; DOI=10.1128/MCB.23.6.2096-2108.2003;
RA   Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A.,
RA   Meng T.C., Tonks N.K., Tiganis T.;
RT   "Regulation of insulin receptor signaling by the protein tyrosine
RT   phosphatase TCPTP.";
RL   Mol. Cell. Biol. 23:2096-2108(2003).
RN   [43]
RP   INTERACTION WITH SOCS7.
RX   PubMed=16127460; DOI=10.1172/JCI23853;
RA   Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D.,
RA   Rothman P.B.;
RT   "Deletion of SOCS7 leads to enhanced insulin action and enlarged
RT   islets of Langerhans.";
RL   J. Clin. Invest. 115:2462-2471(2005).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=16314505; DOI=10.1128/MCB.25.24.10803-10814.2005;
RA   Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I.,
RA   Corbo V., Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S.,
RA   Formisano P., Beguinot F.;
RT   "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by
RT   the insulin receptor is necessary for insulin metabolic signaling.";
RL   Mol. Cell. Biol. 25:10803-10814(2005).
RN   [45]
RP   DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=15738637; DOI=10.2108/zsj.22.169;
RA   Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N.,
RA   Miyazaki H.;
RT   "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a
RT   negative regulator of insulin signaling in primary hepatocytes and
RT   liver.";
RL   Zool. Sci. 22:169-175(2005).
RN   [46]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [47]
RP   REVIEW ON SIGNALING PATHWAYS.
RX   PubMed=16493415; DOI=10.1038/nrg1767;
RA   Taniguchi C.M., Emanuelli B., Kahn C.R.;
RT   "Critical nodes in signalling pathways: insights into insulin
RT   action.";
RL   Nat. Rev. Mol. Cell Biol. 7:85-96(2006).
RN   [48]
RP   REVIEW ON REGULATION OF INSR FUNCTION.
RX   PubMed=17347799; DOI=10.1007/s00018-007-6359-9;
RA   Youngren J.F.;
RT   "Regulation of insulin receptor function.";
RL   Cell. Mol. Life Sci. 64:873-891(2007).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND
RP   SER-407, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [50]
RP   DOMAIN, AND INSULIN-BINDING SITE.
RX   PubMed=19459609; DOI=10.1021/bi900261q;
RA   Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.;
RT   "A thermodynamic study of ligand binding to the first three domains of
RT   the human insulin receptor: relationship between the receptor alpha-
RT   chain C-terminal peptide and the site 1 insulin mimetic peptides.";
RL   Biochemistry 48:5492-5500(2009).
RN   [51]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [52]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [53]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310.
RX   PubMed=7997262; DOI=10.1038/372746a0;
RA   Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.;
RT   "Crystal structure of the tyrosine kinase domain of the human insulin
RT   receptor.";
RL   Nature 372:746-754(1994).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=9312016; DOI=10.1093/emboj/16.18.5572;
RA   Hubbard S.R.;
RT   "Crystal structure of the activated insulin receptor tyrosine kinase
RT   in complex with peptide substrate and ATP analog.";
RL   EMBO J. 16:5572-5581(1997).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP ANALOG, AND CATALYTIC ACTIVITY.
RX   PubMed=11124964; DOI=10.1074/jbc.M010161200;
RA   Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A.,
RA   Hubbard S.R.;
RT   "Crystallographic and solution studies of an activation loop mutant of
RT   the insulin receptor tyrosine kinase: insights into kinase
RT   mechanism.";
RL   J. Biol. Chem. 276:10049-10055(2001).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT
RP   ASN-1159, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   TYR-1011.
RX   PubMed=12707268; DOI=10.1074/jbc.M302425200;
RA   Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.;
RT   "Structural and biochemical evidence for an autoinhibitory role for
RT   tyrosine 984 in the juxtamembrane region of the insulin receptor.";
RL   J. Biol. Chem. 278:26007-26014(2003).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP
RP   ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=14690593; DOI=10.1016/S1097-2765(03)00487-8;
RA   Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.;
RT   "Structural basis for recruitment of the adaptor protein APS to the
RT   activated insulin receptor.";
RL   Mol. Cell 12:1379-1389(2003).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   GRB14, INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND
RP   PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001;
RA   Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J.,
RA   Hubbard S.R.;
RT   "Structural basis for inhibition of the insulin receptor by the
RT   adaptor protein Grb14.";
RL   Mol. Cell 20:325-333(2005).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   PTPN1, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16271887; DOI=10.1016/j.str.2005.07.019;
RA   Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.;
RT   "Crystal structure of a complex between protein tyrosine phosphatase
RT   1B and the insulin receptor tyrosine kinase.";
RL   Structure 13:1643-1651(2005).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH
RP   INSULIN ANALOG, DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=16957736; DOI=10.1038/nature05106;
RA   McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E.,
RA   Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A.,
RA   Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E.,
RA   Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J.,
RA   Sparrow L.G., Fernley R.T., Epa V.C., Ward C.W.;
RT   "Structure of the insulin receptor ectodomain reveals a folded-over
RT   conformation.";
RL   Nature 443:218-221(2006).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT
RP   ASN-43; ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND
RP   ASN-445, AND DISULFIDE BONDS.
RX   PubMed=16894147; DOI=10.1073/pnas.0605395103;
RA   Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D.,
RA   Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.;
RT   "The first three domains of the insulin receptor differ structurally
RT   from the insulin-like growth factor 1 receptor in the regions
RT   governing ligand specificity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP AND IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185;
RP   TYR-1189 AND TYR-1190, AND INTERACTION WITH IRS2.
RX   PubMed=18278056; DOI=10.1038/nsmb.1388;
RA   Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.;
RT   "Structural and biochemical characterization of the KRLB region in
RT   insulin receptor substrate-2.";
RL   Nat. Struct. Mol. Biol. 15:251-258(2008).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH
RP   INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=18767165; DOI=10.1002/prot.22207;
RA   Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S.,
RA   Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.;
RT   "Identification of a key element for hydrogen-bonding patterns between
RT   protein kinases and their inhibitors.";
RL   Proteins 73:795-801(2008).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077;
RA   Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B.,
RA   Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M.,
RA   Shewchuk L.M., Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C.,
RA   Groy A., Rowand J.L., Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.;
RT   "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R
RT   tyrosine kinase inhibitors towards JNK selectivity.";
RL   Bioorg. Med. Chem. Lett. 19:360-364(2009).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046;
RA   Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M.,
RA   Yang B., Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A.,
RA   Atkins C., Gerding R., Hassell A.M., Lei H., Mook R.A. Jr.,
RA   Moorthy G., Rowand J.L., Stevens K.L., Kumar R., Shotwell J.B.;
RT   "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent
RT   inhibitors of the IGF-1R receptor tyrosine kinase.";
RL   Bioorg. Med. Chem. Lett. 19:469-473(2009).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110;
RA   Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B.,
RA   Tang J., Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M.,
RA   Shewchuck L.M., Kumar R., Lei H., Chamberlain S.D.;
RT   "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent
RT   inhibitors of the insulin-like growth factor-1 receptor (IGF-1R)
RT   tyrosine kinase.";
RL   Bioorg. Med. Chem. Lett. 19:3136-3140(2009).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING
RP   REGION, AND DISULFIDE BONDS.
RX   PubMed=20348418; DOI=10.1073/pnas.1001813107;
RA   Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G.,
RA   Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W.,
RA   Weiss M.A., Lawrence M.C.;
RT   "Structural resolution of a tandem hormone-binding element in the
RT   insulin receptor and its implications for design of peptide
RT   agonists.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH
RP   INSULIN, DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND
RP   ASN-282, AND DISULFIDE BONDS.
RX   PubMed=23302862; DOI=10.1038/nature11781;
RA   Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K.,
RA   Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J.,
RA   Chan S.J., Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A.,
RA   Ward C.W., Lawrence M.C.;
RT   "How insulin engages its primary binding site on the insulin
RT   receptor.";
RL   Nature 493:241-245(2013).
RN   [71]
RP   VARIANT IRAN TYPE A SER-762.
RX   PubMed=3283938; DOI=10.1126/science.3283938;
RA   Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H.,
RA   Imura H., Bell G.I., Steiner D.F.;
RT   "Insulin-resistant diabetes due to a point mutation that prevents
RT   insulin proreceptor processing.";
RL   Science 240:784-787(1988).
RN   [72]
RP   VARIANT LEPRCH GLU-487.
RX   PubMed=2834824; DOI=10.1126/science.2834824;
RA   Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B.,
RA   Kadowaki H., Beitz L., McKeon C., Taylor S.I.;
RT   "Two mutant alleles of the insulin receptor gene in a patient with
RT   extreme insulin resistance.";
RL   Science 240:787-790(1988).
RN   [73]
RP   VARIANT LEPRCH PRO-260.
RX   PubMed=2479553;
RA   Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D.,
RA   Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.;
RT   "A leucine-to-proline mutation in the insulin receptor in a family
RT   with insulin resistance.";
RL   EMBO J. 8:2503-2507(1989).
RN   [74]
RP   VARIANT IRAN TYPE A VAL-1035.
RX   PubMed=2544998; DOI=10.1126/science.2544998;
RA   Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K.,
RA   Accili D., Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F.,
RA   Taylor S.I., Kasuga M.;
RT   "Human diabetes associated with a mutation in the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:66-68(1989).
RN   [75]
RP   VARIANT IRAN TYPE A THR-1161.
RX   PubMed=2168397;
RA   Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.;
RT   "A naturally occurring mutation of insulin receptor alanine 1134
RT   impairs tyrosine kinase function and is associated with dominantly
RT   inherited insulin resistance.";
RL   J. Biol. Chem. 265:14979-14985(1990).
RN   [76]
RP   CHARACTERIZATION OF VARIANT RMS LYS-42.
RX   PubMed=2121734;
RA   Kadowaki T., Kadowaki H., Accili D., Taylor S.I.;
RT   "Substitution of lysine for asparagine at position 15 in the alpha-
RT   subunit of the human insulin receptor. A mutation that impairs
RT   transport of receptors to the cell surface and decreases the affinity
RT   of insulin binding.";
RL   J. Biol. Chem. 265:19143-19150(1990).
RN   [77]
RP   VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A
RP   SER-489.
RX   PubMed=2365819; DOI=10.1172/JCI114693;
RA   Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J.,
RA   Gorden P., Taylor S.I.;
RT   "Five mutant alleles of the insulin receptor gene in patients with
RT   genetic forms of insulin resistance.";
RL   J. Clin. Invest. 86:254-264(1990).
RN   [78]
RP   VARIANT IRAN TYPE A SER-1227.
RX   PubMed=1963473; DOI=10.1210/mend-4-8-1183;
RA   Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.;
RT   "Functional properties of a naturally occurring Trp1200-->Ser1200
RT   mutation of the insulin receptor.";
RL   Mol. Endocrinol. 4:1183-1191(1990).
RN   [79]
RP   VARIANT GLU-1095.
RX   PubMed=2040394; DOI=10.2337/diab.40.6.777;
RA   O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S.,
RA   Moller D.E.;
RT   "Detection of mutations in insulin-receptor gene in NIDDM patients by
RT   analysis of single-stranded conformation polymorphisms.";
RL   Diabetes 40:777-782(1991).
RN   [80]
RP   VARIANT IRAN TYPE A GLN-1020.
RX   PubMed=2002058;
RA   Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O.,
RA   Olefsky J.M.;
RT   "Insulin resistance and diabetes due to different mutations in the
RT   tyrosine kinase domain of both insulin receptor gene alleles.";
RL   J. Biol. Chem. 266:5260-5267(1991).
RN   [81]
RP   VARIANT INS RESISTANCE ILE-1180.
RX   PubMed=1890161; DOI=10.1210/jcem-73-4-894;
RA   Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P.,
RA   Imperato-Mcginley J., Taylor S.I.;
RT   "A mutation in the tyrosine kinase domain of the insulin receptor
RT   associated with insulin resistance in an obese woman.";
RL   J. Clin. Endocrinol. Metab. 73:894-901(1991).
RN   [82]
RP   VARIANTS LEPRCH ALA-55 AND ARG-393.
RX   PubMed=1607067; DOI=10.2337/diab.41.4.408;
RA   Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E.,
RA   Pizzo P., Moghetti P., Muggeo M., Roth J.;
RT   "Detection of mutations in insulin receptor gene by denaturing
RT   gradient gel electrophoresis.";
RL   Diabetes 41:408-415(1992).
RN   [83]
RP   VARIANT NIDDM GLN-1191.
RX   PubMed=1607076; DOI=10.2337/diab.41.4.521;
RA   Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G.,
RA   Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.;
RT   "NIDDM associated with mutation in tyrosine kinase domain of insulin
RT   receptor gene.";
RL   Diabetes 41:521-526(1992).
RN   [84]
RP   VARIANT IRAN TYPE A LEU-1205.
RX   PubMed=1563582; DOI=10.1007/BF00400927;
RA   Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y.,
RA   Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I.,
RA   Kadowaki T.;
RT   "Detection of mutations in the insulin receptor gene in patients with
RT   insulin resistance by analysis of single-stranded conformational
RT   polymorphisms.";
RL   Diabetologia 35:261-266(1992).
RN   [85]
RP   VARIANT LEPRCH ARG-58.
RX   PubMed=1730625;
RA   van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J.,
RA   Lindhout D., Maassen J.A.;
RT   "An Arg for Gly substitution at position 31 in the insulin receptor,
RT   linked to insulin resistance, inhibits receptor processing and
RT   transport.";
RL   J. Biol. Chem. 267:66-71(1992).
RN   [86]
RP   VARIANT NIDDM GLN-1158.
RX   PubMed=1470163;
RA   Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T.,
RA   Hagino H., Shii K.;
RT   "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic
RT   loop of insulin receptor observed in insulin resistant diabetes.";
RL   Nihon Geka Gakkai Zasshi 93:968-971(1992).
RN   [87]
RP   VARIANT MET-1012.
RX   PubMed=8432414; DOI=10.2337/diab.42.3.429;
RA   Elbein S.C., Sorensen L.K., Schumacher M.C.;
RT   "Methionine for valine substitution in exon 17 of the insulin receptor
RT   gene in a pedigree with familial NIDDM.";
RL   Diabetes 42:429-434(1993).
RN   [88]
RP   VARIANT IRAN TYPE A ASP-1075.
RX   PubMed=8243830; DOI=10.2337/diab.42.12.1837;
RA   Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K.,
RA   Itazu T., Kobayashi M.;
RT   "Ala1048-->Asp mutation in the kinase domain of insulin receptor
RT   causes defective kinase activity and insulin resistance.";
RL   Diabetes 42:1837-1844(1993).
RN   [89]
RP   VARIANT MET-1012.
RX   PubMed=8458533; DOI=10.1007/BF00400701;
RA   van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J.,
RA   van Maldergem L., Herwig J., Maassen J.A.;
RT   "Patients with lipodystrophic diabetes mellitus of the Seip-
RT   Berardinelli type, express normal insulin receptors.";
RL   Diabetologia 36:172-174(1993).
RN   [90]
RP   VARIANT INS RESISTANCE LEU-1220.
RX   PubMed=8390949; DOI=10.1007/BF00402277;
RA   Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K.,
RA   Imamura T., Naitou K., Itazu T., Kobayashi M.;
RT   "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the
RT   insulin receptor associated with type A syndrome of insulin
RT   resistance.";
RL   Diabetologia 36:414-422(1993).
RN   [91]
RP   VARIANT INS RESISTANCE LEU-220.
RX   PubMed=8242067; DOI=10.1093/hmg/2.9.1437;
RA   Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R.,
RA   Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I.,
RA   Micossi P., Barbetti F.;
RT   "Substitution of Leu for Pro-193 in the insulin receptor in a patient
RT   with a genetic form of severe insulin resistance.";
RL   Hum. Mol. Genet. 2:1437-1441(1993).
RN   [92]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162.
RX   PubMed=8096518;
RA   Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P.,
RA   Taylor S.I.;
RT   "Substitution of glutamic acid for alanine 1135 in the putative
RT   'catalytic loop' of the tyrosine kinase domain of the human insulin
RT   receptor. A mutation that impairs proteolytic processing into subunits
RT   and inhibits receptor tyrosine kinase activity.";
RL   J. Biol. Chem. 268:8060-8069(1993).
RN   [93]
RP   VARIANT IRAN TYPE A VAL-409.
RX   PubMed=8388389;
RA   Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J.,
RA   Taylor S.I., Accili D., van Obberghen E.;
RT   "Antibodies to the extracellular receptor domain restore the hormone-
RT   insensitive kinase and conformation of the mutant insulin receptor
RT   valine 382.";
RL   J. Biol. Chem. 268:11272-11277(1993).
RN   [94]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=8326490; DOI=10.1136/jmg.30.6.470;
RA   Al-Gazali L.I., Khalil M., Devadas K.;
RT   "A syndrome of insulin resistance resembling leprechaunism in five
RT   sibs of consanguineous parents.";
RL   J. Med. Genet. 30:470-475(1993).
RN   [95]
RP   VARIANT LEPRCH PRO-113.
RX   PubMed=8419945; DOI=10.1073/pnas.90.1.60;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Activation of glucose transport by a natural mutation in the human
RT   insulin receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993).
RN   [96]
RP   VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8288049; DOI=10.2337/diab.43.2.247;
RA   Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F.,
RA   Eberle A., Morrow L.A., Moses A.C., Flier J.S.;
RT   "Prevalence of mutations in the insulin receptor gene in subjects with
RT   features of the type A syndrome of insulin resistance.";
RL   Diabetes 43:247-255(1994).
RN   [97]
RP   VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND
RP   GLN-1378, AND VARIANT MET-1012.
RX   PubMed=8314008; DOI=10.2337/diab.43.3.357;
RA   Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.;
RT   "Molecular scanning of the insulin receptor gene in syndromes of
RT   insulin resistance.";
RL   Diabetes 43:357-368(1994).
RN   [98]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0;
RA   Moritz W., Froesch E.R., Boeni-Schnetzler M.;
RT   "Functional properties of a heterozygous mutation (Arg1174-->Gln) in
RT   the tyrosine kinase domain of the insulin receptor from a type A
RT   insulin resistant patient.";
RL   FEBS Lett. 351:276-280(1994).
RN   [99]
RP   VARIANT LEPRCH SER-439.
RX   PubMed=8188715;
RA   van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J.,
RA   Moller W., Maassen J.A.;
RT   "A mutation in the insulin receptor that impairs proreceptor
RT   processing but not insulin binding.";
RL   J. Biol. Chem. 269:14297-14302(1994).
RN   [100]
RP   CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220.
RX   PubMed=7983039;
RA   Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T.,
RA   Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.;
RT   "Two naturally occurring mutations in the kinase domain of insulin
RT   receptor accelerate degradation of the insulin receptor and impair the
RT   kinase activity.";
RL   J. Biol. Chem. 269:31019-31027(1994).
RN   [101]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=7815442; DOI=10.1136/jmg.31.9.715;
RA   Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T.,
RA   Taylor S.I.;
RT   "Homozygosity for a new mutation (Ile119-->Met) in the insulin
RT   receptor gene in five sibs with familial insulin resistance.";
RL   J. Med. Genet. 31:715-716(1994).
RN   [102]
RP   VARIANT NIDDM ALA-858, AND VARIANT CYS-1361.
RX   PubMed=7657032; DOI=10.2337/diab.44.9.1081;
RA   Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T.,
RA   Ito K., Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T.,
RA   Kagawa S., Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.;
RT   "Frequency of mutations of insulin receptor gene in Japanese patients
RT   with NIDDM.";
RL   Diabetes 44:1081-1086(1995).
RN   [103]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=7538143; DOI=10.1210/jcem.80.5.7538143;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Two mutations in the insulin receptor gene of a patient with
RT   leprechaunism: application to prenatal diagnosis.";
RL   J. Clin. Endocrinol. Metab. 80:1496-1501(1995).
RN   [104]
RP   VARIANT PHE-1023.
RX   PubMed=8890729; DOI=10.1530/eje.0.1350357;
RA   Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.;
RT   "In-frame exon 2 deletion in insulin receptor RNA in a family with
RT   extreme insulin resistance in association with defective insulin
RT   binding: a case report.";
RL   Eur. J. Endocrinol. 135:357-363(1996).
RN   [105]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=8636294; DOI=10.1210/jc.81.2.719;
RA   Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J.,
RA   Flori E., Besmond C., Capeau J., Caron M.;
RT   "Deletion of Asn281 in the alpha-subunit of the human insulin receptor
RT   causes constitutive activation of the receptor and insulin
RT   desensitization.";
RL   J. Clin. Endocrinol. Metab. 81:719-727(1996).
RN   [106]
RP   VARIANT MET-1012.
RX   PubMed=9199575; DOI=10.1086/515464;
RA   Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A.,
RA   Rasmussen S.K., Pedersen O.;
RT   "The Val985Met insulin-receptor variant in the Danish Caucasian
RT   population: lack of associations with non-insulin-dependent diabetes
RT   mellitus or insulin resistance.";
RL   Am. J. Hum. Genet. 60:1532-1535(1997).
RN   [107]
RP   VARIANTS IRAN TYPE A GLY-86 AND PRO-89.
RX   PubMed=9175790; DOI=10.1006/bbrc.1997.6695;
RA   Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P.,
RA   Renard E., Bringer J., Jaffiol C., Grigorescu F.;
RT   "Identification of two novel insulin receptor mutations, Asp59Gly and
RT   Leu62Pro, in type A syndrome of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 234:764-768(1997).
RN   [108]
RP   CHARACTERIZATION OF VARIANT LEPRCH MET-937.
RX   PubMed=9299395; DOI=10.1006/bbrc.1997.7181;
RA   Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y.,
RA   Quin J.D., MacCuish A.C., Koda N., Fukushima Y., Taylor S.I.,
RA   Akanuma Y., Yazaki Y., Kadowaki T.;
RT   "Four mutant alleles of the insulin receptor gene associated with
RT   genetic syndromes of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 237:516-520(1997).
RN   [109]
RP   VARIANTS LEPRCH TRP-1119 AND LYS-1206.
RX   PubMed=9249867;
RX   DOI=10.1002/(SICI)1097-0223(199707)17:7<657::AID-PD132>3.3.CO;2-#;
RA   Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A.,
RA   Conteville P., Magre J., Besmond C., Goossens M., Capeau J.,
RA   Amselem S.;
RT   "Molecular analysis of the insulin receptor gene for prenatal
RT   diagnosis of leprechaunism in two families.";
RL   Prenat. Diagn. 17:657-663(1997).
RN   [110]
RP   VARIANTS LEPRCH TYR-301 AND TRP-1201.
RX   PubMed=9703342; DOI=10.2337/diab.47.8.1362;
RA   Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M.,
RA   O'Rahilly S.;
RT   "Multiple molecular mechanisms of insulin receptor dysfunction in a
RT   patient with Donohue syndrome.";
RL   Diabetes 47:1362-1364(1998).
RN   [111]
RP   VARIANTS RMS THR-1143 AND TRP-1158.
RX   PubMed=10443650; DOI=10.1210/jc.84.8.2623;
RA   Longo N., Wang Y., Pasquali M.;
RT   "Progressive decline in insulin levels in Rabson-Mendenhall
RT   syndrome.";
RL   J. Clin. Endocrinol. Metab. 84:2623-2629(1999).
RN   [112]
RP   VARIANTS IRAN TYPE A LEU-167 AND VAL-1055.
RX   PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x;
RA   Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J.,
RA   Carrascosa A., Potau N.;
RT   "Identification of three novel mutations in the insulin receptor gene
RT   in type A insulin resistant patients.";
RL   Clin. Genet. 57:67-69(2000).
RN   [113]
RP   VARIANT IRAN TYPE A TYR-280.
RX   PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x;
RA   Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F.,
RA   Kaino Y., Kida K., Makino H.;
RT   "Identification of novel C253Y missense and Y864X nonsense mutations
RT   in the insulin receptor gene in type A insulin-resistant patients.";
RL   Clin. Genet. 59:194-197(2001).
RN   [114]
RP   VARIANT IRAN TYPE A CYS-279.
RX   PubMed=12107746; DOI=10.1007/s00125-002-0798-5;
RA   Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J.,
RA   De Meyts P., Maeder C., Kahn C.R., Carpentier J.-L.;
RT   "An arginine to cysteine(252) mutation in insulin receptors from a
RT   patient with severe insulin resistance inhibits receptor
RT   internalisation but preserves signalling events.";
RL   Diabetologia 45:657-667(2002).
RN   [115]
RP   CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL;
RP   THR-925 AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND
RP   TRP-1201.
RX   PubMed=12023989; DOI=10.1093/hmg/11.12.1465;
RA   Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A.,
RA   Giannella-Neto D.;
RT   "Genotype-phenotype correlation in inherited severe insulin
RT   resistance.";
RL   Hum. Mol. Genet. 11:1465-1475(2002).
RN   [116]
RP   VARIANT LEPRCH VAL-362 DEL.
RX   PubMed=12538626; DOI=10.1210/en.2002-220815;
RA   George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S.,
RA   Saudek V., Siddle K., Hansen L., O'Rahilly S.;
RT   "Deletion of V335 from the L2 domain of the insulin receptor results
RT   in a conformationally abnormal receptor that is unable to bind insulin
RT   and causes Donohue's syndrome in a human subject.";
RL   Endocrinology 144:631-637(2003).
RN   [117]
RP   VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458
RP   AND TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND
RP   CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458.
RX   PubMed=12970295; DOI=10.1210/jc.2003-030034;
RA   Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M.,
RA   D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.;
RT   "Identification and functional assessment of novel and known insulin
RT   receptor mutations in five patients with syndromes of severe insulin
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 88:4251-4257(2003).
RN   [118]
RP   VARIANT HHF5 GLN-1201.
RX   PubMed=15161766; DOI=10.2337/diabetes.53.6.1592;
RA   Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K.,
RA   Lindholm J., Pedersen O., Bech-Nielsen H.;
RT   "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia
RT   linked to a mutation in the human insulin receptor gene.";
RL   Diabetes 53:1592-1598(2004).
RN   [119]
RP   VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS
RP   ARG-236 AND SER-386.
RX   PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x;
RA   Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J.,
RA   Didi M., O'Rahilly S.;
RT   "Functional characterization of a novel insulin receptor mutation
RT   contributing to Rabson-Mendenhall syndrome.";
RL   Clin. Endocrinol. (Oxf.) 66:21-26(2007).
RN   [120]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012;
RP   VAL-1065 AND ALA-1282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic
CC       actions of insulin. Binding of insulin leads to phosphorylation of
CC       several intracellular substrates, including, insulin receptor
CC       substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling
CC       intermediates. Each of these phosphorylated proteins serve as
CC       docking proteins for other signaling proteins that contain Src-
CC       homology-2 domains (SH2 domain) that specifically recognize
CC       different phosphotyrosines residues, including the p85 regulatory
CC       subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to
CC       the activation of two main signaling pathways: the PI3K-AKT/PKB
CC       pathway, which is responsible for most of the metabolic actions of
CC       insulin, and the Ras-MAPK pathway, which regulates expression of
CC       some genes and cooperates with the PI3K pathway to control cell
CC       growth and differentiation. Binding of the SH2 domains of PI3K to
CC       phosphotyrosines on IRS1 leads to the activation of PI3K and the
CC       generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3),
CC       a lipid second messenger, which activates several PIP3-dependent
CC       serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB.
CC       The net effect of this pathway is to produce a translocation of
CC       the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to
CC       the cell membrane to facilitate glucose transport. Moreover, upon
CC       insulin stimulation, activated AKT/PKB is responsible for: anti-
CC       apoptotic effect of insulin by inducing phosphorylation of BAD;
CC       regulates the expression of gluconeogenic and lipogenic enzymes by
CC       controlling the activity of the winged helix or forkhead (FOX)
CC       class of transcription factors. Another pathway regulated by PI3K-
CC       AKT/PKB activation is mTORC1 signaling pathway which regulates
CC       cell growth and metabolism and integrates signals from insulin.
CC       AKT mediates insulin-stimulated protein synthesis by
CC       phosphorylating TSC2 thereby activating mTORC1 pathway. The
CC       Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell
CC       growth, survival and cellular differentiation of insulin.
CC       Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the
CC       activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to
CC       binding insulin, the insulin receptor can bind insulin-like growth
CC       factors (IGFI and IGFII). Isoform Short has a higher affinity for
CC       IGFII binding. When present in a hybrid receptor with IGF1R, binds
CC       IGF1. PubMed:12138094 shows that hybrid receptors composed of
CC       IGF1R and INSR isoform Long are activated with a high affinity by
CC       IGF1, with low affinity by IGF2 and not significantly activated by
CC       insulin, and that hybrid receptors composed of IGF1R and INSR
CC       isoform Short are activated by IGF1, IGF2 and insulin. In
CC       contrast, PubMed:16831875 shows that hybrid receptors composed of
CC       IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R
CC       and INSR isoform Short have similar binding characteristics, both
CC       bind IGF1 and have a low affinity for insulin.
CC       {ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688,
CC       ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530,
CC       ECO:0000269|PubMed:9428692}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11124964,
CC       ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:12707268,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:19056263,
CC       ECO:0000269|PubMed:19071018, ECO:0000269|PubMed:19394223,
CC       ECO:0000269|PubMed:9312016}.
CC   -!- ENZYME REGULATION: Activated in response to insulin.
CC       Autophosphorylation activates the kinase activity. PTPN1, PTPRE
CC       and PTPRF dephosphorylate important tyrosine residues, thereby
CC       reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14
CC       inhibit the catalytic activity of the INSR, they block access of
CC       substrates to the activated receptor. SOCS1 and SOCS3 act as
CC       negative regulators of INSR activity, they bind to the activated
CC       INRS and interfere with the phosphorylation of INSR substrates.
CC       {ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:11598120,
CC       ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740,
CC       ECO:0000269|PubMed:2211730}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains carry the insulin-binding regions, while
CC       the beta chains carry the kinase domain. Forms a hybrid receptor
CC       with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain
CC       and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of
CC       IGF1R. Interacts with SORBS1 but dissociates from it following
CC       insulin stimulation. Binds SH2B2. Activated form of INSR interacts
CC       (via Tyr-999) with the PTB/PID domains of IRS1 and SHC1. The
CC       sequences surrounding the phosphorylated NPXY motif contribute
CC       differentially to either IRS1 or SHC1 recognition. Interacts (via
CC       tyrosines in the C-terminus) with IRS2 (via PTB domain and 591-786
CC       AA); the 591-786 would be the primary anchor of IRS2 to INSR while
CC       the PTB domain would have a stabilizing action on the interaction
CC       with INSR. Interacts with the SH2 domains of the 85 kDa regulatory
CC       subunit of PI3K (PIK3R1) in vitro, when autophosphorylated on
CC       tyrosine residues. Interacts with SOCS7. Interacts (via the
CC       phosphorylated Tyr-999), with SOCS3. Interacts (via the
CC       phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts
CC       with CAV2 (tyrosine-phosphorylated form); the interaction is
CC       increased with 'Tyr-27'phosphorylation of CAV2 (By similarity).
CC       Interacts with ARRB2 (By similarity). Interacts with GRB10; this
CC       interaction blocks the association between IRS1/IRS2 and INSR,
CC       significantly reduces insulin-stimulated tyrosine phosphorylation
CC       of IRS1 and IRS2 and thus decreases insulin signaling. Interacts
CC       with GRB7. Interacts with PDPK1. Interacts (via Tyr-1190) with
CC       GRB14 (via BPS domain); this interaction protects the tyrosines in
CC       the activation loop from dephosphorylation, but promotes
CC       dephosphorylation of Tyr-999, this results in decreased
CC       interaction with, and phosphorylation of, IRS1. Interacts (via
CC       subunit alpha) with ENPP1 (via 485-599 AA); this interaction
CC       blocks autophosphorylation. Interacts with PTPRE; this interaction
CC       is dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR.
CC       Interacts with STAT5B (via SH2 domain). Interacts with PTPRF.
CC       Interacts with ATIC; ATIC together with PRKAA2/AMPK2 and
CC       HACD3/PTPLAD1 is proposed to be part of a signaling netwok
CC       regulating INSR autophosphorylation and endocytosis (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:P15127,
CC       ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466,
CC       ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898,
CC       ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740,
CC       ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460,
CC       ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
CC       ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
CC       ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018,
CC       ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:2211730,
CC       ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:7537849,
CC       ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809,
CC       ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839,
CC       ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}.
CC   -!- INTERACTION:
CC       Q99490:AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824;
CC       P22413:ENPP1; NbExp=2; IntAct=EBI-475899, EBI-3197846;
CC       Q13322:GRB10; NbExp=3; IntAct=EBI-475899, EBI-80275;
CC       P05019:IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275;
CC       P01317:INS (xeno); NbExp=5; IntAct=EBI-475899, EBI-3989070;
CC       P35568:IRS1; NbExp=3; IntAct=EBI-475899, EBI-517592;
CC       P35570:Irs1 (xeno); NbExp=5; IntAct=EBI-475899, EBI-520230;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001;
CC       P27986:PIK3R1; NbExp=3; IntAct=EBI-475899, EBI-79464;
CC       P19174:PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387;
CC       P18031:PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-475899, EBI-297779;
CC       Q9NRF2:SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491;
CC       P29353:SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=HIR-B;
CC         IsoId=P06213-1; Sequence=Displayed;
CC       Name=Short; Synonyms=HIR-A;
CC         IsoId=P06213-2; Sequence=VSP_002898;
CC   -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are
CC       predominantly expressed in tissue targets of insulin metabolic
CC       effects: liver, adipose tissue and skeletal muscle but are also
CC       expressed in the peripheral nerve, kidney, pulmonary alveoli,
CC       pancreatic acini, placenta vascular endothelium, fibroblasts,
CC       monocytes, granulocytes, erythrocytes and skin. Isoform Short is
CC       preferentially expressed in fetal cells such as fetal fibroblasts,
CC       muscle, liver and kidney. Found as a hybrid receptor with IGF1R in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Overexpressed
CC       in several tumors, including breast, colon, lung, ovary, and
CC       thyroid carcinomas. {ECO:0000269|PubMed:10207053,
CC       ECO:0000269|PubMed:2369896, ECO:0000269|PubMed:9202395,
CC       ECO:0000269|PubMed:9355755}.
CC   -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-
CC       identical regions from two alpha chains, primarily via the C-
CC       terminal region of the first INSR alpha chain. Residues from the
CC       leucine-rich N-terminus of the other INSR alpha chain also
CC       contribute to this insulin binding site. A secondary insulin-
CC       binding site is formed by residues at the junction of fibronectin
CC       type-III domain 1 and 2. {ECO:0000269|PubMed:16957736,
CC       ECO:0000269|PubMed:19459609, ECO:0000269|PubMed:23302862}.
CC   -!- PTM: After being transported from the endoplasmic reticulum to the
CC       Golgi apparatus, the single glycosylated precursor is further
CC       glycosylated and then cleaved, followed by its transport to the
CC       plasma membrane. {ECO:0000269|PubMed:1472036,
CC       ECO:0000269|PubMed:16894147, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:23302862,
CC       ECO:0000269|PubMed:2983222}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin. Phosphorylation of Tyr-999 is required for binding to
CC       IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-
CC       1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1.
CC       Dephosphorylated by PTPN2; down-regulates insulin-induced
CC       signaling. {ECO:0000269|PubMed:10734133,
CC       ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593,
CC       ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
CC       ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016}.
CC   -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe
CC       insulin resistance syndrome characterized by insulin-resistant
CC       diabetes mellitus with pineal hyperplasia and somatic
CC       abnormalities. Typical features include coarse, senile-appearing
CC       facies, dental and skin abnormalities, abdominal distension, and
CC       phallic enlargement. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989,
CC       ECO:0000269|PubMed:17201797, ECO:0000269|PubMed:2365819,
CC       ECO:0000269|PubMed:8314008}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most
CC       severe form of insulin resistance syndrome, characterized by
CC       intrauterine and postnatal growth retardation and death in early
CC       infancy. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:12538626, ECO:0000269|PubMed:12970295,
CC       ECO:0000269|PubMed:1607067, ECO:0000269|PubMed:1730625,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2479553,
CC       ECO:0000269|PubMed:2834824, ECO:0000269|PubMed:7538143,
CC       ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715,
CC       ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945,
CC       ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867,
CC       ECO:0000269|PubMed:9703342}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:1470163,
CC       ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 5 (HHF5)
CC       [MIM:609968]: Familial hyperinsulinemic hypoglycemia [MIM:256450],
CC       also referred to as congenital hyperinsulinism, nesidioblastosis,
CC       or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is
CC       the most common cause of persistent hypoglycemia in infancy and is
CC       due to defective negative feedback regulation of insulin secretion
CC       by low glucose levels. {ECO:0000269|PubMed:15161766}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis
CC       nigricans type A (IRAN type A) [MIM:610549]: Characterized by the
CC       association of severe insulin resistance (manifested by marked
CC       hyperinsulinemia and a failure to respond to exogenous insulin)
CC       with the skin lesion acanthosis nigricans and ovarian
CC       hyperandrogenism in adolescent female subjects. Women frequently
CC       present with hirsutism, acne, amenorrhea or oligomenorrhea, and
CC       virilization. This syndrome is different from the type B that has
CC       been demonstrated to be secondary to the presence of circulating
CC       autoantibodies against the insulin receptor.
CC       {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230,
CC       ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295,
CC       ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473,
CC       ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998,
CC       ECO:0000269|PubMed:3283938, ECO:0000269|PubMed:8243830,
CC       ECO:0000269|PubMed:8288049, ECO:0000269|PubMed:8314008,
CC       ECO:0000269|PubMed:8388389, ECO:0000269|PubMed:9175790}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Insulin_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M10051; AAA59174.1; -; mRNA.
DR   EMBL; X02160; CAA26096.1; -; mRNA.
DR   EMBL; M32972; AAA59452.1; -; Genomic_DNA.
DR   EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117172; AAI17173.1; -; mRNA.
DR   EMBL; J03466; AAA59175.1; -; Genomic_DNA.
DR   EMBL; J05043; AAA59190.1; -; Genomic_DNA.
DR   EMBL; M76592; AAC37604.1; -; Genomic_DNA.
DR   EMBL; AB208861; BAD92098.1; -; mRNA.
DR   EMBL; M24555; AAA59178.1; -; mRNA.
DR   EMBL; M29929; AAA59176.1; -; Genomic_DNA.
DR   EMBL; M29930; AAA59177.1; -; Genomic_DNA.
DR   EMBL; M27197; AAA86791.1; -; Genomic_DNA.
DR   EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS12176.1; -. [P06213-1]
DR   CCDS; CCDS42487.1; -. [P06213-2]
DR   PIR; A37348; INHUR.
DR   RefSeq; NP_000199.2; NM_000208.3. [P06213-1]
DR   RefSeq; NP_001073285.1; NM_001079817.2. [P06213-2]
DR   UniGene; Hs.465744; -.
DR   PDB; 1GAG; X-ray; 2.70 A; A=1005-1310.
DR   PDB; 1I44; X-ray; 2.40 A; A=1005-1310.
DR   PDB; 1IR3; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1IRK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 1P14; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310.
DR   PDB; 2AUH; X-ray; 3.20 A; A=1005-1310.
DR   PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310.
DR   PDB; 2HR7; X-ray; 2.32 A; A/B=28-512.
DR   PDB; 2MFR; NMR; -; A=940-988.
DR   PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310.
DR   PDB; 3BU3; X-ray; 1.65 A; A=1005-1310.
DR   PDB; 3BU5; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3BU6; X-ray; 1.95 A; A=1005-1310.
DR   PDB; 3EKK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3EKN; X-ray; 2.20 A; A=1005-1310.
DR   PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322.
DR   PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744.
DR   PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744.
DR   PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744.
DR   PDB; 3W14; X-ray; 4.40 A; E/F=28-746.
DR   PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310.
DR   PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744.
DR   PDB; 4XLV; X-ray; 2.30 A; A=983-1310.
DR   PDB; 4XSS; X-ray; 3.00 A; E=28-337.
DR   PDB; 4XST; X-ray; 3.00 A; E=28-337.
DR   PDB; 4ZXB; X-ray; 3.30 A; E=28-956.
DR   PDB; 5E1S; X-ray; 2.26 A; A=1005-1310.
DR   PDB; 5HHW; X-ray; 1.79 A; A=1005-1310.
DR   PDB; 5J3H; X-ray; 3.27 A; E=28-337.
DR   PDBsum; 1GAG; -.
DR   PDBsum; 1I44; -.
DR   PDBsum; 1IR3; -.
DR   PDBsum; 1IRK; -.
DR   PDBsum; 1P14; -.
DR   PDBsum; 1RQQ; -.
DR   PDBsum; 2AUH; -.
DR   PDBsum; 2B4S; -.
DR   PDBsum; 2HR7; -.
DR   PDBsum; 2MFR; -.
DR   PDBsum; 2Z8C; -.
DR   PDBsum; 3BU3; -.
DR   PDBsum; 3BU5; -.
DR   PDBsum; 3BU6; -.
DR   PDBsum; 3EKK; -.
DR   PDBsum; 3EKN; -.
DR   PDBsum; 3ETA; -.
DR   PDBsum; 3W11; -.
DR   PDBsum; 3W12; -.
DR   PDBsum; 3W13; -.
DR   PDBsum; 3W14; -.
DR   PDBsum; 4IBM; -.
DR   PDBsum; 4OGA; -.
DR   PDBsum; 4XLV; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 4XST; -.
DR   PDBsum; 4ZXB; -.
DR   PDBsum; 5E1S; -.
DR   PDBsum; 5HHW; -.
DR   PDBsum; 5J3H; -.
DR   ProteinModelPortal; P06213; -.
DR   SMR; P06213; 28-988, 1009-1309.
DR   BioGrid; 109854; 77.
DR   DIP; DIP-480N; -.
DR   IntAct; P06213; 50.
DR   MINT; MINT-1516246; -.
DR   STRING; 9606.ENSP00000303830; -.
DR   BindingDB; P06213; -.
DR   ChEMBL; CHEMBL1981; -.
DR   DrugBank; DB01306; Insulin Aspart.
DR   DrugBank; DB01307; Insulin Detemir.
DR   DrugBank; DB00047; Insulin Glargine.
DR   DrugBank; DB01309; Insulin Glulisine.
DR   DrugBank; DB00046; Insulin Lispro.
DR   DrugBank; DB00030; Insulin Regular.
DR   DrugBank; DB01277; Mecasermin.
DR   GuidetoPHARMACOLOGY; 1800; -.
DR   iPTMnet; P06213; -.
DR   PhosphoSite; P06213; -.
DR   BioMuta; INSR; -.
DR   DMDM; 308153655; -.
DR   EPD; P06213; -.
DR   MaxQB; P06213; -.
DR   PaxDb; P06213; -.
DR   PeptideAtlas; P06213; -.
DR   PRIDE; P06213; -.
DR   DNASU; 3643; -.
DR   Ensembl; ENST00000302850; ENSP00000303830; ENSG00000171105. [P06213-1]
DR   Ensembl; ENST00000341500; ENSP00000342838; ENSG00000171105. [P06213-2]
DR   GeneID; 3643; -.
DR   KEGG; hsa:3643; -.
DR   UCSC; uc002mgd.2; human. [P06213-1]
DR   CTD; 3643; -.
DR   GeneCards; INSR; -.
DR   H-InvDB; HIX0040111; -.
DR   HGNC; HGNC:6091; INSR.
DR   HPA; HPA036302; -.
DR   HPA; HPA036303; -.
DR   MalaCards; INSR; -.
DR   MIM; 125853; phenotype.
DR   MIM; 147670; gene.
DR   MIM; 246200; phenotype.
DR   MIM; 262190; phenotype.
DR   MIM; 609968; phenotype.
DR   MIM; 610549; phenotype.
DR   neXtProt; NX_P06213; -.
DR   Orphanet; 263458; Hyperinsulinism due to INSR deficiency.
DR   Orphanet; 2297; Insulin-resistance syndrome type A.
DR   Orphanet; 508; Leprechaunism.
DR   Orphanet; 769; Rabson-Mendenhall syndrome.
DR   PharmGKB; PA202; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P06213; -.
DR   KO; K04527; -.
DR   OMA; GAAGHLY; -.
DR   OrthoDB; EOG091G00GE; -.
DR   PhylomeDB; P06213; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-74713; IRS activation.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-74752; Signaling by Insulin receptor.
DR   Reactome; R-HSA-77387; Insulin receptor recycling.
DR   SABIO-RK; P06213; -.
DR   SignaLink; P06213; -.
DR   SIGNOR; P06213; -.
DR   ChiTaRS; INSR; human.
DR   EvolutionaryTrace; P06213; -.
DR   GeneWiki; Insulin_receptor; -.
DR   GenomeRNAi; 3643; -.
DR   PRO; PR:P06213; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000171105; -.
DR   CleanEx; HS_INSR; -.
DR   ExpressionAtlas; P06213; baseline and differential.
DR   Genevisible; P06213; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005899; C:insulin receptor complex; IMP:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IC:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0005525; F:GTP binding; IDA:BHF-UCL.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0031405; F:lipoic acid binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:BHF-UCL.
DR   GO; GO:0032147; P:activation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0008544; P:epidermis development; IEA:Ensembl.
DR   GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL.
DR   GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0010042; P:response to manganese ion; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0019087; P:transformation of host cell by virus; IMP:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Carbohydrate metabolism; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Diabetes mellitus; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     27       {ECO:0000269|PubMed:2211730,
FT                                ECO:0000269|PubMed:2983222,
FT                                ECO:0000269|PubMed:8257688}.
FT   CHAIN        28    758       Insulin receptor subunit alpha.
FT                                /FTId=PRO_0000016687.
FT   CHAIN       763   1382       Insulin receptor subunit beta.
FT                                /FTId=PRO_0000016689.
FT   TOPO_DOM     28    758       Extracellular. {ECO:0000305}.
FT   TOPO_DOM    763    956       Extracellular. {ECO:0000305}.
FT   TRANSMEM    957    979       Helical. {ECO:0000255}.
FT   TOPO_DOM    980   1382       Cytoplasmic. {ECO:0000305}.
FT   DOMAIN      624    726       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      757    842       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      853    947       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1023   1298       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1104   1110       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   NP_BIND    1163   1164       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   REGION      733    741       Insulin-binding.
FT   REGION      999    999       Important for interaction with IRS1, SHC1
FT                                and STAT5B.
FT   REGION     1361   1364       PIK3R1-binding.
FT   COMPBIAS     28    174       Leu-rich.
FT   COMPBIAS    182    339       Cys-rich.
FT   ACT_SITE   1159   1159       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:9312016}.
FT   BINDING    1033   1033       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   BINDING    1057   1057       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   BINDING    1177   1177       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   SITE         66     66       Insulin-binding. {ECO:0000305}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     401    401       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     992    992       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES     999    999       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   MOD_RES    1011   1011       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES    1185   1185       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1189   1189       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1190   1190       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1355   1355       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   MOD_RES    1361   1361       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862,
FT                                ECO:0000269|PubMed:2983222}.
FT   CARBOHYD     52     52       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    105    105       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    242    242       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    282    282       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    364    364       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147}.
FT   CARBOHYD    424    424       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    541    541       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1472036,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    633    633       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    651    651       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    698    698       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    769    769       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:2983222}.
FT   CARBOHYD    782    782       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    920    920       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    933    933       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     35     53
FT   DISULFID    153    182
FT   DISULFID    186    209
FT   DISULFID    196    215
FT   DISULFID    219    228
FT   DISULFID    223    234
FT   DISULFID    235    243
FT   DISULFID    239    252
FT   DISULFID    255    264
FT   DISULFID    268    280
FT   DISULFID    286    311
FT   DISULFID    293    301
FT   DISULFID    315    328
FT   DISULFID    331    335
FT   DISULFID    339    360
FT   DISULFID    462    495       {ECO:0000269|PubMed:1472036}.
FT   DISULFID    551    551       Interchain. {ECO:0000269|PubMed:1472036}.
FT   DISULFID    674    899
FT   DISULFID    825    834
FT   VAR_SEQ     745    756       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2983222,
FT                                ECO:0000303|Ref.13}.
FT                                /FTId=VSP_002898.
FT   VARIANT       2      2       A -> G (in dbSNP:rs7508518).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2210055,
FT                                ECO:0000269|PubMed:2280779,
FT                                ECO:0000269|PubMed:2777789,
FT                                ECO:0000269|PubMed:2806055,
FT                                ECO:0000269|PubMed:2859121,
FT                                ECO:0000269|PubMed:2983222,
FT                                ECO:0000269|PubMed:3680248}.
FT                                /FTId=VAR_058395.
FT   VARIANT      42     42       N -> K (in RMS; impairs transport to the
FT                                plasma membrane and reduces the affinity
FT                                to bind insulin; dbSNP:rs121913143).
FT                                {ECO:0000269|PubMed:2121734,
FT                                ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004079.
FT   VARIANT      55     55       V -> A (in LEPRCH; Verona-1;
FT                                dbSNP:rs121913152).
FT                                {ECO:0000269|PubMed:1607067}.
FT                                /FTId=VAR_004080.
FT   VARIANT      58     58       G -> R (in LEPRCH; Helmond; inhibits
FT                                processing and transport;
FT                                dbSNP:rs52836744).
FT                                {ECO:0000269|PubMed:1730625}.
FT                                /FTId=VAR_004081.
FT   VARIANT      86     86       D -> G (in IRAN type A).
FT                                {ECO:0000269|PubMed:9175790}.
FT                                /FTId=VAR_015907.
FT   VARIANT      89     89       L -> P (in IRAN type A).
FT                                {ECO:0000269|PubMed:9175790}.
FT                                /FTId=VAR_015908.
FT   VARIANT     113    113       R -> P (in LEPRCH; Atlanta-1; abolishes
FT                                insulin binding; dbSNP:rs121913153).
FT                                {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:8419945}.
FT                                /FTId=VAR_004082.
FT   VARIANT     119    119       A -> V (in LEPRCH; markedly impairs
FT                                insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015909.
FT   VARIANT     120    120       L -> Q (in LEPRCH; inhibits receptor
FT                                processing).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031518.
FT   VARIANT     146    146       I -> M (in LEPRCH; mild;
FT                                dbSNP:rs121913159).
FT                                {ECO:0000269|PubMed:7815442,
FT                                ECO:0000269|PubMed:8326490}.
FT                                /FTId=VAR_015539.
FT   VARIANT     167    167       V -> L (in IRAN type A).
FT                                {ECO:0000269|PubMed:10733238}.
FT                                /FTId=VAR_015910.
FT   VARIANT     171    171       Y -> H (in dbSNP:rs1051692).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_058396.
FT   VARIANT     220    220       P -> L (in Ins resistance; severe;
FT                                dbSNP:rs749094324).
FT                                {ECO:0000269|PubMed:8242067}.
FT                                /FTId=VAR_004083.
FT   VARIANT     228    228       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041429.
FT   VARIANT     236    236       H -> R (in RMS and LEPRCH; Winnipeg; may
FT                                impair receptor processing;
FT                                dbSNP:rs121913145).
FT                                {ECO:0000269|PubMed:17201797,
FT                                ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004084.
FT   VARIANT     260    260       L -> P (in LEPRCH; Geldeimalsen;
FT                                dbSNP:rs121913141).
FT                                {ECO:0000269|PubMed:2479553}.
FT                                /FTId=VAR_004085.
FT   VARIANT     279    279       R -> C (in IRAN type A; inhibits receptor
FT                                internalization).
FT                                {ECO:0000269|PubMed:12107746}.
FT                                /FTId=VAR_015540.
FT   VARIANT     279    279       R -> H (in IRAN type A; interferes with
FT                                receptor processing).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031519.
FT   VARIANT     280    280       C -> Y (in IRAN type A).
FT                                {ECO:0000269|PubMed:11260230}.
FT                                /FTId=VAR_015911.
FT   VARIANT     301    301       C -> Y (in LEPRCH).
FT                                {ECO:0000269|PubMed:9703342}.
FT                                /FTId=VAR_015912.
FT   VARIANT     308    308       Missing (in LEPRCH; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:7538143,
FT                                ECO:0000269|PubMed:8636294}.
FT                                /FTId=VAR_015913.
FT   VARIANT     350    350       S -> L (in RMS and LEPRCH).
FT                                {ECO:0000269|PubMed:12970295,
FT                                ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_015914.
FT   VARIANT     362    362       Missing (in LEPRCH).
FT                                {ECO:0000269|PubMed:12538626}.
FT                                /FTId=VAR_015541.
FT   VARIANT     386    386       G -> S (in RMS; may impair receptor
FT                                processing; dbSNP:rs764221583).
FT                                {ECO:0000269|PubMed:17201797}.
FT                                /FTId=VAR_031520.
FT   VARIANT     393    393       G -> R (in LEPRCH; Verona-1;
FT                                dbSNP:rs267607184).
FT                                {ECO:0000269|PubMed:1607067}.
FT                                /FTId=VAR_004086.
FT   VARIANT     409    409       F -> V (in IRAN type A;
FT                                dbSNP:rs121913142).
FT                                {ECO:0000269|PubMed:8388389}.
FT                                /FTId=VAR_004087.
FT   VARIANT     439    439       W -> S (in LEPRCH; impairs transport of
FT                                the receptor to the cell surface;
FT                                dbSNP:rs121913158).
FT                                {ECO:0000269|PubMed:8188715}.
FT                                /FTId=VAR_015542.
FT   VARIANT     448    448       I -> T (in dbSNP:rs1051691).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_015915.
FT   VARIANT     458    458       N -> D (in LEPRCH; partially inhibits
FT                                receptor processing and
FT                                autophosphorylation; strongly impairs ERK
FT                                phosphorylation; induces wild-type levels
FT                                of IRS-1 phosphorylation;
FT                                dbSNP:rs121913160).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031521.
FT   VARIANT     487    487       K -> E (in LEPRCH; ARK-1;
FT                                dbSNP:rs28933083).
FT                                {ECO:0000269|PubMed:2834824}.
FT                                /FTId=VAR_004088.
FT   VARIANT     489    489       N -> S (in IRAN type A;
FT                                dbSNP:rs28933085).
FT                                {ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004089.
FT   VARIANT     492    492       Q -> K (in dbSNP:rs1131851).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_015916.
FT   VARIANT     695    695       Q -> R (in dbSNP:rs55906835).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041430.
FT   VARIANT     762    762       R -> S (in IRAN type A;
FT                                dbSNP:rs121913138).
FT                                {ECO:0000269|PubMed:3283938}.
FT                                /FTId=VAR_004090.
FT   VARIANT     811    811       G -> S (in dbSNP:rs35045353).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041431.
FT   VARIANT     830    830       P -> L (in dbSNP:rs2162771).
FT                                /FTId=VAR_055986.
FT   VARIANT     858    858       T -> A (in NIDDM; dbSNP:rs182552223).
FT                                {ECO:0000269|PubMed:7657032}.
FT                                /FTId=VAR_015917.
FT   VARIANT     925    925       I -> T (in LEPRCH; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015918.
FT   VARIANT     926    926       R -> W (in LEPRCH; markedly impairs
FT                                insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015919.
FT   VARIANT     937    937       T -> M (in LEPRCH; impaired receptor
FT                                processing).
FT                                {ECO:0000269|PubMed:9299395}.
FT                                /FTId=VAR_015920.
FT   VARIANT     997    997       P -> T (in RMS; reduces insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015921.
FT   VARIANT    1012   1012       V -> M (rare polymorphism;
FT                                dbSNP:rs1799816).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8314008,
FT                                ECO:0000269|PubMed:8432414,
FT                                ECO:0000269|PubMed:8458533,
FT                                ECO:0000269|PubMed:9199575}.
FT                                /FTId=VAR_004091.
FT   VARIANT    1020   1020       R -> Q (in IRAN type A;
FT                                dbSNP:rs121913148).
FT                                {ECO:0000269|PubMed:2002058}.
FT                                /FTId=VAR_004092.
FT   VARIANT    1023   1023       I -> F. {ECO:0000269|PubMed:8890729}.
FT                                /FTId=VAR_015922.
FT   VARIANT    1035   1035       G -> V (in IRAN type A;
FT                                dbSNP:rs121913135).
FT                                {ECO:0000269|PubMed:2544998}.
FT                                /FTId=VAR_004093.
FT   VARIANT    1055   1055       A -> V (in IRAN type A).
FT                                {ECO:0000269|PubMed:10733238}.
FT                                /FTId=VAR_015923.
FT   VARIANT    1065   1065       L -> V (in dbSNP:rs56395521).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041432.
FT   VARIANT    1075   1075       A -> D (in IRAN type A).
FT                                {ECO:0000269|PubMed:8243830}.
FT                                /FTId=VAR_004094.
FT   VARIANT    1095   1095       K -> E (in a NIDDM subject).
FT                                {ECO:0000269|PubMed:2040394}.
FT                                /FTId=VAR_015924.
FT   VARIANT    1119   1119       R -> W (in LEPRCH).
FT                                {ECO:0000269|PubMed:12970295,
FT                                ECO:0000269|PubMed:9249867}.
FT                                /FTId=VAR_015925.
FT   VARIANT    1143   1143       I -> T (in RMS; reduces insulin binding).
FT                                {ECO:0000269|PubMed:10443650,
FT                                ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015926.
FT   VARIANT    1158   1158       R -> Q (in NIDDM).
FT                                {ECO:0000269|PubMed:1470163}.
FT                                /FTId=VAR_015927.
FT   VARIANT    1158   1158       R -> W (in RMS; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:10443650,
FT                                ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015928.
FT   VARIANT    1161   1161       A -> T (in IRAN type A;
FT                                dbSNP:rs28933084).
FT                                {ECO:0000269|PubMed:2168397}.
FT                                /FTId=VAR_004095.
FT   VARIANT    1162   1162       A -> E (in IRAN type A; impairs
FT                                proteolytic processing;
FT                                dbSNP:rs121913154).
FT                                {ECO:0000269|PubMed:8096518}.
FT                                /FTId=VAR_004096.
FT   VARIANT    1180   1180       M -> I (in a patient with insulin
FT                                resistance; dbSNP:rs121913157).
FT                                {ECO:0000269|PubMed:1890161}.
FT                                /FTId=VAR_004097.
FT   VARIANT    1191   1191       R -> Q (in NIDDM; dbSNP:rs121913150).
FT                                {ECO:0000269|PubMed:1607076}.
FT                                /FTId=VAR_004098.
FT   VARIANT    1201   1201       R -> Q (in HHF5 and IRAN type A;
FT                                interferes with kinase activation by
FT                                insulin; dbSNP:rs28933086).
FT                                {ECO:0000269|PubMed:15161766,
FT                                ECO:0000269|PubMed:8082780,
FT                                ECO:0000269|PubMed:8288049}.
FT                                /FTId=VAR_015929.
FT   VARIANT    1201   1201       R -> W (in LEPRCH and RMS; reduces
FT                                insulin binding possibly due to reduced
FT                                receptor levels on the cell surface).
FT                                {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:9703342}.
FT                                /FTId=VAR_015930.
FT   VARIANT    1205   1205       P -> L (in IRAN type A; moderate).
FT                                {ECO:0000269|PubMed:1563582,
FT                                ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_004099.
FT   VARIANT    1206   1206       E -> D (in IRAN type A; accelerates
FT                                degradation of the protein and impairs
FT                                kinase activity).
FT                                {ECO:0000269|PubMed:7983039}.
FT                                /FTId=VAR_015931.
FT   VARIANT    1206   1206       E -> K (in LEPRCH).
FT                                {ECO:0000269|PubMed:9249867}.
FT                                /FTId=VAR_015932.
FT   VARIANT    1220   1220       W -> L (in IRAN type A; accelerates
FT                                degradation of the protein and impairs
FT                                kinase activity; dbSNP:rs52800171).
FT                                {ECO:0000269|PubMed:7983039,
FT                                ECO:0000269|PubMed:8390949}.
FT                                /FTId=VAR_004100.
FT   VARIANT    1227   1227       W -> S (in IRAN type A;
FT                                dbSNP:rs121913140).
FT                                {ECO:0000269|PubMed:1963473}.
FT                                /FTId=VAR_004101.
FT   VARIANT    1282   1282       T -> A (in dbSNP:rs55875349).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041433.
FT   VARIANT    1361   1361       Y -> C (in dbSNP:rs13306449).
FT                                {ECO:0000269|PubMed:7657032}.
FT                                /FTId=VAR_015933.
FT   VARIANT    1378   1378       R -> Q (in IRAN type A;
FT                                dbSNP:rs52826008).
FT                                {ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_015934.
FT   MUTAGEN     991    991       L->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     992    992       Y->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     996    997       NP->AA: Abolishes interaction with IRS1.
FT                                Severely disrupts, but does not abolish
FT                                interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     996    996       N->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1. {ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     997    997       P->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1. {ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     998    998       E->A: Does not affect interaction with
FT                                IRS1, SHC1 or PIK3R1.
FT                                {ECO:0000269|PubMed:7537849}.
FT   MUTAGEN     999    999       Y->E: Abolishes interaction with IRS1 and
FT                                SHC1. {ECO:0000269|PubMed:2842060,
FT                                ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478,
FT                                ECO:0000269|PubMed:9428692}.
FT   MUTAGEN     999    999       Y->F: Has no effect on insulin-stimulated
FT                                autophosphorylation, but inhibits the
FT                                biological activity of the receptor.
FT                                Abolishes interaction with IRS1 and
FT                                almost completely prevents interaction
FT                                with SHC1. Has no effect on interaction
FT                                with PIK3R1. Abolishes interaction with
FT                                STAT5B. {ECO:0000269|PubMed:2842060,
FT                                ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478,
FT                                ECO:0000269|PubMed:9428692}.
FT   MUTAGEN    1000   1000       L->A,R: Severely reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                IRS1. {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN    1002   1002       A->D: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN    1011   1011       Y->A: Increases kinase activity.
FT                                {ECO:0000269|PubMed:12707268}.
FT   MUTAGEN    1057   1057       K->A: Abolishes the kinase activity and
FT                                abolishes interaction with IRS1, SHC1,
FT                                GRB7 and PIK3R1.
FT                                {ECO:0000269|PubMed:10803466,
FT                                ECO:0000269|PubMed:3101064,
FT                                ECO:0000269|PubMed:7537849}.
FT   MUTAGEN    1057   1057       K->M,R: Abolishes the kinase activity.
FT                                {ECO:0000269|PubMed:10803466,
FT                                ECO:0000269|PubMed:3101064,
FT                                ECO:0000269|PubMed:7537849}.
FT   MUTAGEN    1159   1159       D->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11598120}.
FT   MUTAGEN    1163   1163       R->Q: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11598120}.
FT   MUTAGEN    1189   1189       Y->F: Reduced interaction with GRB7.
FT                                {ECO:0000269|PubMed:10803466}.
FT   MUTAGEN    1190   1190       Y->F: Strongly reduced interaction with
FT                                GRB7. {ECO:0000269|PubMed:10803466}.
FT   CONFLICT    601    601       D -> N (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    830    830       P -> E (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1278   1278       K -> N (in Ref. 2; CAA26096).
FT                                {ECO:0000305}.
FT   STRAND       33     42       {ECO:0000244|PDB:2HR7}.
FT   HELIX        45     50       {ECO:0000244|PDB:2HR7}.
FT   STRAND       53     65       {ECO:0000244|PDB:2HR7}.
FT   HELIX        70     72       {ECO:0000244|PDB:2HR7}.
FT   TURN         73     75       {ECO:0000244|PDB:2HR7}.
FT   STRAND       83     86       {ECO:0000244|PDB:2HR7}.
FT   STRAND       88     93       {ECO:0000244|PDB:2HR7}.
FT   TURN        100    102       {ECO:0000244|PDB:2HR7}.
FT   STRAND      118    124       {ECO:0000244|PDB:2HR7}.
FT   STRAND      141    149       {ECO:0000244|PDB:2HR7}.
FT   HELIX       160    162       {ECO:0000244|PDB:2HR7}.
FT   STRAND      171    175       {ECO:0000244|PDB:2HR7}.
FT   HELIX       176    178       {ECO:0000244|PDB:2HR7}.
FT   TURN        187    192       {ECO:0000244|PDB:2HR7}.
FT   STRAND      199    201       {ECO:0000244|PDB:2HR7}.
FT   STRAND      204    206       {ECO:0000244|PDB:2HR7}.
FT   STRAND      209    211       {ECO:0000244|PDB:2HR7}.
FT   HELIX       221    223       {ECO:0000244|PDB:2HR7}.
FT   STRAND      243    247       {ECO:0000244|PDB:2HR7}.
FT   STRAND      251    260       {ECO:0000244|PDB:2HR7}.
FT   STRAND      263    267       {ECO:0000244|PDB:2HR7}.
FT   STRAND      273    275       {ECO:0000244|PDB:2HR7}.
FT   TURN        276    278       {ECO:0000244|PDB:2HR7}.
FT   STRAND      279    281       {ECO:0000244|PDB:2HR7}.
FT   HELIX       283    295       {ECO:0000244|PDB:2HR7}.
FT   STRAND      298    300       {ECO:0000244|PDB:2HR7}.
FT   STRAND      305    307       {ECO:0000244|PDB:2HR7}.
FT   STRAND      310    314       {ECO:0000244|PDB:2HR7}.
FT   STRAND      319    321       {ECO:0000244|PDB:2HR7}.
FT   TURN        323    325       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      327    330       {ECO:0000244|PDB:2HR7}.
FT   STRAND      332    334       {ECO:0000244|PDB:2HR7}.
FT   STRAND      338    348       {ECO:0000244|PDB:2HR7}.
FT   HELIX       351    355       {ECO:0000244|PDB:2HR7}.
FT   TURN        356    359       {ECO:0000244|PDB:2HR7}.
FT   STRAND      361    369       {ECO:0000244|PDB:2HR7}.
FT   HELIX       377    385       {ECO:0000244|PDB:2HR7}.
FT   STRAND      390    393       {ECO:0000244|PDB:2HR7}.
FT   STRAND      395    399       {ECO:0000244|PDB:2HR7}.
FT   STRAND      404    406       {ECO:0000244|PDB:2HR7}.
FT   TURN        422    424       {ECO:0000244|PDB:2HR7}.
FT   STRAND      425    430       {ECO:0000244|PDB:2HR7}.
FT   STRAND      437    439       {ECO:0000244|PDB:4ZXB}.
FT   TURN        441    443       {ECO:0000244|PDB:2HR7}.
FT   STRAND      452    458       {ECO:0000244|PDB:2HR7}.
FT   HELIX       463    472       {ECO:0000244|PDB:2HR7}.
FT   TURN        476    478       {ECO:0000244|PDB:2HR7}.
FT   TURN        481    483       {ECO:0000244|PDB:2HR7}.
FT   STRAND      486    490       {ECO:0000244|PDB:2HR7}.
FT   STRAND      498    500       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      502    507       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      512    516       {ECO:0000244|PDB:4ZXB}.
FT   HELIX       524    526       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      527    536       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      538    540       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      559    561       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      577    580       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      588    597       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      601    603       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      608    610       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      613    616       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      626    631       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      633    636       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      638    643       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      654    658       {ECO:0000244|PDB:4ZXB}.
FT   HELIX       666    669       {ECO:0000244|PDB:4ZXB}.
FT   HELIX       722    735       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      798    803       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      805    809       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      817    827       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      838    843       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      858    861       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      867    870       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      881    890       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      896    901       {ECO:0000244|PDB:4ZXB}.
FT   HELIX       902    908       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      910    913       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      918    931       {ECO:0000244|PDB:4ZXB}.
FT   STRAND      940    944       {ECO:0000244|PDB:4ZXB}.
FT   HELIX       953    979       {ECO:0000244|PDB:2MFR}.
FT   TURN       1003   1005       {ECO:0000244|PDB:4XLV}.
FT   HELIX      1009   1011       {ECO:0000244|PDB:1IR3}.
FT   HELIX      1014   1016       {ECO:0000244|PDB:1IRK}.
FT   HELIX      1020   1022       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1023   1031       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1033   1043       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1046   1048       {ECO:0000244|PDB:2Z8C}.
FT   STRAND     1050   1057       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1065   1078       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1089   1093       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1095   1098       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1100   1104       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1111   1117       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1119   1121       {ECO:0000244|PDB:3ETA}.
FT   HELIX      1133   1152       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1154   1156       {ECO:0000244|PDB:2AUH}.
FT   HELIX      1162   1164       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1165   1167       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1173   1175       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1181   1183       {ECO:0000244|PDB:1IRK}.
FT   TURN       1185   1187       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1190   1192       {ECO:0000244|PDB:5HHW}.
FT   STRAND     1194   1198       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1200   1202       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1205   1210       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1215   1230       {ECO:0000244|PDB:3BU3}.
FT   TURN       1236   1239       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1242   1250       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1263   1272       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1277   1279       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1283   1290       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1291   1293       {ECO:0000244|PDB:5HHW}.
FT   HELIX      1298   1301       {ECO:0000244|PDB:3BU3}.
FT   TURN       1303   1305       {ECO:0000244|PDB:4XLV}.
FT   HELIX      1307   1309       {ECO:0000244|PDB:1I44}.
SQ   SEQUENCE   1382 AA;  156333 MW;  709A955660739066 CRC64;
     MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL
     QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL
     VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE
     ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL
     GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG
     CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC
     TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL
     EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE
     RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ
     NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS
     DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE
     RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL
     KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF
     PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV
     SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV
     SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG
     PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR
     EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG
     FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA
     AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV
     RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN
     CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME
     FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN
     PS
//
ID   INSR_XENLA              Reviewed;        1362 AA.
AC   Q9PVZ4; Q99084;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-SEP-2016, entry version 103.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: Full=XTK-1b;
DE   AltName: Full=Xe-InsR;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=insr;
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Pipoidea; Pipidae; Xenopodinae; Xenopus;
OC   Xenopus.
OX   NCBI_TaxID=8355;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAB46565.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RC   TISSUE=Oocyte {ECO:0000269|PubMed:10446274};
RX   PubMed=10446274; DOI=10.1016/S0925-4773(99)00102-1;
RA   Groigno L., Richard-Parpaillon L., Boujard D.;
RT   "Expression pattern of insulin receptor mRNA during Xenopus laevis
RT   embryogenesis.";
RL   Mech. Dev. 86:151-154(1999).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAA50006.1, ECO:0000312|PIR:B41122}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1023-1178, SUBCELLULAR LOCATION, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Embryo {ECO:0000269|PubMed:1648732};
RX   PubMed=1648732; DOI=10.1073/pnas.88.14.6214;
RA   Scavo L.M., Shuldiner A.R., Serrano J., Dashner R., Roth J.,
RA   de Pablo F.;
RT   "Genes encoding receptors for insulin and insulin-like growth factor I
RT   are expressed in Xenopus oocytes and embryos.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6214-6218(1991).
RN   [3] {ECO:0000305}
RP   FUNCTION, TISSUE SPECIFICITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=1847619; DOI=10.1042/bj2730673;
RA   Hainaut P., Kowalski A., Giorgetti S., Baron V., Van Obberghen E.;
RT   "Insulin and insulin-like-growth-factor-I (IGF-I) receptors in Xenopus
RT   laevis oocytes. Comparison with insulin receptors from liver and
RT   muscle.";
RL   Biochem. J. 273:673-678(1991).
RN   [4] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=7595277; DOI=10.1002/jez.1402730206;
RA   Cowan B.J., Foty R.A., Liversage R.A.;
RT   "Insulin receptors in Xenopus laevis liver and forelimb regenerates
RT   and the effects of local insulin deprivation on regeneration.";
RL   J. Exp. Zool. 273:130-141(1995).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin. May be required for forelimb regeneration.
CC       {ECO:0000269|PubMed:1847619, ECO:0000269|PubMed:7595277}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity. {ECO:0000250|UniProtKB:P06213}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chains carry the kinase domain (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1648732,
CC       ECO:0000269|PubMed:7595277}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:1648732, ECO:0000269|PubMed:7595277}.
CC   -!- TISSUE SPECIFICITY: Localized mainly to the envelope in oocytes.
CC       Localized to the animal hemisphere during early embryonic
CC       cleavage. Expressed during organogenesis in regions of ecto- and
CC       mesodermic origins. Expressed in the entire encephalon, the otic
CC       and optic vesicles, the gills, the somites and the pronephric
CC       tubules of the embryo. Also found in adult liver, muscle and
CC       regenerated forelimbs. {ECO:0000269|PubMed:10446274,
CC       ECO:0000269|PubMed:1847619, ECO:0000269|PubMed:7595277}.
CC   -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically.
CC       Weakly expressed in embryos through gastrulation and neurulation.
CC       Expressed in the tailbud stage and in older tadpoles.
CC       {ECO:0000269|PubMed:10446274, ECO:0000269|PubMed:1648732}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin. {ECO:0000269|PubMed:1847619, ECO:0000269|PubMed:7595277}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ132556; CAB46565.1; -; mRNA.
DR   EMBL; M64660; AAA50006.1; -; mRNA.
DR   PIR; B41122; B41122.
DR   RefSeq; NP_001081702.1; NM_001088233.1.
DR   UniGene; Xl.201; -.
DR   ProteinModelPortal; Q9PVZ4; -.
DR   SMR; Q9PVZ4; 997-1299.
DR   GeneID; 398006; -.
DR   KEGG; xla:398006; -.
DR   CTD; 3643; -.
DR   Xenbase; XB-GENE-920741; insr.
DR   HOVERGEN; HBG006134; -.
DR   KO; K04527; -.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Cleavage on pair of basic residues;
KW   Developmental protein; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     37       {ECO:0000255}.
FT   CHAIN        38    754       Insulin receptor subunit alpha.
FT                                {ECO:0000305}.
FT                                /FTId=PRO_0000045751.
FT   CHAIN       759   1362       Insulin receptor subunit beta.
FT                                {ECO:0000305}.
FT                                /FTId=PRO_0000045752.
FT   TOPO_DOM    759    951       Extracellular. {ECO:0000255}.
FT   TRANSMEM    952    972       Helical. {ECO:0000255}.
FT   TOPO_DOM    973   1362       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      508    629       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      633    730       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      849    944       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1012   1287       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1093   1099       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1152   1153       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       38    184       Leucine-rich region. {ECO:0000250}.
FT   REGION      741    749       Insulin-binding. {ECO:0000250}.
FT   ACT_SITE   1148   1148       Proton donor/acceptor. {ECO:0000250}.
FT   BINDING    1022   1022       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    1046   1046       ATP. {ECO:0000250|UniProtKB:P06213,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   BINDING    1166   1166       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         76     76       Insulin-binding. {ECO:0000250}.
FT   MOD_RES     993    993       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1174   1174       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1178   1178       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1179   1179       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1335   1335       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1341   1341       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     53     53       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    115    115       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    148    148       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    332    332       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    374    374       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    434    434       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    455    455       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    551    551       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    627    627       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    642    642       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    660    660       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    707    707       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    765    765       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    779    779       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    917    917       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    930    930       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     45     63       {ECO:0000250}.
FT   DISULFID    163    192       {ECO:0000250}.
FT   DISULFID    196    219       {ECO:0000250}.
FT   DISULFID    206    225       {ECO:0000250}.
FT   DISULFID    229    238       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    233    244       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    245    253       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    249    262       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    265    274       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    278    290       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    296    321       {ECO:0000250}.
FT   DISULFID    303    311       {ECO:0000250}.
FT   DISULFID    325    338       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    341    345       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    349    370       {ECO:0000250}.
FT   DISULFID    472    505       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    561    561       Interchain.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    683    896       {ECO:0000250}.
FT   DISULFID    822    830       {ECO:0000250}.
SQ   SEQUENCE   1362 AA;  153757 MW;  7B8BF2FB7EFDA01B CRC64;
     MGQGVLRGEG HPNNNPNSKV GWKSLVGIIT IFMLILCDQS DGKICYSMDI RNNISQFSML
     EDCTVIEGHL QILLMFTSKP ENFRGLRFPK LTTITDYLLL FRVYGLESLK DLFPNLTVIR
     GTRLFFNYAL VIFEMVHXKE IGLYNLMNIT RGSVRIEKNN ELCYLSTIDW SIILDSVEDN
     YIELNRDNKE ECGDVCPGTV KGKSKCKHTL VNGALVERCW TQDHCQKVCP SDCKGSGCLP
     DGQCCHPECL GSCRKPNDPS ECTACRHFQN EGVCVTACPK GSYQFQGWRC IDFNTCQELN
     SRCQNSRDNS CPPYVIHKGE CMPDCPSGYI ANSTTRTCTP CAGPCPKVCT IFQNVKTIDS
     VTSAQELRGC TVINGSLIIN LRGGNNIATE LEANLGLIEE ISGYLKIRRS YALVSLSFFR
     KLRLIRGEVL EAGNYSFYAL DNPSLRQLWD WHKHNLTIIH GKLFFHHNPR LCLSQIHQME
     EVTGTKGRQD KNDIATKTNG DQASCEDNLL TFNFIKTSHD MVLLRWDAYW PPDYRDLLGF
     MVHYKEAPFQ NVTEFDGQDA CGSNSWTVVD MDAPERSADG KTQSPGCLLR SLKPWTQYAV
     FVKTLVSGSD EGRTYGAKSK IIYIRTNETI PSVPLDPFSV SNSTSQIILK WKPPSEPNGN
     VTHYLVYWQE QPEDSDLYEV DYCNKGLKLP SRTWTPPTEI DENGNENQTE HTSVNKCCPC
     PKTEFQIQKE QDESAFRKTF ENYLHNEVFI PRPVRKRRDL FGVANGTLPD PVTAPPLFNV
     SSTRAPDEPE PKIYSQKVWF KESVLISGLK HFTGYRIEIH ACNHELSMGC SVAAYVNART
     MPEATADKVV GPITYEYVEP NIIHLKWQEP KDPNGLIVLY EVHYSRVGGI EEVITCVSQK
     QYNTDKGGKL RVLTPGNYSV KIRATSLAGN GSWTEQAYFQ VPDHPHSNIV KIITGPIIAV
     FLLLIVLVYC VVQKKKDAEG PAGPLYTSSN PEYLSASEVY IPDEWEVPRD KINLLRELGQ
     GSFGMVYEGI AKDIIKGEPE VRVAVKTVNE SASLRERIEF LNEASVMKAF NCHHVVRLLG
     VVSKGQPTLV IMELMAHGDL KSYLRSLRPD AENNPGRLAP TLKEIIQMAA EISDGMAYLN
     AKKFVHRDLA ARNCMVADDY AVKIGDFGMT RDIYETDYYR KGGKGLLPVR WMSPESLKDG
     VFTAFSDVWS FGVVLWEITS LAEQPYQGLS NEQVLKFVMD GGSLDHPENC PPRLHSLMQM
     CWQYNPKMRP TFLEIIDMLK DDLRPSFQDV SFYYSDENKP PETDDLEIDF ENMESTPLDP
     SSCSLRDQSS RTNIYEEHIP YTHMNGGRKN GRILSLPRSS PS
//
ID   IGF1R_XENLA             Reviewed;        1358 AA.
AC   O73798;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   07-SEP-2016, entry version 111.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            Short=xIGF-1R;
DE            Short=xIGFR;
DE            EC=2.7.10.1;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=igf1r;
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Pipoidea; Pipidae; Xenopodinae; Xenopus;
OC   Xenopus.
OX   NCBI_TaxID=8355;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC12942.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY,
RP   DEVELOPMENTAL STAGE, AND AUTOPHOSPHORYLATION.
RC   TISSUE=Oocyte {ECO:0000269|PubMed:9492024};
RX   PubMed=9492024; DOI=10.1210/en.139.3.949;
RA   Zhu L., Ohan N., Agazie Y., Cummings C., Farah S., Liu X.J.;
RT   "Molecular cloning and characterization of Xenopus insulin-like growth
RT   factor-1 receptor: its role in mediating insulin-induced Xenopus
RT   oocyte maturation and expression during embryogenesis.";
RL   Endocrinology 139:949-954(1998).
RN   [2] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=1847619; DOI=10.1042/bj2730673;
RA   Hainaut P., Kowalski A., Giorgetti S., Baron V., Van Obberghen E.;
RT   "Insulin and insulin-like-growth-factor-I (IGF-I) receptors in Xenopus
RT   laevis oocytes. Comparison with insulin receptors from liver and
RT   muscle.";
RL   Biochem. J. 273:673-678(1991).
RN   [3]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=11709186; DOI=10.1016/S1534-5807(01)00069-7;
RA   Pera E.M., Wessely O., Li S.-Y., De Robertis E.M.;
RT   "Neural and head induction by insulin-like growth factor signals.";
RL   Dev. Cell 1:655-665(2001).
RN   [4]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=11944947; DOI=10.1006/dbio.2002.0605;
RA   Richard-Parpaillon L., Heligon C., Chesnel F., Boujard D.,
RA   Philpott A.;
RT   "The IGF pathway regulates head formation by inhibiting Wnt signaling
RT   in Xenopus.";
RL   Dev. Biol. 244:407-417(2002).
CC   -!- FUNCTION: This receptor binds insulin-like growth factor 1 (IGF1)
CC       with a high affinity and IGF2 with a lower affinity. It has a
CC       tyrosine-protein kinase activity, which is necessary for the
CC       activation of the IGF1-stimulated downstream signaling cascade.
CC       Plays a role in oocyte maturation. Promotes head development by
CC       inhibiting Wnt signaling during embryogenesis.
CC       {ECO:0000269|PubMed:11944947, ECO:0000269|PubMed:1847619,
CC       ECO:0000269|PubMed:9492024}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:9492024}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity. {ECO:0000250|UniProtKB:P08069}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q5HZ83:gipc2; NbExp=2; IntAct=EBI-8068109, EBI-8068143;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1847619};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:1847619}.
CC       Note=Expressed at the oocyte surface.
CC   -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically.
CC       Shows biphasic expression during early development. Expressed
CC       ubiquitously in fertilized eggs and throughout the midblastula
CC       transition. Expression then decreases at mid-gastrulation. Shortly
CC       after gastrulation, expression is seen throughout the dorsal side
CC       of the embryo with expression strongest in the anterior and absent
CC       ventrally. Expression increases along the dorsal midline at early
CC       neurulation and is seen in the head region as neurulation
CC       progresses, particularly in the area of the cement gland
CC       primordium. Also present in the anterior mesoderm but is absent
CC       from the neural tube and the most ventral part of the embryo.
CC       Remains expressed throughout early embryogenesis. By the tailbud
CC       stages, expression is anterior, in the head and the most rostral
CC       part of the neural tube. {ECO:0000269|PubMed:11709186,
CC       ECO:0000269|PubMed:11944947, ECO:0000269|PubMed:9492024}.
CC   -!- PTM: The cytoplasmic domain of the beta subunit is
CC       autophosphorylated on Tyr residues in response to low
CC       concentrations of insulin-like growth factor (IGF 1) and higher
CC       concentrations of insulin.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF055980; AAC12942.1; -; mRNA.
DR   RefSeq; NP_001081734.1; NM_001088265.1.
DR   UniGene; Xl.269; -.
DR   ProteinModelPortal; O73798; -.
DR   SMR; O73798; 26-483, 973-1285.
DR   IntAct; O73798; 1.
DR   MINT; MINT-609362; -.
DR   PRIDE; O73798; -.
DR   GeneID; 398022; -.
DR   KEGG; xla:398022; -.
DR   CTD; 3480; -.
DR   Xenbase; XB-GENE-865040; igf1r.
DR   HOVERGEN; HBG006134; -.
DR   KO; K05087; -.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0001556; P:oocyte maturation; IEP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Cleavage on pair of basic residues;
KW   Developmental protein; Disulfide bond; Glycoprotein; Kinase;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    730       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                {ECO:0000303|PubMed:9492024}.
FT                                /FTId=PRO_0000045749.
FT   CHAIN       735   1358       Insulin-like growth factor 1 receptor
FT                                beta chain. {ECO:0000303|PubMed:9492024}.
FT                                /FTId=PRO_0000045750.
FT   TOPO_DOM    735    934       Extracellular. {ECO:0000255}.
FT   TRANSMEM    935    955       Helical. {ECO:0000255}.
FT   TOPO_DOM    956   1358       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      483    603       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      604    702       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      727    818       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      829    924       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      995   1270       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1001   1009       ATP. {ECO:0000250|UniProtKB:P08069,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE   1131   1131       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:P08069,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10028}.
FT   BINDING    1029   1029       ATP. {ECO:0000250|UniProtKB:P08069,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   MOD_RES     976    976       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1157   1157       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1161   1161       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1162   1162       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     99     99       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    132    132       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    310    310       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    432    432       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    488    488       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    669    669       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    741    741       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    750    750       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    758    758       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    895    895       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    908    908       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    212    221       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    216    227       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    228    236       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    232    245       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    248    257       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    261    273       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    279    299       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    303    317       {ECO:0000250|UniProtKB:P08069}.
FT   DISULFID    320    324       {ECO:0000250|UniProtKB:P08069}.
SQ   SEQUENCE   1358 AA;  153864 MW;  2E4E1F8EA6696776 CRC64;
     MKAELVPVCT AWILGLLLCL GPAAAKVCGP NMDIRNDVSE LKQLRDCVVI EGYLQILLIS
     NAKAEDFRNL RFPNLTVITD YLLLFRVSGL VSLSNLFPNL TVIRGRVLFY NYALVIFEMT
     DLKEIGLYNL RNITRGAVRI EKNSELCYVS TVDWSLVLDA VYNNYIVGNK PPKECVDLCP
     GAREKMQICE KSSINNEFAD RCWSDEHCQK VCPSVCGKRA CSDNNECCHP ECLGSCTAPD
     NDTACVACHH YFYEGRCVPT CPSNTYKFEG WRCITREVCA KMHIWIHSTI PFIIHKGECV
     YECPSGYMLN KSQSMTCSPC EGPCPKICEE KMKTIDSVTS AQMLEGCTVL KGNLQLNIRK
     GQNIAAELEN FLGLIETVTG YVKIRHSHAL VSLSFLKSLR YILGEEQMPG NYSFYVFDNN
     NLQQLWDWSK HNLTIKEGKI RFAFNSKLCA SEIYRMEEVT GTKGRQAEED ISLSTNGNMA
     SCESHVLNFT SRSKIKNRIK LTWERYRPPD YRDLISFTVY YKEAPFRNVT EYDGQDACGS
     NSWNMVDVDL PASKESDPGI LLQGLKPWTQ YAIYVKAITL TMLENRHIHG AKSKIIYMRT
     DAAVPSIPQD MISASNSSSQ LVVKWNPPSL PNGNLSYYIV RWQQQPQDRH LYQYNYCFKD
     KVPNRKYANG TIDTEGGTEP TKPEGSVGEK GHYCACPKTE AEEKAEKDEA EYRKVFENFL
     HNSIFVPRPN RRRRDVLAVG NSTVTSYEKN STTEDFSNFS DSERDDIEYP FYETKVDYKW
     ERTVISNLQP FTLYRIDIHS CNHEAEKLGC SASNFVFART MPAAGADDIP GIVNTKEEDD
     GVIFLGWPEP LRPNGLILMY EIEYKHQGEV HRECVSRQDY RKNGGIKLVR LPPGNYSAQV
     QAISLYGNGS WTEMVSFCVK LKPDVRNNIL QMVVAIPLAL SFLLVGIISI VCFVFKKRNS
     NRLGNGVLYA SVNPEYFSAA EMYVPDKWEV PREKITMNRE LGQGSFGMVY EGIAKGVVKD
     EAETKVAIKT VNEAASMRER IEFLNEASVM KEFNCHHVVR LLGVVSQGQP TLVIMELMTR
     GDLKSYLRSL RPDTESNSGQ PTPSLKKMIQ MAGEIADGMS YLNANKFVHR DLAARNCMVT
     EDFTVKIGDF GMTRDIYETD YYRKGGKGLL PVRWMSPESL KDGVFTTNSD VWSFGVVLWE
     IATLAEQPYQ GMSNEQVLRF VMEGGLLEKP DNCPDMLFEL MRMCWQFNPK MRPSFLEIIS
     SIKDELDPGF KEVSFFYSEE NKPPDTEELD LEAENMESIP LDPSCALQNS EHHAGHKSEN
     GPGVVVLRAS FDERQPYAHM NGGRKNERAL PLPQSSAC
//
ID   IGF1R_HUMAN             Reviewed;        1367 AA.
AC   P08069; B1B5Y2; Q14CV2; Q9UCC0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   07-SEP-2016, entry version 197.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=IGF1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-56; 446-453;
RP   503-524; 561-579; 668-672 AND 721-729.
RC   TISSUE=Placenta;
RX   PubMed=2877871;
RA   Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C.,
RA   Henzel W., Bon T.L., Kathuria S., Chen E., Jacobs S., Francke U.,
RA   Ramachandran J., Fujita-Yamaguchi Y.;
RT   "Insulin-like growth factor I receptor primary structure: comparison
RT   with insulin receptor suggests structural determinants that define
RT   functional specificity.";
RL   EMBO J. 5:2503-2512(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1316909;
RA   Abbot A.M., Bueno R., Pedrini M.T., Murray J.M., Smith R.J.;
RT   "Insulin-like growth factor I receptor gene structure.";
RL   J. Biol. Chem. 267:10759-10763(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RA   Nagase T., Kikuno R.F., Yamakawa H., Ohara O.;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-388 AND HIS-605.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RX   PubMed=1711844; DOI=10.1016/0006-291X(91)90654-P;
RA   Cooke D.W., Bankert L.A., Roberts C.T. Jr., Leroith D., Casella S.J.;
RT   "Analysis of the human type I insulin-like growth factor receptor
RT   promoter region.";
RL   Biochem. Biophys. Res. Commun. 177:1113-1120(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 31-45 AND 741-750, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH INSR.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   FUNCTION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=1846292; DOI=10.1021/bi00215a008;
RA   Tollefsen S.E., Stoszek R.M., Thompson K.;
RT   "Interaction of the alpha beta dimers of the insulin-like growth
RT   factor I receptor is required for receptor autophosphorylation.";
RL   Biochemistry 30:48-54(1991).
RN   [11]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=8452530; DOI=10.1042/bj2900419;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=7679099;
RA   Kato H., Faria T.N., Stannard B., Roberts C.T. Jr., LeRoith D.;
RT   "Role of tyrosine kinase activity in signal transduction by the
RT   insulin-like growth factor-I (IGF-I) receptor. Characterization of
RT   kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic
RT   antibody (alpha IR-3).";
RL   J. Biol. Chem. 268:2655-2661(1993).
RN   [13]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, MUTAGENESIS OF TYR-980 AND
RP   LYS-1033, AND PHOSPHORYLATION AT TYR-980.
RX   PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [14]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9355755; DOI=10.1042/bj3270209;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS.
RX   PubMed=9581554; DOI=10.1042/bj3270765;
RA   Furlanetto R.W., Dey B.R., Lopaczynski W., Nissley S.P.;
RT   "14-3-3 proteins interact with the insulin-like growth factor receptor
RT   but not the insulin receptor.";
RL   Biochem. J. 327:765-771(1997).
RN   [16]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [17]
RP   INTERACTION WITH SOCS1 AND SOCS2.
RX   PubMed=9727029; DOI=10.1074/jbc.273.37.24095;
RA   Dey B.R., Spence S.L., Nissley P., Furlanetto R.W.;
RT   "Interaction of human suppressor of cytokine signaling (SOCS)-2 with
RT   the insulin-like growth factor-I receptor.";
RL   J. Biol. Chem. 273:24095-24101(1998).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [19]
RP   FUNCTION IN CANCER.
RX   PubMed=10579905; DOI=10.1006/excr.1999.4667;
RA   Baserga R.;
RT   "The IGF-I receptor in cancer research.";
RL   Exp. Cell Res. 253:1-6(1999).
RN   [20]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281
RP   AND TYR-1346.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [21]
RP   INTERACTION WITH SOCS3.
RX   PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
RA   Dey B.R., Furlanetto R.W., Nissley P.;
RT   "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
RT   insulin-like growth factor-I receptor.";
RL   Biochem. Biophys. Res. Commun. 278:38-43(2000).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=11162456; DOI=10.1006/bbrc.2000.4046;
RA   Lopaczynski W., Terry C., Nissley P.;
RT   "Autophosphorylation of the insulin-like growth factor I receptor
RT   cytoplasmic domain.";
RL   Biochem. Biophys. Res. Commun. 279:955-960(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF STAT3.
RX   PubMed=10747872; DOI=10.1074/jbc.M000089200;
RA   Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H.;
RT   "Mechanism of STAT3 activation by insulin-like growth factor I
RT   receptor.";
RL   J. Biol. Chem. 275:15099-15105(2000).
RN   [24]
RP   TISSUE SPECIFICITY.
RX   PubMed=12019176;
RA   Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F.,
RA   Macaulay V.M.;
RT   "Expression of the type 1 insulin-like growth factor receptor is up-
RT   regulated in primary prostate cancer and commonly persists in
RT   metastatic disease.";
RL   Cancer Res. 62:2942-2950(2002).
RN   [25]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [26]
RP   INTERACTION WITH RACK1.
RX   PubMed=11884618; DOI=10.1128/MCB.22.7.2345-2365.2002;
RA   Hermanto U., Zong C.S., Li W., Wang L.H.;
RT   "RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting
RT   protein, modulates IGF-I-dependent integrin signaling and promotes
RT   cell spreading and contact with extracellular matrix.";
RL   Mol. Cell. Biol. 22:2345-2365(2002).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH MAP3K5.
RX   PubMed=12556535; DOI=10.1074/jbc.M211398200;
RA   Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E.;
RT   "Type 1 insulin-like growth factor receptor (IGF-IR) signaling
RT   inhibits apoptosis signal-regulating kinase 1 (ASK1).";
RL   J. Biol. Chem. 278:13325-13332(2003).
RN   [28]
RP   UBIQUITINATION BY MDM2, AND INTERACTION WITH MDM2.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like
RT   growth factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [29]
RP   ENZYME REGULATION.
RX   PubMed=14729630; DOI=10.1158/0008-5472.CAN-03-2522;
RA   Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O.,
RA   Axelson M.;
RT   "Cyclolignans as inhibitors of the insulin-like growth factor-1
RT   receptor and malignant cell growth.";
RL   Cancer Res. 64:236-242(2004).
RN   [30]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [31]
RP   INTERACTION WITH STAT3.
RX   PubMed=15998644; DOI=10.1074/jbc.M501316200;
RA   Yadav A., Kalita A., Dhillon S., Banerjee K.;
RT   "JAK/STAT3 pathway is involved in survival of neurons in response to
RT   insulin-like growth factor and negatively regulated by suppressor of
RT   cytokine signaling-3.";
RL   J. Biol. Chem. 280:31830-31840(2005).
RN   [32]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [33]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=17524361; DOI=10.1016/j.bbrc.2007.05.062;
RA   McElroy B., Powell J.C., McCarthy J.V.;
RT   "The insulin-like growth factor 1 (IGF-1) receptor is a substrate for
RT   gamma-secretase-mediated intramembrane proteolysis.";
RL   Biochem. Biophys. Res. Commun. 358:1136-1141(2007).
RN   [34]
RP   REVIEW ON IGF1R IN CANCER.
RX   PubMed=17624760; DOI=10.1016/j.ejca.2007.05.021;
RA   Hartog H., Wesseling J., Boezen H.M., van der Graaf W.T.;
RT   "The insulin-like growth factor 1 receptor in cancer: old focus, new
RT   future.";
RL   Eur. J. Cancer 43:1895-1904(2007).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [36]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   IGF1.
RX   PubMed=19578119; DOI=10.1074/jbc.M109.013201;
RA   Saegusa J., Yamaji S., Ieguchi K., Wu C.Y., Lam K.S., Liu F.T.,
RA   Takada Y.K., Takada Y.;
RT   "The direct binding of insulin-like growth factor-1 (IGF-1) to
RT   integrin alphavbeta3 is involved in IGF-1 signaling.";
RL   J. Biol. Chem. 284:24106-24114(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [38]
RP   SUMOYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   UBIQUITINATION AT LYS-1168 AND LYS-1171.
RX   PubMed=21994939; DOI=10.1074/jbc.M111.288514;
RA   Mao Y., Shang Y., Pham V.C., Ernst J.A., Lill J.R., Scales S.J.,
RA   Zha J.;
RT   "Polyubiquitination of insulin-like growth factor I receptor (IGF-IR)
RT   activation loop promotes antibody-induced receptor internalization and
RT   down-regulation.";
RL   J. Biol. Chem. 286:41852-41861(2011).
RN   [41]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   IGF1.
RX   PubMed=22351760; DOI=10.1074/jbc.M111.304170;
RA   Fujita M., Ieguchi K., Davari P., Yamaji S., Taniguchi Y.,
RA   Sekiguchi K., Takada Y.K., Takada Y.;
RT   "Cross-talk between integrin alpha6beta4 and insulin-like growth
RT   factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1
RT   and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in
RT   anchorage-independent conditions.";
RL   J. Biol. Chem. 287:12491-12500(2012).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314.
RX   PubMed=9690478; DOI=10.1038/28668;
RA   Garrett T.P., McKern N.M., Lou M., Frenkel M.J., Bentley J.D.,
RA   Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W.;
RT   "Crystal structure of the first three domains of the type-1 insulin-
RT   like growth factor receptor.";
RL   Nature 394:395-399(1998).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   AMP-PCP AND PEPTIDE SUBSTRATE, CATALYTIC ACTIVITY, ACTIVE SITE, ENZYME
RP   REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION
RP   AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=11694888; DOI=10.1038/nsb721;
RA   Favelyukis S., Till J.H., Hubbard S.R., Miller W.T.;
RT   "Structure and autoregulation of the insulin-like growth factor 1
RT   receptor kinase.";
RL   Nat. Struct. Biol. 8:1058-1063(2001).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   ANP, AUTOPHOSPHORYLATION, ACTIVE SITE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=11591350; DOI=10.1016/S0969-2126(01)00655-4;
RA   Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H.;
RT   "Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight
RT   into domain movements upon kinase activation.";
RL   Structure 9:955-965(2001).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294.
RX   PubMed=12138114; DOI=10.1074/jbc.M205580200;
RA   Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L.,
RA   Stirdivant S.M., Darke P.L., Kuo L.C.;
RT   "Crystal structure of the Apo, unactivated insulin-like growth factor-
RT   1 receptor kinase. Implication for inhibitor specificity.";
RL   J. Biol. Chem. 277:38797-38802(2002).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294.
RX   PubMed=14501110; DOI=10.1107/S0907444903015415;
RA   Munshi S., Hall D.L., Kornienko M., Darke P.L., Kuo L.C.;
RT   "Structure of apo, unactivated insulin-like growth factor-1 receptor
RT   kinase at 1.5 A resolution.";
RL   Acta Crystallogr. D 59:1725-1730(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BENZIMIDAZOLE PYRIDINONE INHIBITOR, CATALYTIC ACTIVITY, AND ENZYME
RP   REGULATION.
RX   PubMed=17317169; DOI=10.1016/j.bmcl.2007.01.102;
RA   Velaparthi U., Wittman M., Liu P., Stoffan K., Zimmermann K., Sang X.,
RA   Carboni J., Li A., Attar R., Gottardis M., Greer A., Chang C.Y.,
RA   Jacobsen B.L., Sack J.S., Sun Y., Langley D.R., Balasubramanian B.,
RA   Vyas D.;
RT   "Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-
RT   2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor
RT   (IGF-1R).";
RL   Bioorg. Med. Chem. Lett. 17:2317-2321(2007).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=18501599; DOI=10.1016/j.bmcl.2008.04.044;
RA   Mayer S.C., Banker A.L., Boschelli F., Di L., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Kutterer K., Moy F., Petusky S., Ravi M., Tkach D.,
RA   Tsou H.R., Xu W.;
RT   "Lead identification to generate isoquinolinedione inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 18:3641-3645(2008).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH
RP   INHIBITOR PQIP, SUBUNIT, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, AND ENZYME REGULATION.
RX   PubMed=18566589; DOI=10.1038/emboj.2008.116;
RA   Wu J., Li W., Craddock B.P., Foreman K.W., Mulvihill M.J., Ji Q.S.,
RA   Miller W.T., Hubbard S.R.;
RT   "Small-molecule inhibition and activation-loop trans-phosphorylation
RT   of the IGF1 receptor.";
RL   EMBO J. 27:1985-1994(2008).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   3-CYANOQUINOLINE INHIBITOR, CATALYTIC ACTIVITY, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=19041240; DOI=10.1016/j.bmcl.2008.11.037;
RA   Miller L.M., Mayer S.C., Berger D.M., Boschelli D.H., Boschelli F.,
RA   Di L., Du X., Dutia M., Floyd M.B., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Moy F., Petusky S., Tkach D., Torres N., Wu B.,
RA   Xu W.;
RT   "Lead identification to generate 3-cyanoquinoline inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 19:62-66(2009).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BMS-754807, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=19778024; DOI=10.1021/jm900786r;
RA   Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R.,
RA   Balimane P., Chang C., Chen C., Discenza L., Frennesson D.,
RA   Gottardis M.M., Greer A., Hurlburt W., Johnson W., Langley D.R.,
RA   Li A., Li J., Liu P., Mastalerz H., Mathur A., Menard K., Patel K.,
RA   Sack J., Sang X., Saulnier M., Smith D., Stefanski K., Trainor G.,
RA   Velaparthi U., Zhang G., Zimmermann K., Vyas D.M.;
RT   "Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine
RT   inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R)
RT   kinase in clinical development.";
RL   J. Med. Chem. 52:7360-7363(2009).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH
RP   MSC1609119A-1, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   DOI=10.1021/ml100044h;
RA   Heinrich T., Graedler U., Boettcher H., Blaukat A., Shutes A.;
RT   "Allosteric IGF-1R Inhibitors.";
RL   ACS Med. Chem. Lett. 1:199-203(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20675137; DOI=10.1016/j.bmcl.2010.07.045;
RA   Sampognaro A.J., Wittman M.D., Carboni J.M., Chang C., Greer A.F.,
RA   Hurlburt W.W., Sack J.S., Vyas D.M.;
RT   "Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-
RT   f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.";
RL   Bioorg. Med. Chem. Lett. 20:5027-5030(2010).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH
RP   BIS-AZAINDOLE INHIBITOR, AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=20545947; DOI=10.1111/j.1747-0285.2010.00991.x;
RA   Nemecek C., Metz W.A., Wentzler S., Ding F.X., Venot C., Souaille C.,
RA   Dagallier A., Maignan S., Guilloteau J.P., Bernard F., Henry A.,
RA   Grapinet S., Lesuisse D.;
RT   "Design of potent IGF1-R inhibitors related to bis-azaindoles.";
RL   Chem. Biol. Drug Des. 76:100-106(2010).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   HYDANTOIN DERIVATIVE, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=21441024; DOI=10.1016/j.bmcl.2011.03.003;
RA   Lesuisse D., Mauger J., Nemecek C., Maignan S., Boiziau J., Harlow G.,
RA   Hittinger A., Ruf S., Strobel H., Nair A., Ritter K., Malleron J.L.,
RA   Dagallier A., El-Ahmad Y., Guilloteau J.P., Guizani H., Bouchard H.,
RA   Venot C.;
RT   "Discovery of the first non-ATP competitive IGF-1R kinase inhibitors:
RT   advantages in comparison with competitive inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2224-2228(2011).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR, CATALYTIC ACTIVITY, AND
RP   ENZYME REGULATION.
RX   PubMed=21414779; DOI=10.1016/j.bmcl.2011.02.075;
RA   Buchanan J.L., Newcomb J.R., Carney D.P., Chaffee S.C., Chai L.,
RA   Cupples R., Epstein L.F., Gallant P., Gu Y., Harmange J.C., Hodge K.,
RA   Houk B.E., Huang X., Jona J., Joseph S., Jun H.T., Kumar R., Li C.,
RA   Lu J., Menges T., Morrison M.J., Novak P.M., van der Plas S.,
RA   Radinsky R., Rose P.E., Sawant S., Sun J.R., Surapaneni S.,
RA   Turci S.M., Xu K., Yanez E., Zhao H., Zhu X.;
RT   "Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth
RT   factor-1 receptor (IGF-1R) inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2394-2399(2011).
RN   [57]
RP   VARIANTS IGF1RES GLN-138 AND ASN-145, AND CHARACTERIZATION OF VARIANTS
RP   IGF1RES GLN-138 AND ASN-145.
RX   PubMed=14657428; DOI=10.1056/NEJMoa010107;
RG   The intrauterine growth retardation (IUGR) study group;
RA   Abuzzahab M.J., Schneider A., Goddard A., Grigorescu F., Lautier C.,
RA   Keller E., Kiess W., Klammt J., Kratzsch J., Osgood D., Pfaeffle R.,
RA   Raile K., Seidel B., Smith R.J., Chernausek S.D.;
RT   "IGF-I receptor mutations resulting in intrauterine and postnatal
RT   growth retardation.";
RL   N. Engl. J. Med. 349:2211-2222(2003).
RN   [58]
RP   VARIANT IGF1RES GLN-739, AND CHARACTERIZATION OF VARIANT IGF1RES
RP   GLN-739.
RX   PubMed=15928254; DOI=10.1210/jc.2004-1947;
RA   Kawashima Y., Kanzaki S., Yang F., Kinoshita T., Hanaki K.,
RA   Nagaishi J., Ohtsuka Y., Hisatome I., Ninomoya H., Nanba E.,
RA   Fukushima T., Takahashi S.;
RT   "Mutation at cleavage site of insulin-like growth factor receptor in a
RT   short-stature child born with intrauterine growth retardation.";
RL   J. Clin. Endocrinol. Metab. 90:4679-4687(2005).
RN   [59]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857;
RP   THR-1338 AND VAL-1347.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [60]
RP   VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND CYS-1337, AND
RP   CHARACTERIZATION OF VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND
RP   CYS-1337.
RX   PubMed=25040157; DOI=10.1111/cen.12555;
RA   Juanes M., Guercio G., Marino R., Berensztein E., Warman D.M.,
RA   Ciaccio M., Gil S., Bailez M., Rivarola M.A., Belgorosky A.;
RT   "Three novel IGF1R mutations in microcephalic patients with prenatal
RT   and postnatal growth impairment.";
RL   Clin. Endocrinol. (Oxf.) 82:704-711(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity
CC       and IGF2 and insulin (INS) with a lower affinity. The activated
CC       IGF1R is involved in cell growth and survival control. IGF1R is
CC       crucial for tumor transformation and survival of malignant cell.
CC       Ligand binding activates the receptor kinase, leading to receptor
CC       autophosphorylation, and tyrosines phosphorylation of multiple
CC       substrates, that function as signaling adapter proteins including,
CC       the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
CC       Phosphorylation of IRSs proteins lead to the activation of two
CC       main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK
CC       pathway. The result of activating the MAPK pathway is increased
CC       cellular proliferation, whereas activating the PI3K pathway
CC       inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1), leading to activation of several downstream
CC       substrates, including protein AKT/PKB. AKT phosphorylation, in
CC       turn, enhances protein synthesis through mTOR activation and
CC       triggers the antiapoptotic effects of IGFIR through
CC       phosphorylation and inactivation of BAD. In parallel to PI3K-
CC       driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1
CC       or Shc leads to recruitment of Ras and activation of the ras-MAPK
CC       pathway. In addition to these two main signaling pathways IGF1R
CC       signals also through the Janus kinase/signal transducer and
CC       activator of transcription pathway (JAK/STAT). Phosphorylation of
CC       JAK proteins can lead to phosphorylation/activation of signal
CC       transducers and activators of transcription (STAT) proteins. In
CC       particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates
CC       gene transcription and may be responsible for the transforming
CC       activity. JNK kinases can also be activated by the IGF1R. IGF1
CC       exerts inhibiting activities on JNK activation via phosphorylation
CC       and inhibition of MAP3K5/ASK1, which is able to directly associate
CC       with the IGF1R.
CC   -!- FUNCTION: When present in a hybrid receptor with INSR, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long are activated with a high affinity by IGF1, with
CC       low affinity by IGF2 and not significantly activated by insulin,
CC       and that hybrid receptors composed of IGF1R and INSR isoform Short
CC       are activated by IGF1, IGF2 and insulin. In contrast,
CC       PubMed:16831875 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long and hybrid receptors composed of IGF1R and INSR
CC       isoform Short have similar binding characteristics, both bind IGF1
CC       and have a low affinity for insulin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20675137, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:7679099,
CC       ECO:0000269|Ref.52}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation at Tyr-1165,
CC       Tyr-1161 and Tyr-1166 on the kinase activation loop;
CC       phosphorylation at all three tyrosine residues is required for
CC       optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807,
CC       PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole,
CC       3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine,
CC       pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin
CC       (PPP), tyrphostin derivatives. While most inhibitors bind to the
CC       ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation
CC       loop. {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:14729630,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:20675137,
CC       ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC       ECO:0000269|Ref.52}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10. Interacts with RACK1. Interacts with SOCS1, SOCS2 and
CC       SOCS3. Interacts with 14-3-3 proteins. Interacts with NMD2.
CC       Interacts with MAP3K5. Interacts with STAT3. Found in a ternary
CC       complex with IGF1 and ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:19578119,
CC       PubMed:22351760). {ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:11071852, ECO:0000269|PubMed:11591350,
CC       ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:11884618,
CC       ECO:0000269|PubMed:12556535, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:15998644,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:1846292,
CC       ECO:0000269|PubMed:18566589, ECO:0000269|PubMed:19041240,
CC       ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:22351760,
CC       ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:9581554,
CC       ECO:0000269|PubMed:9727029, ECO:0000269|PubMed:9822622,
CC       ECO:0000269|Ref.52}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-475981, EBI-475981;
CC       Q9NZN5:ARHGEF12; NbExp=7; IntAct=EBI-475981, EBI-821440;
CC       P49913:CAMP; NbExp=3; IntAct=EBI-475981, EBI-6378485;
CC       Q64010:Crk (xeno); NbExp=3; IntAct=EBI-475981, EBI-2906540;
CC       P41240:CSK; NbExp=5; IntAct=EBI-475981, EBI-1380630;
CC       P35222:CTNNB1; NbExp=3; IntAct=EBI-475981, EBI-491549;
CC       P05019:IGF1; NbExp=5; IntAct=EBI-475981, EBI-7902275;
CC       P01317:INS (xeno); NbExp=4; IntAct=EBI-475981, EBI-3989070;
CC       Q9Y2W7:KCNIP3; NbExp=3; IntAct=EBI-475981, EBI-751501;
CC       Q9UJU2:LEF1; NbExp=5; IntAct=EBI-475981, EBI-926131;
CC       Q00987:MDM2; NbExp=2; IntAct=EBI-475981, EBI-389668;
CC       P27986:PIK3R1; NbExp=4; IntAct=EBI-475981, EBI-79464;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-475981, EBI-968788;
CC       Q06124:PTPN11; NbExp=3; IntAct=EBI-475981, EBI-297779;
CC       P29353-2:SHC1; NbExp=2; IntAct=EBI-475981, EBI-1000553;
CC       Q01995:TAGLN; NbExp=2; IntAct=EBI-475981, EBI-1054248;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17524361};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:17524361}.
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with INSR in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Expressed in
CC       a variety of tissues. Overexpressed in tumors, including
CC       melanomas, cancers of the colon, pancreas prostate and kidney.
CC       {ECO:0000269|PubMed:12019176, ECO:0000269|PubMed:8247543,
CC       ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner; Tyr-
CC       1165 is predominantly phosphorylated first, followed by
CC       phosphorylation of Tyr-1161 and Tyr-1166. While every single
CC       phosphorylation increases kinase activity, all three tyrosine
CC       residues in the kinase activation loop (Tyr-1165, Tyr-1161 and
CC       Tyr-1166) have to be phosphorylated for optimal activity. Can be
CC       autophosphorylated at additional tyrosine residues (in vitro).
CC       Autophosphorylated is followed by phosphorylation of juxtamembrane
CC       tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is
CC       required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278
CC       by GSK-3beta restrains kinase activity and promotes cell surface
CC       expression, it requires a priming phosphorylation at Ser-1282.
CC       Dephosphorylated by PTPN1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-
CC       48' and 'Lys-29' linkages, promoting receptor endocytosis and
CC       subsequent degradation by the proteasome. Ubiquitination is
CC       facilitated by pre-existing phosphorylation.
CC       {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240,
CC       ECO:0000269|PubMed:21994939, ECO:0000269|PubMed:7541045}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000269|PubMed:20596523}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP).
CC       Undergoes metalloprotease-dependent constitutive ectodomain
CC       shedding to produce a membrane-anchored 52 kDa C-Terminal fragment
CC       which is further processed by presenilin gamma-secretase to yield
CC       an intracellular 50 kDa fragment. {ECO:0000269|PubMed:17524361}.
CC   -!- DISEASE: Insulin-like growth factor 1 resistance (IGF1RES)
CC       [MIM:270450]: A disorder characterized by intrauterine growth
CC       retardation, poor postnatal growth and increased plasma IGF1
CC       levels. {ECO:0000269|PubMed:14657428, ECO:0000269|PubMed:15928254,
CC       ECO:0000269|PubMed:25040157}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG11657.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IGF1RID40928ch15q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=IGF-1 receptor entry;
CC       URL="https://en.wikipedia.org/wiki/IGF-1_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04434; CAA28030.1; -; mRNA.
DR   EMBL; AB425196; BAG11657.1; ALT_INIT; mRNA.
DR   EMBL; AY332722; AAP81165.1; -; Genomic_DNA.
DR   EMBL; AC055807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118660; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113610; AAI13611.1; -; mRNA.
DR   EMBL; BC113612; AAI13613.1; -; mRNA.
DR   EMBL; M69229; AAB59399.1; -; Genomic_DNA.
DR   CCDS; CCDS10378.1; -.
DR   PIR; A25690; IGHUR1.
DR   RefSeq; NP_000866.1; NM_000875.4.
DR   RefSeq; NP_001278787.1; NM_001291858.1.
DR   UniGene; Hs.643120; -.
DR   UniGene; Hs.714012; -.
DR   PDB; 1IGR; X-ray; 2.60 A; A=31-492.
DR   PDB; 1JQH; X-ray; 2.10 A; A/B/C=979-1286.
DR   PDB; 1K3A; X-ray; 2.10 A; A=988-1286.
DR   PDB; 1M7N; X-ray; 2.70 A; A/B=974-1294.
DR   PDB; 1P4O; X-ray; 1.50 A; A/B=974-1294.
DR   PDB; 2OJ9; X-ray; 2.00 A; A=982-1286.
DR   PDB; 2ZM3; X-ray; 2.50 A; A/B/C/D=981-1286.
DR   PDB; 3D94; X-ray; 2.30 A; A=986-1286.
DR   PDB; 3F5P; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286.
DR   PDB; 3I81; X-ray; 2.08 A; A=982-1286.
DR   PDB; 3LVP; X-ray; 3.00 A; A/B/C/D=951-1286.
DR   PDB; 3LW0; X-ray; 1.79 A; A/B/C/D=983-1286.
DR   PDB; 3NW5; X-ray; 2.14 A; A=982-1286.
DR   PDB; 3NW6; X-ray; 2.20 A; A=982-1286.
DR   PDB; 3NW7; X-ray; 2.11 A; A=982-1286.
DR   PDB; 3O23; X-ray; 2.10 A; A=982-1286.
DR   PDB; 3QQU; X-ray; 2.90 A; A/B/C/D=988-1286.
DR   PDB; 4D2R; X-ray; 2.10 A; A=985-1286.
DR   PDB; 4XSS; X-ray; 3.00 A; F=721-736.
DR   PDB; 5HZN; X-ray; 2.20 A; A/B/C/D/E/F/G/H=983-1286.
DR   PDBsum; 1IGR; -.
DR   PDBsum; 1JQH; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1M7N; -.
DR   PDBsum; 1P4O; -.
DR   PDBsum; 2OJ9; -.
DR   PDBsum; 2ZM3; -.
DR   PDBsum; 3D94; -.
DR   PDBsum; 3F5P; -.
DR   PDBsum; 3I81; -.
DR   PDBsum; 3LVP; -.
DR   PDBsum; 3LW0; -.
DR   PDBsum; 3NW5; -.
DR   PDBsum; 3NW6; -.
DR   PDBsum; 3NW7; -.
DR   PDBsum; 3O23; -.
DR   PDBsum; 3QQU; -.
DR   PDBsum; 4D2R; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 5HZN; -.
DR   ProteinModelPortal; P08069; -.
DR   SMR; P08069; 31-491, 991-1283.
DR   BioGrid; 109701; 71.
DR   DIP; DIP-476N; -.
DR   IntAct; P08069; 54.
DR   MINT; MINT-85902; -.
DR   STRING; 9606.ENSP00000268035; -.
DR   BindingDB; P08069; -.
DR   ChEMBL; CHEMBL1957; -.
DR   DrugBank; DB00047; Insulin Glargine.
DR   DrugBank; DB00046; Insulin Lispro.
DR   DrugBank; DB00030; Insulin Regular.
DR   DrugBank; DB01277; Mecasermin.
DR   GuidetoPHARMACOLOGY; 1801; -.
DR   iPTMnet; P08069; -.
DR   PhosphoSite; P08069; -.
DR   BioMuta; IGF1R; -.
DR   DMDM; 124240; -.
DR   EPD; P08069; -.
DR   MaxQB; P08069; -.
DR   PaxDb; P08069; -.
DR   PeptideAtlas; P08069; -.
DR   PRIDE; P08069; -.
DR   DNASU; 3480; -.
DR   Ensembl; ENST00000268035; ENSP00000268035; ENSG00000140443.
DR   GeneID; 3480; -.
DR   KEGG; hsa:3480; -.
DR   UCSC; uc002bul.4; human.
DR   CTD; 3480; -.
DR   GeneCards; IGF1R; -.
DR   HGNC; HGNC:5465; IGF1R.
DR   HPA; CAB010268; -.
DR   HPA; HPA045563; -.
DR   MalaCards; IGF1R; -.
DR   MIM; 147370; gene.
DR   MIM; 270450; phenotype.
DR   neXtProt; NX_P08069; -.
DR   Orphanet; 73273; Growth delay due to insulin-like growth factor I resistance.
DR   PharmGKB; PA29698; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P08069; -.
DR   KO; K05087; -.
DR   OMA; GYLYRHN; -.
DR   OrthoDB; EOG091G00GE; -.
DR   PhylomeDB; P08069; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   SignaLink; P08069; -.
DR   SIGNOR; P08069; -.
DR   ChiTaRS; IGF1R; human.
DR   EvolutionaryTrace; P08069; -.
DR   GeneWiki; Insulin-like_growth_factor_1_receptor; -.
DR   GenomeRNAi; 3480; -.
DR   PRO; PR:P08069; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000140443; -.
DR   CleanEx; HS_IGF1R; -.
DR   ExpressionAtlas; P08069; baseline and differential.
DR   Genevisible; P08069; HS.
DR   GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:AgBase.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IPI:BHF-UCL.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IDA:UniProtKB.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0051389; P:inactivation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:MGI.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IC:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Isopeptide bond; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:2877871,
FT                                ECO:0000269|PubMed:8257688}.
FT   CHAIN        31    736       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016681.
FT   CHAIN       741   1367       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016682.
FT   TOPO_DOM    741    935       Extracellular. {ECO:0000255}.
FT   TRANSMEM    936    959       Helical. {ECO:0000255}.
FT   TOPO_DOM    960   1367       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      491    609       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      610    708       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      735    828       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      834    927       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      999   1274       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1005   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       977    980       IRS1- and SHC1-binding.
FT   ACT_SITE   1135   1135       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1033   1033       ATP.
FT   MOD_RES     980    980       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:7541045}.
FT   MOD_RES    1161   1161       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1165   1165       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1166   1166       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1278   1278       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES    1282   1282       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q60751}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    314    314       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    534    534       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    607    607       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    622    622       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    640    640       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    747    747       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    764    764       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    900    900       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    913    913       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     33     52       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    150    178       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    182    205       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    192    211       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    215    224       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    219    230       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    231    239       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    235    248       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    251    260       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    264    276       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    282    303       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    307    321       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    324    328       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    332    353       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    455    488       {ECO:0000269|PubMed:9690478}.
FT   CROSSLNK   1168   1168       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   CROSSLNK   1171   1171       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   VARIANT     105    105       V -> L (in a renal chromophobe sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041424.
FT   VARIANT     138    138       R -> Q (in IGF1RES; has decreased IGF1R
FT                                function; dbSNP:rs121912426).
FT                                {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034891.
FT   VARIANT     145    145       K -> N (in IGF1RES; has decreased IGF1R
FT                                function; dbSNP:rs121912427).
FT                                {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034892.
FT   VARIANT     359    359       N -> Y (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076247.
FT   VARIANT     388    388       V -> M (in dbSNP:rs45445894).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018855.
FT   VARIANT     437    437       R -> H (in dbSNP:rs34516635).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034893.
FT   VARIANT     511    511       R -> Q (in dbSNP:rs33958176).
FT                                /FTId=VAR_034894.
FT   VARIANT     595    595       R -> H (in dbSNP:rs56248469).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041425.
FT   VARIANT     605    605       R -> H (in dbSNP:rs45553041).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018856.
FT   VARIANT     739    739       R -> Q (in IGF1RES; leads to failure of
FT                                processing of the IGF1R proreceptor to
FT                                mature IGF1R; dbSNP:rs121912429).
FT                                {ECO:0000269|PubMed:15928254}.
FT                                /FTId=VAR_034895.
FT   VARIANT     808    808       H -> R (in dbSNP:rs34061581).
FT                                /FTId=VAR_034896.
FT   VARIANT     828    828       A -> T (in dbSNP:rs35224135).
FT                                /FTId=VAR_034897.
FT   VARIANT     857    857       N -> S (in dbSNP:rs45611935).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041426.
FT   VARIANT     865    865       Y -> C (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076248.
FT   VARIANT    1256   1256       R -> S (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076249.
FT   VARIANT    1337   1337       R -> C (in IGF1RES; a benign mutation or
FT                                a rare polymorphism, significant decrease
FT                                in IGF1-induced DNA synthesis;
FT                                significant increase in IGF1-induced AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076250.
FT   VARIANT    1338   1338       A -> T (in dbSNP:rs34102392).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041427.
FT   VARIANT    1347   1347       A -> V (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041428.
FT   MUTAGEN     980    980       Y->F: Reduces tyrosine phosphorylation.
FT                                Abolishes interaction with IRS1 and SHC1.
FT                                Does not abolish interaction with PIK3R1,
FT                                nor with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1033   1033       K->A: Kinase inactive. Abolishes tyrosine
FT                                phosphorylation and abolishes interaction
FT                                with IRS1, SHC1 and PIK3R1.
FT                                {ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1280   1280       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1281   1281       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1346   1346       Y->F: Loss of GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   CONFLICT    928    929       TG -> R (in Ref. 3; BAG11657).
FT                                {ECO:0000305}.
FT   STRAND       37     41       {ECO:0000244|PDB:1IGR}.
FT   HELIX        43     49       {ECO:0000244|PDB:1IGR}.
FT   STRAND       53     57       {ECO:0000244|PDB:1IGR}.
FT   STRAND       59     65       {ECO:0000244|PDB:1IGR}.
FT   STRAND       68     70       {ECO:0000244|PDB:1IGR}.
FT   STRAND       80     83       {ECO:0000244|PDB:1IGR}.
FT   STRAND       85     92       {ECO:0000244|PDB:1IGR}.
FT   HELIX        96     98       {ECO:0000244|PDB:1IGR}.
FT   STRAND      115    121       {ECO:0000244|PDB:1IGR}.
FT   STRAND      138    144       {ECO:0000244|PDB:1IGR}.
FT   HELIX       157    160       {ECO:0000244|PDB:1IGR}.
FT   HELIX       164    166       {ECO:0000244|PDB:1IGR}.
FT   STRAND      168    171       {ECO:0000244|PDB:1IGR}.
FT   HELIX       175    178       {ECO:0000244|PDB:1IGR}.
FT   TURN        183    188       {ECO:0000244|PDB:1IGR}.
FT   STRAND      194    199       {ECO:0000244|PDB:1IGR}.
FT   STRAND      201    203       {ECO:0000244|PDB:1IGR}.
FT   STRAND      205    209       {ECO:0000244|PDB:1IGR}.
FT   HELIX       217    219       {ECO:0000244|PDB:1IGR}.
FT   STRAND      235    241       {ECO:0000244|PDB:1IGR}.
FT   STRAND      247    255       {ECO:0000244|PDB:1IGR}.
FT   STRAND      257    263       {ECO:0000244|PDB:1IGR}.
FT   STRAND      269    271       {ECO:0000244|PDB:1IGR}.
FT   TURN        272    274       {ECO:0000244|PDB:1IGR}.
FT   STRAND      275    277       {ECO:0000244|PDB:1IGR}.
FT   HELIX       279    283       {ECO:0000244|PDB:1IGR}.
FT   STRAND      297    299       {ECO:0000244|PDB:1IGR}.
FT   STRAND      302    306       {ECO:0000244|PDB:1IGR}.
FT   STRAND      311    315       {ECO:0000244|PDB:1IGR}.
FT   STRAND      321    323       {ECO:0000244|PDB:1IGR}.
FT   STRAND      325    327       {ECO:0000244|PDB:1IGR}.
FT   STRAND      331    341       {ECO:0000244|PDB:1IGR}.
FT   HELIX       345    347       {ECO:0000244|PDB:1IGR}.
FT   TURN        349    352       {ECO:0000244|PDB:1IGR}.
FT   STRAND      354    362       {ECO:0000244|PDB:1IGR}.
FT   HELIX       375    378       {ECO:0000244|PDB:1IGR}.
FT   STRAND      383    386       {ECO:0000244|PDB:1IGR}.
FT   STRAND      388    392       {ECO:0000244|PDB:1IGR}.
FT   TURN        415    417       {ECO:0000244|PDB:1IGR}.
FT   STRAND      418    423       {ECO:0000244|PDB:1IGR}.
FT   TURN        434    436       {ECO:0000244|PDB:1IGR}.
FT   STRAND      440    443       {ECO:0000244|PDB:1IGR}.
FT   STRAND      445    451       {ECO:0000244|PDB:1IGR}.
FT   HELIX       456    466       {ECO:0000244|PDB:1IGR}.
FT   STRAND      474    477       {ECO:0000244|PDB:1IGR}.
FT   TURN        479    481       {ECO:0000244|PDB:1IGR}.
FT   HELIX       724    730       {ECO:0000244|PDB:4XSS}.
FT   STRAND      980    982       {ECO:0000244|PDB:1P4O}.
FT   HELIX       983    985       {ECO:0000244|PDB:2ZM3}.
FT   TURN        990    992       {ECO:0000244|PDB:2OJ9}.
FT   HELIX       996    998       {ECO:0000244|PDB:1P4O}.
FT   STRAND      999   1007       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1009   1022       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1025   1034       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1037   1039       {ECO:0000244|PDB:3F5P}.
FT   HELIX      1041   1053       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1054   1056       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1065   1069       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1071   1074       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1076   1080       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1087   1100       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1109   1128       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1138   1140       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1141   1143       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1149   1151       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1155   1157       {ECO:0000244|PDB:3D94}.
FT   HELIX      1159   1164       {ECO:0000244|PDB:1P4O}.
FT   TURN       1165   1167       {ECO:0000244|PDB:3LVP}.
FT   HELIX      1168   1170       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1171   1174       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1176   1178       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1181   1186       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1191   1207       {ECO:0000244|PDB:1P4O}.
FT   TURN       1212   1215       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1218   1226       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1239   1248       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1253   1255       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1259   1266       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1267   1269       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1274   1277       {ECO:0000244|PDB:1P4O}.
FT   TURN       1279   1281       {ECO:0000244|PDB:3O23}.
FT   TURN       1283   1285       {ECO:0000244|PDB:3LVP}.
FT   STRAND     1286   1288       {ECO:0000244|PDB:1P4O}.
SQ   SEQUENCE   1367 AA;  154793 MW;  AE8A735F87F745C8 CRC64;
     MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
     APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
     GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
     LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
     YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
     NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
     QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
     ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
     NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
     VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
     RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
     EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
     YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
     KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
     VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
     LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
     CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
     VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
     EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
     SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC
//
ID   IGF1R_RAT               Reviewed;        1370 AA.
AC   P24062;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   07-SEP-2016, entry version 162.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=Igf1r;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7758167; DOI=10.1161/01.RES.76.6.963;
RA   Du J., Delafontaine P.;
RT   "Inhibition of vascular smooth muscle cell growth through antisense
RT   transcription of a rat insulin-like growth factor I receptor cDNA.";
RL   Circ. Res. 76:963-972(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-364.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=2477843; DOI=10.1073/pnas.86.19.7451;
RA   Werner H., Woloschak M., Adamo M., Shen-Orr Z., Roberts C.T. Jr.,
RA   Leroith D.;
RT   "Developmental regulation of the rat insulin-like growth factor I
RT   receptor gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7451-7455(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 913-1017.
RX   PubMed=1530648; DOI=10.1016/0006-291X(92)91287-Z;
RA   Kurachi H., Jobo K., Ohta M., Kawasaki T., Itoh N.;
RT   "A new member of the insulin receptor family, insulin receptor-related
RT   receptor, is expressed preferentially in the kidney.";
RL   Biochem. Biophys. Res. Commun. 187:934-939(1992).
RN   [4]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16803852; DOI=10.1152/ajpendo.00565.2005;
RA   Johansson G.S., Arnqvist H.J.;
RT   "Insulin and IGF-I action on insulin receptors, IGF-I receptors, and
RT   hybrid insulin/IGF-I receptors in vascular smooth muscle cells.";
RL   Am. J. Physiol. 291:E1124-E1130(2006).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity
CC       and IGF2 and insulin (INS) with a lower affinity. The activated
CC       IGF1R is involved in cell growth and survival control. IGF1R is
CC       crucial for tumor transformation and survival of malignant cell.
CC       Ligand binding activates the receptor kinase, leading to receptor
CC       autophosphorylation, and tyrosines phosphorylation of multiple
CC       substrates, that function as signaling adapter proteins including,
CC       the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
CC       Phosphorylation of IRSs proteins lead to the activation of two
CC       main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK
CC       pathway. The result of activating the MAPK pathway is increased
CC       cellular proliferation, whereas activating the PI3K pathway
CC       inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1), leading to activation of several downstream
CC       substrates, including protein AKT/PKB. AKT phosphorylation, in
CC       turn, enhances protein synthesis through mTOR activation and
CC       triggers the antiapoptotic effects of IGFIR through
CC       phosphorylation and inactivation of BAD. In parallel to PI3K-
CC       driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1
CC       or Shc leads to recruitment of Ras and activation of the ras-MAPK
CC       pathway. In addition to these two main signaling pathways IGF1R
CC       signals also through the Janus kinase/signal transducer and
CC       activator of transcription pathway (JAK/STAT). Phosphorylation of
CC       JAK proteins can lead to phosphorylation/activation of signal
CC       transducers and activators of transcription (STAT) proteins. In
CC       particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates
CC       gene transcription and may be responsible for the transforming
CC       activity. JNK kinases can also be activated by the IGF1R. IGF1
CC       exerts inhibiting activities on JNK activation via phosphorylation
CC       and inhibition of MAP3K5/ASK1, which is able to directly associate
CC       with the IGF1R (By similarity). When present in a hybrid receptor
CC       with INSR, binds IGF1 (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16803852}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation at Tyr-1162,
CC       Tyr-1166 and Tyr-1167 on the kinase activation loop;
CC       phosphorylation at all three tyrosine residues is required for
CC       optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807,
CC       PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole,
CC       3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine,
CC       pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin
CC       (PPP), tyrphostin derivatives. While most inhibitors bind to the
CC       ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation loop
CC       (By similarity). Dephosphorylated by PTPN1 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10. Interacts with RACK1 (By similarity). Interacts with
CC       SOCS1, SOCS2 and SOCS3 (By similarity). Interacts with 14-3-3
CC       proteins (By similarity). Interacts with NMD2 (By similarity).
CC       Interacts with MAP3K5 (By similarity). Interacts with STAT3. Found
CC       in a ternary complex with IGF1 and ITGAV:ITGB3 or ITGA6:ITGB4 (By
CC       similarity). {ECO:0000250|UniProtKB:P08069}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner; Tyr-
CC       1166 is predominantly phosphorylated first, followed by
CC       phosphorylation of Tyr-1162 and Tyr-1167. While every single
CC       phosphorylation increases kinase activity, all three tyrosine
CC       residues in the kinase activation loop (Tyr-1162, Tyr-1166 and
CC       Tyr-1167) have to be phosphorylated for optimal activity. Can be
CC       autophosphorylated at additional tyrosine residues (in vitro).
CC       Autophosphorylated is followed by phosphorylation of juxtamembrane
CC       tyrosines and C-terminal serines. Phosphorylation of Tyr-981 is
CC       required for IRS1- and SHC1-binding. Phosphorylation of Ser-1279
CC       by GSK-3beta restrains kinase activity and promotes cell surface
CC       expression, it requires a priming phosphorylation at Ser-1283 (By
CC       similarity). Dephosphorylated by PTPN1. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated at Lys-1169 and Lys-1172 through both 'Lys-
CC       48' and 'Lys-29' linkages, promoting receptor endocytosis and
CC       subsequent degradation by the proteasome. Ubiquitination is
CC       facilitated by pre-existing phosphorylation (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP).
CC       Undergoes metalloprotease-dependent constitutive ectodomain
CC       shedding to produce a membrane-anchored 52 kDa C-Terminal fragment
CC       which is further processed by presenilin gamma-secretase to yield
CC       an intracellular 50 kDa fragment (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L29232; AAA41392.1; -; mRNA.
DR   EMBL; M27293; AAA41384.1; -; mRNA.
DR   RefSeq; NP_434694.1; NM_052807.2.
DR   UniGene; Rn.10957; -.
DR   UniGene; Rn.165078; -.
DR   ProteinModelPortal; P24062; -.
DR   SMR; P24062; 31-492, 978-1291.
DR   BioGrid; 247747; 2.
DR   STRING; 10116.ENSRNOP00000019267; -.
DR   BindingDB; P24062; -.
DR   ChEMBL; CHEMBL1075098; -.
DR   iPTMnet; P24062; -.
DR   PhosphoSite; P24062; -.
DR   PaxDb; P24062; -.
DR   PRIDE; P24062; -.
DR   GeneID; 25718; -.
DR   KEGG; rno:25718; -.
DR   UCSC; RGD:2869; rat.
DR   CTD; 3480; -.
DR   RGD; 2869; Igf1r.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P24062; -.
DR   KO; K05087; -.
DR   OrthoDB; EOG091G00GE; -.
DR   PhylomeDB; P24062; -.
DR   BRENDA; 2.7.10.1; 5301.
DR   PRO; PR:P24062; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Bgee; ENSRNOG00000014187; -.
DR   Genevisible; P24062; RN.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005901; C:caveola; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043005; C:neuron projection; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0030315; C:T-tubule; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IPI:RGD.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; ISS:UniProtKB.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0007409; P:axonogenesis; IMP:RGD.
DR   GO; GO:1904045; P:cellular response to aldosterone; IEP:RGD.
DR   GO; GO:1904385; P:cellular response to angiotensin; IDA:RGD.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEP:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEP:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; IEP:RGD.
DR   GO; GO:0090398; P:cellular senescence; IEP:RGD.
DR   GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR   GO; GO:0030010; P:establishment of cell polarity; IMP:RGD.
DR   GO; GO:0044849; P:estrous cycle; IMP:RGD.
DR   GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR   GO; GO:0051389; P:inactivation of MAPKK activity; ISS:UniProtKB.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:1904193; P:negative regulation of cholangiocyte apoptotic process; IMP:RGD.
DR   GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IMP:RGD.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IMP:RGD.
DR   GO; GO:0031175; P:neuron projection development; IDA:RGD.
DR   GO; GO:0048680; P:positive regulation of axon regeneration; IMP:RGD.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:RGD.
DR   GO; GO:0051054; P:positive regulation of DNA metabolic process; IMP:RGD.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IMP:RGD.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0090031; P:positive regulation of steroid hormone biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; IDA:RGD.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:1902065; P:response to L-glutamate; IDA:RGD.
DR   GO; GO:0033197; P:response to vitamin E; IEP:RGD.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cell membrane; Cleavage on pair of basic residues;
KW   Complete proteome; Disulfide bond; Glycoprotein; Isopeptide bond;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     30       {ECO:0000255}.
FT   CHAIN        31    737       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016685.
FT   CHAIN       742   1370       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016686.
FT   TOPO_DOM    742    936       Extracellular. {ECO:0000255}.
FT   TRANSMEM    937    960       Helical. {ECO:0000255}.
FT   TOPO_DOM    961   1370       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      490    610       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      611    709       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      835    928       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1000   1275       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1006   1014       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       978    981       IRS1- and SHC1-binding. {ECO:0000250}.
FT   ACT_SITE   1136   1136       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1034   1034       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1162   1162       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1166   1166       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1167   1167       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1279   1279       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES    1283   1283       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q60751}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    245    245       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    314    314       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    418    418       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    439    439       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    535    535       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    608    608       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    623    623       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    641    641       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    748    748       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    757    757       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    765    765       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    901    901       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    914    914       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     33     52       {ECO:0000250}.
FT   DISULFID    150    178       {ECO:0000250}.
FT   DISULFID    182    205       {ECO:0000250}.
FT   DISULFID    192    211       {ECO:0000250}.
FT   DISULFID    215    224       {ECO:0000250}.
FT   DISULFID    219    230       {ECO:0000250}.
FT   DISULFID    231    239       {ECO:0000250}.
FT   DISULFID    235    248       {ECO:0000250}.
FT   DISULFID    251    260       {ECO:0000250}.
FT   DISULFID    264    276       {ECO:0000250}.
FT   DISULFID    282    303       {ECO:0000250}.
FT   DISULFID    307    321       {ECO:0000250}.
FT   DISULFID    324    328       {ECO:0000250}.
FT   DISULFID    332    354       {ECO:0000250}.
FT   DISULFID    456    489       {ECO:0000250}.
FT   CROSSLNK   1169   1169       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08069}.
FT   CROSSLNK   1172   1172       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08069}.
FT   CONFLICT    985    986       AD -> PY (in Ref. 3; no nucleotide
FT                                entry). {ECO:0000305}.
SQ   SEQUENCE   1370 AA;  155396 MW;  A5946897A41CB145 CRC64;
     MKSGSGGGSP TSLWGLVFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGFLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTIDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTLEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSVCG KRACTENNEC CHPECLGSCH
     TPDDNTTCVA CRHYYYKGVC VPACPPGTYR FEGWRCVDRD FCANIPNAES SDSDGFVIHD
     GECMQECPSG FIRNSTQSMY CIPCEGPCPK VCGDEEKKTK TIDSVTSAQM LQGCTILKGN
     LLINIRRGNN IASELENFMG LIEVVTGYVK IRHSHALVSL SFLKNLRLIL GEEQLEGNYS
     FYVLDNQNLQ QLWDWNHRNL TVRSGKMYFA FNPKLCVSEI YRMEEVTGTK GRQSKGDINT
     RNNGERASCE SDVLRFTSTT TWKNRIIITW HRYRPPDYRD LISFTVYYKE APFKNVTEYD
     GQDACGSNSW NMVDVDLPPN KEGEPGILLH GLKPWTQYAV YVKAVTLTMV ENDHIRGAKS
     EILYIRTNAS VPSIPLDVLS ASNSSSQLIV KWNPPTLPNG NLSYYIVRWQ RQPQDGYLFR
     HNYCSKDKIP IRKYADGTID VEEVTENPKT EVCGGDKGPC CACPKTEAEK QAEKEEAEYR
     KVFENFLHNS IFVPRPERRR RDVLQVANTT MSSRSRNTTV ADTYNITDPE EFETEYPFFE
     SRVDNKERTV ISNLRPFTLY RIDIHSCNHE AEKLGCSASN FVFARTMPAE GADDIPGPVT
     WEPRPENSIF LKWPEPENPN GLILMYEIKY GSQVEDQREC VSRQEYRKYG GAKLNRLNPG
     NYTARIQATS LSGNGSWTDP VFFYVPAKTT YENFMHLIIA LPVAILLIVG GLVIMLYVFH
     RKRNNSRLGN GVLYASVNPE YFSAADVYVP DEWEVAREKI TMNRELGQGS FGMVYEGVAK
     GVVKDEPETR VAIKTVNEAA SMRERIEFLN EASVMKEFNC HHVVRLLGVV SQGQPTLVIM
     ELMTRGDLKS YLRSLRPEVE NNLVLIPPSL SKMIQMAGEI ADGMAYLNAN KFVHRDLAAR
     NCMVAEDFTV KIGDFGMTRD IYETDYYRKG GKGLLPVRWM SPESLKDGVF TTHSDVWSFG
     VVLWEIATLA EQPYQGLSNE QVLRFVMEGG LLDKPDNCPD MLFELMRMCW QYNPKMRPSF
     LEIIGSIKDE MEPSFQEVSF YYSEENKPPE PEELEMELEL EPENMESVPL DPSASSASLP
     LPERHSGHKA ENGPGVLVLR ASFDERQPYA HMNGGRANER ALPLPQSSTC
//
ID   IGF1R_MOUSE             Reviewed;        1373 AA.
AC   Q60751; O70438; Q62123;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 3.
DT   07-SEP-2016, entry version 168.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=Igf1r;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Navarro M., Garandel V., Barenton B., Bernardi H.;
RT   "Cloning of cDNA for the mouse insulin-like growth factor I
RT   receptor.";
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-329.
RC   STRAIN=CD-1; TISSUE=Kidney;
RX   PubMed=8234298; DOI=10.1073/pnas.90.21.10360;
RA   Wada J., Liu Z.Z., Alvares K., Kumar A., Wallner E.I., Makino H.,
RA   Kanwar Y.S.;
RT   "Cloning of cDNA for the alpha subunit of mouse insulin-like growth
RT   factor I receptor and the role of the receptor in metanephric
RT   development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10360-10364(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1134-1203.
RX   PubMed=2482828; DOI=10.1016/0378-1119(89)90465-4;
RA   Wilks A.F., Kurban R.R., Hovens C.M., Ralph S.J.;
RT   "The application of the polymerase chain reaction to cloning members
RT   of the protein tyrosine kinase family.";
RL   Gene 85:67-74(1989).
RN   [4]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=8402901; DOI=10.1016/S0092-8674(05)80084-4;
RA   Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A.;
RT   "Mice carrying null mutations of the genes encoding insulin-like
RT   growth factor I (Igf-1) and type 1 IGF receptor (Igf1r).";
RL   Cell 75:59-72(1993).
RN   [5]
RP   ENZYME REGULATION.
RX   PubMed=11884589; DOI=10.1128/MCB.22.7.1998-2010.2002;
RA   Buckley D.A., Cheng A., Kiely P.A., Tremblay M.L., O'Connor R.;
RT   "Regulation of insulin-like growth factor type I (IGF-I) receptor
RT   kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and
RT   enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-
RT   1B-deficient fibroblasts.";
RL   Mol. Cell. Biol. 22:1998-2010(2002).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-748 AND ASN-901.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [7]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-639; ASN-641; ASN-757 AND
RP   ASN-765.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney, Lung, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [9]
RP   PHOSPHORYLATION AT SER-1280 AND SER-1284.
RX   PubMed=22685298; DOI=10.1074/jbc.M112.385757;
RA   Kelly G.M., Buckley D.A., Kiely P.A., Adams D.R., O'Connor R.;
RT   "Serine phosphorylation of the insulin-like growth factor I (IGF-1)
RT   receptor C-terminal tail restrains kinase activity and cell growth.";
RL   J. Biol. Chem. 287:28180-28194(2012).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity
CC       and IGF2 and insulin (INS) with a lower affinity. The activated
CC       IGF1R is involved in cell growth and survival control. IGF1R is
CC       crucial for tumor transformation and survival of malignant cell.
CC       Ligand binding activates the receptor kinase, leading to receptor
CC       autophosphorylation, and tyrosines phosphorylation of multiple
CC       substrates, that function as signaling adapter proteins including,
CC       the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
CC       Phosphorylation of IRSs proteins lead to the activation of two
CC       main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK
CC       pathway. The result of activating the MAPK pathway is increased
CC       cellular proliferation, whereas activating the PI3K pathway
CC       inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1), leading to activation of several downstream
CC       substrates, including protein AKT/PKB. AKT phosphorylation, in
CC       turn, enhances protein synthesis through mTOR activation and
CC       triggers the antiapoptotic effects of IGFIR through
CC       phosphorylation and inactivation of BAD. In parallel to PI3K-
CC       driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1
CC       or Shc leads to recruitment of Ras and activation of the ras-MAPK
CC       pathway. In addition to these two main signaling pathways IGF1R
CC       signals also through the Janus kinase/signal transducer and
CC       activator of transcription pathway (JAK/STAT). Phosphorylation of
CC       JAK proteins can lead to phosphorylation/activation of signal
CC       transducers and activators of transcription (STAT) proteins. In
CC       particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates
CC       gene transcription and may be responsible for the transforming
CC       activity. JNK kinases can also be activated by the IGF1R. IGF1
CC       exerts inhibiting activities on JNK activation via phosphorylation
CC       and inhibition of MAP3K5/ASK1, which is able to directly associate
CC       with the IGF1R (By similarity). When present in a hybrid receptor
CC       with INSR, binds IGF1 (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation at Tyr-1163,
CC       Tyr-1167 and Tyr-1168 on the kinase activation loop;
CC       phosphorylation at all three tyrosine residues is required for
CC       optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807,
CC       PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole,
CC       3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine,
CC       pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin
CC       (PPP), tyrphostin derivatives. While most inhibitors bind to the
CC       ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation loop
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10. Interacts with RACK1. Interacts with SOCS1, SOCS2 and
CC       SOCS3. Interacts with 14-3-3 proteins. Interacts with NMD2.
CC       Interacts with MAP3K5. Interacts with STAT3. Found in a ternary
CC       complex with IGF1 and ITGAV:ITGB3 or ITGA6:ITGB4 (By similarity).
CC       {ECO:0000250|UniProtKB:P08069}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner; Tyr-
CC       1167 is predominantly phosphorylated first, followed by
CC       phosphorylation of Tyr-1163 and Tyr-1168. While every single
CC       phosphorylation increases kinase activity, all three tyrosine
CC       residues in the kinase activation loop (Tyr-1163, Tyr-1167 and
CC       Tyr-1168) have to be phosphorylated for optimal activity. Can be
CC       autophosphorylated at additional tyrosine residues (in vitro).
CC       Autophosphorylated is followed by phosphorylation of juxtamembrane
CC       tyrosines and C-terminal serines. Phosphorylation of Tyr-981 is
CC       required for IRS1- and SHC1-binding (By similarity).
CC       Phosphorylation of Ser-1280 by GSK-3beta restrains kinase activity
CC       and promotes cell surface expression, it requires a priming
CC       phosphorylation at Ser-1284. Dephosphorylated by PTPN1.
CC       {ECO:0000250, ECO:0000269|PubMed:22685298}.
CC   -!- PTM: Polyubiquitinated at Lys-1170 and Lys-1173 through both 'Lys-
CC       48' and 'Lys-29' linkages, promoting receptor endocytosis and
CC       subsequent degradation by the proteasome. Ubiquitination is
CC       facilitated by pre-existing phosphorylation (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP).
CC       Undergoes metalloprotease-dependent constitutive ectodomain
CC       shedding to produce a membrane-anchored 52 kDa C-Terminal fragment
CC       which is further processed by presenilin gamma-secretase to yield
CC       an intracellular 50 kDa fragment (By similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Deficient mice are 45% of the size of wild-
CC       type littermates at birth, and die shortly due to severe organ
CC       hypoplasia. {ECO:0000269|PubMed:8402901}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF056187; AAC12782.1; -; mRNA.
DR   EMBL; U00182; AAC52123.1; -; mRNA.
DR   EMBL; M33422; AAA40013.1; -; mRNA.
DR   PIR; A48805; A48805.
DR   PIR; JH0113; JH0113.
DR   RefSeq; NP_034643.2; NM_010513.2.
DR   UniGene; Mm.275742; -.
DR   ProteinModelPortal; Q60751; -.
DR   SMR; Q60751; 31-492, 986-1288.
DR   BioGrid; 200548; 5.
DR   IntAct; Q60751; 2.
DR   MINT; MINT-219894; -.
DR   STRING; 10090.ENSMUSP00000005671; -.
DR   BindingDB; Q60751; -.
DR   ChEMBL; CHEMBL5381; -.
DR   iPTMnet; Q60751; -.
DR   PhosphoSite; Q60751; -.
DR   MaxQB; Q60751; -.
DR   PaxDb; Q60751; -.
DR   PeptideAtlas; Q60751; -.
DR   PRIDE; Q60751; -.
DR   GeneID; 16001; -.
DR   KEGG; mmu:16001; -.
DR   CTD; 3480; -.
DR   MGI; MGI:96433; Igf1r.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; Q60751; -.
DR   KO; K05087; -.
DR   PhylomeDB; Q60751; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Igf1r; mouse.
DR   PRO; PR:Q60751; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; ENSMUSG00000005533; -.
DR   CleanEx; MM_IGF1R; -.
DR   GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IDA:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0030315; C:T-tubule; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0043559; F:insulin binding; ISO:MGI.
DR   GO; GO:0005158; F:insulin receptor binding; ISO:MGI.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; ISS:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; ISO:MGI.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IGI:CACAO.
DR   GO; GO:0007420; P:brain development; IMP:MGI.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IMP:MGI.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:MGI.
DR   GO; GO:0008544; P:epidermis development; IMP:MGI.
DR   GO; GO:0031017; P:exocrine pancreas development; IMP:MGI.
DR   GO; GO:0006955; P:immune response; ISO:MGI.
DR   GO; GO:0051389; P:inactivation of MAPKK activity; ISO:MGI.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030238; P:male sex determination; IMP:MGI.
DR   GO; GO:0030879; P:mammary gland development; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:MGI.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IMP:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:MGI.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:0051446; P:positive regulation of meiotic cell cycle; IGI:CACAO.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IGI:CACAO.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IMP:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0051262; P:protein tetramerization; ISS:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; ISO:MGI.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Cleavage on pair of basic residues;
KW   Complete proteome; Disulfide bond; Glycoprotein; Isopeptide bond;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     30       {ECO:0000255}.
FT   CHAIN        31    737       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016683.
FT   CHAIN       742   1373       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016684.
FT   TOPO_DOM    742    936       Extracellular. {ECO:0000255}.
FT   TRANSMEM    937    960       Helical. {ECO:0000255}.
FT   TOPO_DOM    961   1373       Cytoplasmic. {ECO:0000250}.
FT   DOMAIN      490    610       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      611    709       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      735    829       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      835    928       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1000   1276       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1006   1014       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       978    981       IRS1- and SHC1-binding. {ECO:0000250}.
FT   ACT_SITE   1137   1137       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1034   1034       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1163   1163       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1167   1167       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1168   1168       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1280   1280       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000269|PubMed:22685298}.
FT   MOD_RES    1284   1284       Phosphoserine.
FT                                {ECO:0000269|PubMed:22685298}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    245    245       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    314    314       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    418    418       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    439    439       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    535    535       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    608    608       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    623    623       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    639    639       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    641    641       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    748    748       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    757    757       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    765    765       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    901    901       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    914    914       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     33     52       {ECO:0000250}.
FT   DISULFID    150    178       {ECO:0000250}.
FT   DISULFID    182    205       {ECO:0000250}.
FT   DISULFID    192    211       {ECO:0000250}.
FT   DISULFID    215    224       {ECO:0000250}.
FT   DISULFID    219    230       {ECO:0000250}.
FT   DISULFID    231    239       {ECO:0000250}.
FT   DISULFID    235    248       {ECO:0000250}.
FT   DISULFID    251    260       {ECO:0000250}.
FT   DISULFID    264    276       {ECO:0000250}.
FT   DISULFID    282    303       {ECO:0000250}.
FT   DISULFID    307    321       {ECO:0000250}.
FT   DISULFID    324    328       {ECO:0000250}.
FT   DISULFID    332    354       {ECO:0000250}.
FT   DISULFID    456    489       {ECO:0000250}.
FT   CROSSLNK   1170   1170       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08069}.
FT   CROSSLNK   1173   1173       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08069}.
FT   CONFLICT     58     59       FL -> LV (in Ref. 2; AAC52123).
FT                                {ECO:0000305}.
FT   CONFLICT    260    260       C -> S (in Ref. 2; AAC52123).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       D -> G (in Ref. 2; AAC52123).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       E -> V (in Ref. 2; AAC52123).
FT                                {ECO:0000305}.
FT   CONFLICT    324    324       C -> S (in Ref. 2; AAC52123).
FT                                {ECO:0000305}.
FT   CONFLICT   1134   1134       V -> I (in Ref. 3; AAA40013).
FT                                {ECO:0000305}.
FT   CONFLICT   1145   1145       V -> D (in Ref. 3; AAA40013).
FT                                {ECO:0000305}.
FT   CONFLICT   1202   1202       V -> I (in Ref. 3; AAA40013).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1373 AA;  155788 MW;  5EE3B72EF101E379 CRC64;
     MKSGSGGGSP TSLWGLVFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGFLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTIDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTLEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSVCG KRACTENNEC CHPECLGSCH
     TPDDNTTCVA CRHYYYKGVC VPACPPGTYR FEGWRCVDRD FCANIPNAES SDSDGFVIHD
     DECMQECPSG FIRNSTQSMY CIPCEGPCPK VCGDEEKKTK TIDSVTSAQM LQGCTILKGN
     LLINIRRGNN IASELENFMG LIEVVTGYVK IRHSHALVSL SFLKNLRLIL GEEQLEGNYS
     FYVLDNQNLQ QLWDWNHRNL TVRSGKMYFA FNPKLCVSEI YRMEEVTGTK GRQSKGDINT
     RNNGERASCE SDVLRFTSTT TWKNRIIITW HRYRPPDYRD LISFTVYYKE APFKNVTEYD
     GQDACGSNSW NMVDVDLPPN KEGEPGILLH GLKPWTQYAV YVKAVTLTMV ENDHIRGAKS
     EILYIRTNAS VPSIPLDVLS ASNSSSQLIV KWNPPTLPNG NLSYYIVRWQ RQPQDGYLYR
     HNYCSKDKIP IRKYADGTID VEEVTENPKT EVCGGDKGPC CACPKTEAEK QAEKEEAEYR
     KVFENFLHNS IFVPRPERRR RDVMQVANTT MSSRSRNTTV ADTYNITDPE EFETEYPFFE
     SRVDNKERTV ISNLRPFTLY RIDIHSCNHE AEKLGCSASN FVFARTMPAE GADDIPGPVT
     WEPRPENSIF LKWPEPENPN GLILMYEIKY GSQVEDQREC VSRQEYRKYG GAKLNRLNPG
     NYTARIQATS LSGNGSWTDP VFFYVPAKTT YENFMHLIIA LPVAILLIVG GLVIMLYVFH
     RKRNNSRLGN GVLYASVNPE YFSAADVYVP DEWEVAREKI TMNRELGQGS FGMVYEGVAK
     GVVKDEPETR VAIKTVNEAA SMRERIEFLN EASVMKEFNC HHVVRLLGVV SQGQPTLVIM
     ELMTRGDLKS YLRSLRPEVE QNNLVLIPPS LSKMIQMAGE IADGMAYLNA NKFVHRDLAA
     RNCMVAEDFT VKIGDFGMTR DIYETDYYRK GGKGLLPVRW MSPESLKDGV FTTHSDVWSF
     GVVLWEIATL AEQPYQGLSN EQVLRFVMEG GLLDKPDNCP DMLFELMRMC WQYNPKMRPS
     FLEIIGSIKD EMEPSFQEVS FYYSEENKPP EPEELEMELE MEPENMESVP LDPSASSASL
     PLPERHSGHK AENGPGPGVL VLRASFDERQ PYAHMNGGRA NERALPLPQS STC
//
ID   INSRR_MOUSE             Reviewed;        1300 AA.
AC   Q9WTL4; B2RQC5;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   07-SEP-2016, entry version 138.
DE   RecName: Full=Insulin receptor-related protein;
DE            Short=IRR;
DE            EC=2.7.10.1;
DE   AltName: Full=IR-related receptor;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein alpha chain;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein beta chain;
DE   Flags: Precursor;
GN   Name=Insrr; Synonyms=Irr;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Pancreas;
RX   PubMed=10342810; DOI=10.2337/diabetes.48.6.1237;
RA   Hirayama I., Tamemoto H., Yokota H., Kubo S.-K., Wang J., Kuwano H.,
RA   Nagamachi Y., Takeuchi T., Izumi T.;
RT   "Insulin receptor-related receptor is expressed in pancreatic beta-
RT   cells and stimulates tyrosine phosphorylation of insulin receptor
RT   substrate-1 and-2.";
RL   Diabetes 48:1237-1244(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=11463843; DOI=10.1128/MCB.21.16.5624-5630.2001;
RA   Kitamura T., Kido Y., Nef S., Merenmies J., Parada L.F., Accili D.;
RT   "Preserved pancreatic beta-cell development and function in mice
RT   lacking the insulin receptor-related receptor.";
RL   Mol. Cell. Biol. 21:5624-5630(2001).
RN   [5]
RP   DISRUPTION PHENOTYPE, FUNCTION, AND AUTOPHOSPHORYLATION.
RX   PubMed=21641549; DOI=10.1016/j.cmet.2011.03.022;
RA   Deyev I.E., Sohet F., Vassilenko K.P., Serova O.V., Popova N.V.,
RA   Zozulya S.A., Burova E.B., Houillier P., Rzhevsky D.I.,
RA   Berchatova A.A., Murashev A.N., Chugunov A.O., Efremov R.G.,
RA   Nikol'sky N.N., Bertelli E., Eladari D., Petrenko A.G.;
RT   "Insulin receptor-related receptor as an extracellular alkali
RT   sensor.";
RL   Cell Metab. 13:679-689(2011).
CC   -!- FUNCTION: Receptor with tyrosine-protein kinase activity.
CC       Functions as a pH sensing receptor which is activated by increased
CC       extracellular pH. Activates an intracellular signaling pathway
CC       that involves IRS1 and AKT1/PKB. {ECO:0000269|PubMed:21641549}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the islets as well as in
CC       pancreatic beta-cells. {ECO:0000269|PubMed:10342810}.
CC   -!- DOMAIN: The extracellular domain is required for sensing
CC       alterations in external pH. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues between pH 7.9 and pH
CC       10.5.
CC   -!- DISRUPTION PHENOTYPE: Renal function is impaired, with reduced
CC       ability of the collecting duct to adapt to alkalosis.
CC       {ECO:0000269|PubMed:11463843, ECO:0000269|PubMed:21641549}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB007135; BAA77835.1; -; mRNA.
DR   EMBL; CH466547; EDL15346.1; -; Genomic_DNA.
DR   EMBL; BC137855; AAI37856.1; -; mRNA.
DR   CCDS; CCDS17454.1; -.
DR   RefSeq; NP_035962.2; NM_011832.2.
DR   UniGene; Mm.42041; -.
DR   ProteinModelPortal; Q9WTL4; -.
DR   SMR; Q9WTL4; 28-911, 913-1292.
DR   STRING; 10090.ENSMUSP00000029711; -.
DR   iPTMnet; Q9WTL4; -.
DR   PhosphoSite; Q9WTL4; -.
DR   PaxDb; Q9WTL4; -.
DR   PeptideAtlas; Q9WTL4; -.
DR   PRIDE; Q9WTL4; -.
DR   Ensembl; ENSMUST00000029711; ENSMUSP00000029711; ENSMUSG00000005640.
DR   Ensembl; ENSMUST00000107582; ENSMUSP00000103208; ENSMUSG00000005640.
DR   GeneID; 23920; -.
DR   KEGG; mmu:23920; -.
DR   UCSC; uc008psy.2; mouse.
DR   CTD; 3645; -.
DR   MGI; MGI:1346037; Insrr.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; Q9WTL4; -.
DR   KO; K05086; -.
DR   OMA; FARTMPH; -.
DR   OrthoDB; EOG091G00GE; -.
DR   TreeFam; TF351636; -.
DR   PRO; PR:Q9WTL4; -.
DR   Proteomes; UP000000589; Chromosome 3.
DR   Bgee; ENSMUSG00000005640; -.
DR   CleanEx; MM_INSRR; -.
DR   Genevisible; Q9WTL4; MM.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0071469; P:cellular response to alkaline pH; IDA:UniProtKB.
DR   GO; GO:0030238; P:male sex determination; IMP:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR028792; INSRR.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF338; PTHR24416:SF338; 3.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cleavage on pair of basic residues; Complete proteome;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1300       Insulin receptor-related protein.
FT                                /FTId=PRO_0000016704.
FT   CHAIN        27    742       Insulin receptor-related protein alpha
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016705.
FT   CHAIN       747   1300       Insulin receptor-related protein beta
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016706.
FT   TOPO_DOM    747    921       Extracellular. {ECO:0000255}.
FT   TRANSMEM    922    943       Helical. {ECO:0000255}.
FT   TOPO_DOM    944   1300       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      483    603       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      607    707       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      818    913       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      979   1254       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     985    993       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1115   1115       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1013   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1145   1145       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1146   1146       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     47     47       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    885    885       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    214    222       {ECO:0000250}.
FT   DISULFID    216    228       {ECO:0000250}.
FT   DISULFID    229    237       {ECO:0000250}.
FT   DISULFID    233    246       {ECO:0000250}.
FT   DISULFID    249    258       {ECO:0000250}.
FT   DISULFID    262    274       {ECO:0000250}.
FT   DISULFID    280    300       {ECO:0000250}.
FT   DISULFID    304    317       {ECO:0000250}.
FT   DISULFID    320    324       {ECO:0000250}.
FT   DISULFID    657    864       Interchain (between alpha and beta
FT                                chains). {ECO:0000255}.
FT   CONFLICT    272    272       W -> G (in Ref. 1; BAA77835).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1300 AA;  144875 MW;  3DE9FC3C53DB96BB CRC64;
     MAVPALWPWG VHLLMSLLSL GSGLDTLEVC PSLDIRSEVT ELRRLENCSV VEGHLQILLM
     FAATGEDFRG LSFPRLTQVT DYLLLFRVYG LESLRDLFPN LTVIRGTRLF LGYALIIFEM
     PHLRDVGLPS LGAVLRGAVR VEKNQELCHL STIDWGLLQP APGTNHIVGN KLGEECADVC
     PGVLGAAGEP CSRTTFSGRT DYRCWTSSHC QKVCPCPRGM ACTAGGDCCH SECLGGCSQP
     EDPRACVACR HLYFQGVCLR ACPPGTYQYE SWRCVTAELC AHLREVPGLA TTFGIYEGSC
     LAQCPPGFTR NGSSIFCHKC EGLCPKECKV GTKTIDSVQA TQDLVGCTHV EGNLILNLRQ
     GYNLEPELQR NLGLVETITG FLKIKHSFAL VTLGFFKNLK LIRGDSMVDG NYTLYVLDNQ
     NLQQLGSWVT AGLTIPVGKI YFAFNPRLCL EHIYQLEEVT GTRGRQSKAE INPRTNGDRA
     ACQTRTLRFV FNLTEEDRIL LRWERYEPLE ARDLLSFIVY YKESPFQNAT EHVGPDACGT
     QSWNLLDVEL PLSRTQEPGV TLAPLKPWTQ YAVFVRAITL TTAEDSPHQG AQSPIVYLRT
     LPAAPTVPQD VISTSNSSSH LLVRWKPPVQ RNGNITYYLV LWQRLAEDGD LYINDYCHRG
     LRLPTSSHDT RFDREDPALE AEPEQGCCPC QHSPPGQALP ALEAQEVTFQ KKFENFLHHA
     ITIPKAPWKV TSINKNPQRD SERHRREAGL LRLGKNNSDF EIQEDKVPRE RAILSGLRHF
     TEYRIDIHAC NHAAHTVGCS AATFVFARTM PHREADGIPG KVAWKAAGKS SVTLHWLEPP
     DPNGLILKYE IKYRRLGEEA TVLCVSRLRY AKVGGVHLAL LPPGNYSAKV RATSLAGNGS
     WTDGVTFYIT DLEEEDTGGM RIFLTVTPVG FMLLVTLAAL GFFYSRKRNS TLYTSVNPEY
     FSASHMYVPD EWEVPREQIA IIRELGQGSF GMVYEGLARG LEAGEESTPV ALKTVNELAS
     ARERVEFLKE ASVMKAFKCH HVVRLLGVVS QGQPTLVIME LMTRGDLKSH LRSLRPEAEN
     NPGLPQPALS DMIQMAGEIA DGMAYLAAKK FVHRDLAARN CMVSQDFTVK IGDFGMTRDV
     YETDYYRKGG KGLLPVRWMA PESLKDGIFT THSDVWSFGV VLWEIVTLAE QPYQGLSNEQ
     VLKFVMDGGV LEELENCPIQ LQELMRLCWQ HSPRLRPTFV HILDRIQDEL RPSFRLCSFY
     YSPECQRGQA SLLPTEAEPD SPPTLNGASD YSAPNGGPGH
//
ID   INSRR_HUMAN             Reviewed;        1297 AA.
AC   P14616; O60724; Q5VZS3;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   07-SEP-2016, entry version 166.
DE   RecName: Full=Insulin receptor-related protein;
DE            Short=IRR;
DE            EC=2.7.10.1;
DE   AltName: Full=IR-related receptor;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein alpha chain;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein beta chain;
DE   Flags: Precursor;
GN   Name=INSRR; Synonyms=IRR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=10226785;
RA   Haenze J., Berthold A., Klammt J., Gallaher B., Siebler T.,
RA   Kratzsch J., Elmlinger M., Kiess W.;
RT   "Cloning and sequencing of the complete cDNA encoding the human
RT   insulin receptor related receptor.";
RL   Horm. Metab. Res. 31:77-79(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-1297.
RX   PubMed=2768234;
RA   Shier P., Watt V.M.;
RT   "Primary structure of a putative receptor for a ligand of the insulin
RT   family.";
RL   J. Biol. Chem. 264:14605-14608(1989).
RN   [5]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-127; VAL-161; HIS-244; ARG-246;
RP   GLN-278; CYS-554; LEU-928 AND GLU-1065.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF 1145-TYR-TYR-1146, AND AUTOPHOSPHORYLATION.
RX   PubMed=21641549; DOI=10.1016/j.cmet.2011.03.022;
RA   Deyev I.E., Sohet F., Vassilenko K.P., Serova O.V., Popova N.V.,
RA   Zozulya S.A., Burova E.B., Houillier P., Rzhevsky D.I.,
RA   Berchatova A.A., Murashev A.N., Chugunov A.O., Efremov R.G.,
RA   Nikol'sky N.N., Bertelli E., Eladari D., Petrenko A.G.;
RT   "Insulin receptor-related receptor as an extracellular alkali
RT   sensor.";
RL   Cell Metab. 13:679-689(2011).
CC   -!- FUNCTION: Receptor with tyrosine-protein kinase activity.
CC       Functions as a pH sensing receptor which is activated by increased
CC       extracellular pH. Activates an intracellular signaling pathway
CC       that involves IRS1 and AKT1/PKB. {ECO:0000269|PubMed:21641549}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- DOMAIN: The extracellular domain is required for sensing
CC       alterations in external pH.
CC   -!- PTM: Autophosphorylated on tyrosine residues between pH 7.9 and pH
CC       10.5.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF064078; AAC17167.1; -; mRNA.
DR   EMBL; AL158169; CAH70009.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52903.1; -; Genomic_DNA.
DR   EMBL; J05046; AAC31759.1; -; mRNA.
DR   CCDS; CCDS1160.1; -.
DR   PIR; B36502; B36502.
DR   RefSeq; NP_055030.1; NM_014215.2.
DR   UniGene; Hs.248138; -.
DR   ProteinModelPortal; P14616; -.
DR   SMR; P14616; 971-1262.
DR   BioGrid; 109856; 2.
DR   IntAct; P14616; 1.
DR   STRING; 9606.ENSP00000357178; -.
DR   BindingDB; P14616; -.
DR   ChEMBL; CHEMBL5483; -.
DR   GuidetoPHARMACOLOGY; 1802; -.
DR   iPTMnet; P14616; -.
DR   PhosphoSite; P14616; -.
DR   BioMuta; INSRR; -.
DR   DMDM; 12644000; -.
DR   MaxQB; P14616; -.
DR   PaxDb; P14616; -.
DR   PeptideAtlas; P14616; -.
DR   PRIDE; P14616; -.
DR   DNASU; 3645; -.
DR   Ensembl; ENST00000368195; ENSP00000357178; ENSG00000027644.
DR   GeneID; 3645; -.
DR   KEGG; hsa:3645; -.
DR   UCSC; uc010pht.3; human.
DR   CTD; 3645; -.
DR   GeneCards; INSRR; -.
DR   H-InvDB; HIX0028530; -.
DR   HGNC; HGNC:6093; INSRR.
DR   HPA; HPA025285; -.
DR   MIM; 147671; gene.
DR   neXtProt; NX_P14616; -.
DR   PharmGKB; PA29899; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P14616; -.
DR   KO; K05086; -.
DR   OMA; FARTMPH; -.
DR   OrthoDB; EOG091G00GE; -.
DR   PhylomeDB; P14616; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   GeneWiki; INSRR; -.
DR   GenomeRNAi; 3645; -.
DR   PRO; PR:P14616; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000027644; -.
DR   CleanEx; HS_INSRR; -.
DR   Genevisible; P14616; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0071469; P:cellular response to alkaline pH; IDA:UniProtKB.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; NAS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR028792; INSRR.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF338; PTHR24416:SF338; 3.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cleavage on pair of basic residues; Complete proteome;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1297       Insulin receptor-related protein.
FT                                /FTId=PRO_0000016701.
FT   CHAIN        27    742       Insulin receptor-related protein alpha
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016702.
FT   CHAIN       747   1297       Insulin receptor-related protein beta
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016703.
FT   TOPO_DOM    747    921       Extracellular. {ECO:0000255}.
FT   TRANSMEM    922    943       Helical. {ECO:0000255}.
FT   TOPO_DOM    944   1297       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      483    603       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      607    707       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      818    913       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      979   1254       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     985    993       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1115   1115       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1013   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1145   1145       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES    1146   1146       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   CARBOHYD     47     47       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    885    885       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    214    222       {ECO:0000250}.
FT   DISULFID    216    228       {ECO:0000250}.
FT   DISULFID    229    237       {ECO:0000250}.
FT   DISULFID    233    246       {ECO:0000250}.
FT   DISULFID    249    258       {ECO:0000250}.
FT   DISULFID    262    274       {ECO:0000250}.
FT   DISULFID    280    300       {ECO:0000250}.
FT   DISULFID    304    317       {ECO:0000250}.
FT   DISULFID    320    324       {ECO:0000250}.
FT   DISULFID    657    864       Interchain (between alpha and beta
FT                                chains). {ECO:0000255}.
FT   VARIANT     127    127       A -> E (in dbSNP:rs55757706).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041434.
FT   VARIANT     161    161       A -> V (in dbSNP:rs55971900).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041435.
FT   VARIANT     244    244       R -> H (in dbSNP:rs55951840).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041436.
FT   VARIANT     246    246       C -> R (in dbSNP:rs56377825).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041437.
FT   VARIANT     278    278       E -> Q (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041438.
FT   VARIANT     554    554       R -> C (in dbSNP:rs56068937).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041439.
FT   VARIANT     928    928       P -> L (in dbSNP:rs56252149).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041440.
FT   VARIANT    1065   1065       G -> E (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041441.
FT   MUTAGEN    1145   1146       YY->FF: Abolishes autophosphorylation.
FT                                {ECO:0000269|PubMed:21641549}.
SQ   SEQUENCE   1297 AA;  143720 MW;  BB22C7FF61E3065D CRC64;
     MAVPSLWPWG ACLPVIFLSL GFGLDTVEVC PSLDIRSEVA ELRQLENCSV VEGHLQILLM
     FTATGEDFRG LSFPRLTQVT DYLLLFRVYG LESLRDLFPN LAVIRGTRLF LGYALVIFEM
     PHLRDVALPA LGAVLRGAVR VEKNQELCHL STIDWGLLQP APGANHIVGN KLGEECADVC
     PGVLGAAGEP CAKTTFSGHT DYRCWTSSHC QRVCPCPHGM ACTARGECCH TECLGGCSQP
     EDPRACVACR HLYFQGACLW ACPPGTYQYE SWRCVTAERC ASLHSVPGRA STFGIHQGSC
     LAQCPSGFTR NSSSIFCHKC EGLCPKECKV GTKTIDSIQA AQDLVGCTHV EGSLILNLRQ
     GYNLEPQLQH SLGLVETITG FLKIKHSFAL VSLGFFKNLK LIRGDAMVDG NYTLYVLDNQ
     NLQQLGSWVA AGLTIPVGKI YFAFNPRLCL EHIYRLEEVT GTRGRQNKAE INPRTNGDRA
     ACQTRTLRFV SNVTEADRIL LRWERYEPLE ARDLLSFIVY YKESPFQNAT EHVGPDACGT
     QSWNLLDVEL PLSRTQEPGV TLASLKPWTQ YAVFVRAITL TTEEDSPHQG AQSPIVYLRT
     LPAAPTVPQD VISTSNSSSH LLVRWKPPTQ RNGNLTYYLV LWQRLAEDGD LYLNDYCHRG
     LRLPTSNNDP RFDGEDGDPE AEMESDCCPC QHPPPGQVLP PLEAQEASFQ KKFENFLHNA
     ITIPISPWKV TSINKSPQRD SGRHRRAAGP LRLGGNSSDF EIQEDKVPRE RAVLSGLRHF
     TEYRIDIHAC NHAAHTVGCS AATFVFARTM PHREADGIPG KVAWEASSKN SVLLRWLEPP
     DPNGLILKYE IKYRRLGEEA TVLCVSRLRY AKFGGVHLAL LPPGNYSARV RATSLAGNGS
     WTDSVAFYIL GPEEEDAGGL HVLLTATPVG LTLLIVLAAL GFFYGKKRNR TLYASVNPEY
     FSASDMYVPD EWEVPREQIS IIRELGQGSF GMVYEGLARG LEAGEESTPV ALKTVNELAS
     PRECIEFLKE ASVMKAFKCH HVVRLLGVVS QGQPTLVIME LMTRGDLKSH LRSLRPEAEN
     NPGLPQPALG EMIQMAGEIA DGMAYLAANK FVHRDLAARN CMVSQDFTVK IGDFGMTRDV
     YETDYYRKGG KGLLPVRWMA PESLKDGIFT THSDVWSFGV VLWEIVTLAE QPYQGLSNEQ
     VLKFVMDGGV LEELEGCPLQ LQELMSRCWQ PNPRLRPSFT HILDSIQEEL RPSFRLLSFY
     YSPECRGARG SLPTTDAEPD SSPTPRDCSP QNGGPGH
//
ID   INSRR_RAT               Reviewed;        1300 AA.
AC   Q64716; Q63146;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2011, sequence version 3.
DT   07-SEP-2016, entry version 126.
DE   RecName: Full=Insulin receptor-related protein;
DE            Short=IRR;
DE            EC=2.7.10.1;
DE   AltName: Full=IR-related receptor;
DE   Flags: Precursor;
GN   Name=Insrr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T.,
RA   Smith D., Lee H.-M., Gustafson E., Cahill P., Kana A.,
RA   Doucette-Stamm L., Weinstock K., Fechtel K., Weiss R.B., Dunn D.M.,
RA   Green E.D., Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K.,
RA   Zhu B., Marra M., Schein J., Bosdet I., Fjell C., Jones S.,
RA   Krzywinski M., Mathewson C., Siddiqui A., Wye N., McPherson J.,
RA   Zhao S., Fraser C.M., Shetty J., Shatsman S., Geer K., Chen Y.,
RA   Abramzon S., Nierman W.C., Havlak P.H., Chen R., Durbin K.J., Egan A.,
RA   Ren Y., Song X.-Z., Li B., Liu Y., Qin X., Cawley S., Cooney A.J.,
RA   D'Souza L.M., Martin K., Wu J.Q., Gonzalez-Garay M.L., Jackson A.R.,
RA   Kalafus K.J., McLeod M.P., Milosavljevic A., Virk D., Volkov A.,
RA   Wheeler D.A., Zhang Z., Bailey J.A., Eichler E.E., Tuzun E.,
RA   Birney E., Mongin E., Ureta-Vidal A., Woodwark C., Zdobnov E.,
RA   Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D.,
RA   Schmidt J., Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M.,
RA   Abril J.F., Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O.,
RA   Poliakov A., Huebner N., Ganten D., Goesele C., Hummel O.,
RA   Kreitler T., Lee Y.-A., Monti J., Schulz H., Zimdahl H.,
RA   Himmelbauer H., Lehrach H., Jacob H.J., Bromberg S.,
RA   Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E., Lazar J.,
RA   Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E.,
RA   Webber C., Brandt P., Nyakatura G., Adetobi M., Chiaromonte F.,
RA   Elnitski L., Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K.,
RA   Miller W., Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S.,
RA   Zhang Y., Lindpaintner K., Andrews T.D., Caccamo M., Clamp M.,
RA   Clarke L., Curwen V., Durbin R.M., Eyras E., Searle S.M., Cooper G.M.,
RA   Batzoglou S., Brudno M., Sidow A., Stone E.A., Payseur B.A.,
RA   Bourque G., Lopez-Otin C., Puente X.S., Chakrabarti K., Chatterji S.,
RA   Dewey C., Pachter L., Bray N., Yap V.B., Caspi A., Tesler G.,
RA   Pevzner P.A., Haussler D., Roskin K.M., Baertsch R., Clawson H.,
RA   Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J., Rosenbloom K.R.,
RA   Trumbower H., Weirauch M., Cooper D.N., Stenson P.D., Ma B., Brent M.,
RA   Arumugam M., Shteynberg D., Copley R.R., Taylor M.S., Riethman H.,
RA   Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S., Mockrin S.,
RA   Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into
RT   mammalian evolution.";
RL   Nature 428:493-521(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-481, AND TISSUE
RP   SPECIFICITY.
RC   STRAIN=Sprague-Dawley, and Wistar; TISSUE=Kidney, Liver, and Stomach;
RX   PubMed=1603082; DOI=10.1210/me.6.5.723;
RA   Shier P., Watt V.M.;
RT   "Tissue-specific expression of the rat insulin receptor-related
RT   receptor gene.";
RL   Mol. Endocrinol. 6:723-729(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 896-996, AND TISSUE SPECIFICITY.
RC   STRAIN=Wistar; TISSUE=Brain;
RX   PubMed=1530648; DOI=10.1016/0006-291X(92)91287-Z;
RA   Kurachi H., Jobo K., Ohta M., Kawasaki T., Itoh N.;
RT   "A new member of the insulin receptor family, insulin receptor-related
RT   receptor, is expressed preferentially in the kidney.";
RL   Biochem. Biophys. Res. Commun. 187:934-939(1992).
RN   [4]
RP   FUNCTION, AND AUTOPHOSPHORYLATION.
RX   PubMed=21641549; DOI=10.1016/j.cmet.2011.03.022;
RA   Deyev I.E., Sohet F., Vassilenko K.P., Serova O.V., Popova N.V.,
RA   Zozulya S.A., Burova E.B., Houillier P., Rzhevsky D.I.,
RA   Berchatova A.A., Murashev A.N., Chugunov A.O., Efremov R.G.,
RA   Nikol'sky N.N., Bertelli E., Eladari D., Petrenko A.G.;
RT   "Insulin receptor-related receptor as an extracellular alkali
RT   sensor.";
RL   Cell Metab. 13:679-689(2011).
CC   -!- FUNCTION: Receptor with tyrosine-protein kinase activity.
CC       Functions as a pH sensing receptor which is activated by increased
CC       extracellular pH. Activates an intracellular signaling pathway
CC       that involves IRS1 and AKT1/PKB. {ECO:0000269|PubMed:21641549}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed preferentially in the kidney. Also
CC       found in stomach and thymus but not in skeletal muscle, brain,
CC       intestine, and uterus. {ECO:0000269|PubMed:1530648,
CC       ECO:0000269|PubMed:1603082}.
CC   -!- DOMAIN: The extracellular domain is required for sensing
CC       alterations in external pH. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues between pH 7.9 and pH
CC       10.5.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AABR03012734; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M90661; AAB59692.1; -; mRNA.
DR   EMBL; M90660; AAA41452.1; -; Genomic_DNA.
DR   EMBL; D12678; BAA20982.1; -; mRNA.
DR   PIR; PC1130; PC1130.
DR   RefSeq; NP_071548.2; NM_022212.2.
DR   UniGene; Rn.44446; -.
DR   STRING; 10116.ENSRNOP00000018638; -.
DR   iPTMnet; Q64716; -.
DR   PhosphoSite; Q64716; -.
DR   PaxDb; Q64716; -.
DR   PRIDE; Q64716; -.
DR   Ensembl; ENSRNOT00000080693; ENSRNOP00000073224; ENSRNOG00000057702.
DR   GeneID; 60663; -.
DR   KEGG; rno:60663; -.
DR   UCSC; RGD:67399; rat.
DR   CTD; 3645; -.
DR   RGD; 67399; Insrr.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOVERGEN; HBG060167; -.
DR   InParanoid; Q64716; -.
DR   KO; K05086; -.
DR   OMA; FARTMPH; -.
DR   OrthoDB; EOG091G00GE; -.
DR   TreeFam; TF351636; -.
DR   PRO; PR:Q64716; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000013344; -.
DR   Genevisible; Q64716; RN.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0043235; C:receptor complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0071469; P:cellular response to alkaline pH; IEA:Ensembl.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR028792; INSRR.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF338; PTHR24416:SF338; 3.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Disulfide bond; Glycoprotein; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24   1300       Insulin receptor-related protein.
FT                                /FTId=PRO_0000016707.
FT   TOPO_DOM    747    921       Extracellular. {ECO:0000255}.
FT   TRANSMEM    922    942       Helical. {ECO:0000255}.
FT   TOPO_DOM    943   1300       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      483    603       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      607    707       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      818    913       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      979   1254       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     985    993       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    204    262       Cys-rich.
FT   ACT_SITE   1115   1115       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1013   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1145   1145       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1146   1146       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     47     47       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    885    885       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    214    222       {ECO:0000250}.
FT   DISULFID    216    228       {ECO:0000250}.
FT   DISULFID    229    237       {ECO:0000250}.
FT   DISULFID    233    246       {ECO:0000250}.
FT   DISULFID    249    258       {ECO:0000250}.
FT   DISULFID    262    274       {ECO:0000250}.
FT   DISULFID    280    300       {ECO:0000250}.
FT   DISULFID    304    317       {ECO:0000250}.
FT   DISULFID    320    324       {ECO:0000250}.
FT   DISULFID    657    864       Interchain (between alpha and beta
FT                                chains). {ECO:0000255}.
FT   CONFLICT    261    261       T -> A (in Ref. 2; AAB59692).
FT                                {ECO:0000305}.
FT   CONFLICT    425    425       L -> M (in Ref. 2; AAB59692).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1300 AA;  144846 MW;  0CF24D5B96D68225 CRC64;
     MAVPALWPWG VYLLMSLLSL GSCLDTLEVC PSLDIRSEVT ELRRLENCSV VEGHLQILLM
     FAATGEDFRG LSFPRLTQVT DYLLLFRVYG LESLRDLFPN LAVIRGARLF LGYALIIFEM
     PHLRDIGLPS LGAVLRGAVR VEKNQELCHL STIDWGLLQP APGANHIVGN KLGEECADVC
     PGVLGAAGEP CVRTTFGGHT DYRCWTSSHC QRVCPCPRGL ACTVGGECCH SECLGGCSQP
     EDPRACVACR HLYFQGVCLP TCPPGTYQYE SWRCVTAELC GHLREVPGHA TAFGIYEGSC
     LAQCPPGFTR NGSSIFCHKC EGLCPKECKV GTKTIDSVQA TQDLVGCTHV EGSLILNLRQ
     GYNLEPELQR NLGLVETITG FLKIKHSFAL VTLGFFKNLK LIRGDSMVDG NYTLYVLDNQ
     NLQQLGSWVA AGLTIPVGKI YFAFNPRLCL EHIYQLEEVT GTRGRQSKAE INPRTNGDRA
     ACQTRTLRFV FNLTEEDRIL LRWERYEPLE ARDLLSFIVY YKESPFQNAT EHVGPDACGT
     QSWNLLDVEL PLSRTQEPGV TLAPLKPWTQ YAVFVRAITL TTAEDSPHQG AQSPIVYLRT
     LPAAPTVPQD VISTSNSSSH LLVRWKPPVQ RNGNITYYLV LWQRLAEDGD LYINDYCHRG
     LRLPTSSHDT RFDREDPALE AEPEQGCCPC QHSPPGQALP ALEAQEVTFQ KKFENFLHHA
     ITIPKAPWKV TSINKNPQRD SERHRRETGL LRLGKNNSDF EIHEDKVPRE RAVLSGLRHF
     TEYRIDIHAC NHAAHTVGCS AATFVFARTM PHREADGIPG KVVWKAVGKS SVILHWLEPP
     DPNGLILKYE IKYRRLGEEA TVLCVSRLRY AKVGGVHLAL LPPGNYSAKV RATSLAGNGS
     WTDGVAFYIT GPEEEDTGGL RILLTVTPVG FMLLVMLAAL GFFYSKKRNS TLYTSVNPEY
     FSASHMYVPD EWEVPREQIA IIRELGQGSF GMVYEGLARG LEAGEESTPV ALKTVNELAS
     ARERVEFLKE ASVMKAFKCH HVVRLLGVVS QGQPTLVIME LMTRGDLKSH LRSLRPEAEN
     NPGLPQPALS DMIQMAGEIA DGMAYLAAKK FVHRDLAARN CMVSQDFTVK IGDFGMTRDV
     YETDYYRKGG KGLLPVRWMA PESLKDGIFT THSDVWSFGV VLWEIVTLAE QPYQGLSNEQ
     VLKFVMDGGV LEEQEDCPIQ LQELMRRCWQ HTPRLRPTFV HILDRIQDEL RPSFRLCSFY
     YSPECQRGQA SLLPTEAEPD SPPTLNGASD YGPPNGDPGH
//
ID   INSRR_CAVPO             Reviewed;        1300 AA.
AC   P14617;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   06-JUL-2016, entry version 137.
DE   RecName: Full=Insulin receptor-related protein;
DE            Short=IRR;
DE            EC=2.7.10.1;
DE   AltName: Full=IR-related receptor;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein alpha chain;
DE   Contains:
DE     RecName: Full=Insulin receptor-related protein beta chain;
DE   Flags: Precursor;
GN   Name=INSRR;
OS   Cavia porcellus (Guinea pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
OC   Hystricognathi; Caviidae; Cavia.
OX   NCBI_TaxID=10141;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2768234;
RA   Shier P., Watt V.M.;
RT   "Primary structure of a putative receptor for a ligand of the insulin
RT   family.";
RL   J. Biol. Chem. 264:14605-14608(1989).
CC   -!- FUNCTION: Receptor with tyrosine-protein kinase activity.
CC       Functions as a pH sensing receptor which is activated by increased
CC       extracellular pH. Activates an intracellular signaling pathway
CC       that involves IRS1 and AKT1/PKB (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- DOMAIN: The extracellular domain is required for sensing
CC       alterations in external pH. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues between pH 7.9 and pH
CC       10.5. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05047; AAA37044.1; -; Genomic_DNA.
DR   PIR; A36502; A36502.
DR   RefSeq; XP_003475448.1; XM_003475400.2.
DR   ProteinModelPortal; P14617; -.
DR   SMR; P14617; 29-487, 957-1264.
DR   STRING; 10141.ENSCPOP00000017876; -.
DR   Ensembl; ENSCPOT00000003232; ENSCPOP00000002888; ENSCPOG00000003189.
DR   GeneID; 100716566; -.
DR   CTD; 3645; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P14617; -.
DR   BRENDA; 2.7.10.1; 1225.
DR   Proteomes; UP000005447; Unassembled WGS sequence.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0071469; P:cellular response to alkaline pH; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR028792; INSRR.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF338; PTHR24416:SF338; 3.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cleavage on pair of basic residues; Complete proteome;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     26
FT   CHAIN        27    746       Insulin receptor-related protein alpha
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016699.
FT   CHAIN       747   1300       Insulin receptor-related protein beta
FT                                chain. {ECO:0000305}.
FT                                /FTId=PRO_0000016700.
FT   TOPO_DOM    747    921       Extracellular. {ECO:0000255}.
FT   TRANSMEM    922    943       Helical. {ECO:0000255}.
FT   TOPO_DOM    944   1300       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      483    603       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      607    707       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      818    912       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      979   1254       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     985    993       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1115   1115       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1013   1013       ATP.
FT   MOD_RES    1145   1145       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1146   1146       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     47     47       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    634    634       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    885    885       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    214    222       {ECO:0000250}.
FT   DISULFID    216    228       {ECO:0000250}.
FT   DISULFID    229    237       {ECO:0000250}.
FT   DISULFID    233    246       {ECO:0000250}.
FT   DISULFID    249    258       {ECO:0000250}.
FT   DISULFID    262    274       {ECO:0000250}.
FT   DISULFID    280    300       {ECO:0000250}.
FT   DISULFID    304    317       {ECO:0000250}.
FT   DISULFID    320    324       {ECO:0000250}.
FT   DISULFID    657    864       Interchain (between alpha and beta
FT                                chains). {ECO:0000255}.
SQ   SEQUENCE   1300 AA;  144518 MW;  3344DF4B6A57B24F CRC64;
     MARPKLWPWG ILLLVSLLSA GFNLDTMNVC PSLDIRSEVA ELRRLENCSV VEGHLQILLM
     FTATGEDFRS LSFPHLTQVT DYLLLFRVYG LESLRDLFPN LAVIRGAHLF LGYALVIFEM
     PHLRDVGLPA LGAVLHGSVR VEKNQELCHL STIDWGLLQP TPSTNYIVGN KLGEECADVC
     PGTLGAAGEP CARTTFNGHT DYRCWTSSHC QRVCPCPQGL ACTISGECCH TECLGGCSQP
     EDPRACVACR HFYYQSACHR ACPLGTYEHE SWRCVTAESC ANLRSVPGRA STFGIHQGKC
     LAQCPPGFTR NGSSIFCHKC EGLCPKECKV GTKTIDSVQA AQDLVGCTHV EGSLILNLRR
     GYNLEPELQR SLGLVETITG FLKIKHSFAL VSLSFFKNLK LIRGDTMVDG NYTLYVLDNQ
     NLQQLGPWVS AGLTIPVGKI YFAFNPRLCL EHIYRLEEVT GTRGRQNKAE INPRTNGDRA
     ACQTRTLRFV SNVTEADRIL LRWERYEPLE ARDLLSFIVY YKESPFQNAT EHVGPDACGS
     QSWNLLDVEL PLSRTQEPGV ILAPLKPWTQ YAVFVRAITL TTAEDSPHQG AQSPIVYLWT
     LPAAPTVPQD VISSSNSSSH LLVRWKPPTQ RNGNITYYLV LWQRLAEDGD LYLNDYCHRG
     LRLPTSNHDP RFDREDGDLE AELELGCCPC QHAPPGQVLP ALEAQEASFQ KKFENFLHNA
     ITIPKPPWKV TSIHRNLQRD AGRHRRAIGS PRPGGNSSDF EIQEDKVPRE RAVLGGLRHF
     TEYRIDIHAC NHAAHIVGCS AATFVFARTM PRREADDIPG KLSWEAASKS SVLLRWFEPP
     DPNGLILKYE IKYRRLGEEA TVLCVSRLRY AKVGGVQLAL LPPGNYSARV RATSLAGNGS
     WTDSVAFYIP GPEEEDSGGL HILLTVTPAG LMLLIILAAL GFFYSRKRNG TLYTSVNPEY
     LSASDMYIPD EWEVPREQIS IIRELGQGSF GMVYEGVAKG LEAGEESTPV ALKTVNELAS
     PRERIEFLKE ASVMKAFQCH HVVRLLGVVS QGQPTLVIME LMTRGDLKSH LRSLRPEAEN
     NPGIPRPALG DMIQMAGEIA DGMAYLAANK FVHRDLAARN CMVSQDFTVK IGDFGMTRDV
     YETDYYRKGG KGLLPVRWMA PESLKDGIFT THSDVWSFGV VLWEIVTLAE QPYQGLSNEQ
     VLKFVMDGGV LEELEDCPHQ LQELMSSCWQ QNPRLRPTFT QILNSIQKEL RPSFRLLSFY
     HSPECQGGCG LQPTTDAESS SPPTSKGASD CSLQNGGPEH
//
ID   ILPR_BRALA              Reviewed;        1363 AA.
AC   O02466;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   11-MAY-2016, entry version 111.
DE   RecName: Full=Insulin-like peptide receptor;
DE            Short=ILP receptor;
DE            EC=2.7.10.1;
DE   Contains:
DE     RecName: Full=Insulin-like peptide receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like peptide receptor beta chain;
DE   Flags: Precursor;
OS   Branchiostoma lanceolatum (Common lancelet) (Amphioxus lanceolatum).
OC   Eukaryota; Metazoa; Chordata; Cephalochordata; Branchiostomidae;
OC   Branchiostoma.
OX   NCBI_TaxID=7740;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8813726; DOI=10.1210/me.10.7.857;
RA   Pashmforoush M., Chan S.J., Steiner D.F.;
RT   "Structure and expression of the insulin-like peptide receptor from
RT   amphioxus.";
RL   Mol. Endocrinol. 10:857-866(1996).
CC   -!- FUNCTION: This receptor binds to the insulin related peptide and
CC       has a tyrosine-protein kinase activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S83394; AAB50848.1; -; mRNA.
DR   PIR; T43220; T43220.
DR   ProteinModelPortal; O02466; -.
DR   SMR; O02466; 972-1303.
DR   HOVERGEN; HBG006134; -.
DR   BRENDA; 2.7.10.1; 932.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:InterPro.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cleavage on pair of basic residues; Disulfide bond;
KW   Glycoprotein; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     29       {ECO:0000255}.
FT   CHAIN        30    716       Insulin-like peptide receptor alpha
FT                                chain. {ECO:0000255}.
FT                                /FTId=PRO_0000016711.
FT   CHAIN       721   1363       Insulin-like peptide receptor beta chain.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000016713.
FT   TOPO_DOM    721    928       Extracellular. {ECO:0000255}.
FT   TRANSMEM    929    949       Helical. {ECO:0000255}.
FT   TOPO_DOM    950   1363       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      473    586       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      590    680       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      712    804       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      813    912       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      994   1283       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1000   1008       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1148   1148       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1028   1028       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1174   1174       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    137    137       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    278    278       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    483    483       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    599    599       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    617    617       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    665    665       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    666    666       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    711    711       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    732    732       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    736    736       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    743    743       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    816    816       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    885    885       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...). {ECO:0000255}.
SQ   SEQUENCE   1363 AA;  154105 MW;  238120B4EAB1ED65 CRC64;
     MRVVDKMAGL MWAALTLVIG LGLLVPSNGE EYICDSMDIR NRVSNLRQLE NCTVIEGYLQ
     ILLIDFAEEQ DYSGLAFPNL VEITDYFLLY RVRGLTNLSE LFPNLAVIRG TNLFFNYALV
     VFEMLDMQKI GLYSLQNITR GSVRIEKNPN LCYLDTIDWS FIAESGYSNN FIVDNREEEE
     CVNFCPGRCR IKHPVLQDLC WAEEHCQKVC PESCLGNCRD GISGCCHENC IGGCDGPTER
     DCVACKYFVH NGECLIQCPP DTYQYKDRRC ITEEECPNTT NSVWKLHHRK CIPECPSGYT
     TDINNPRLCT ECEGQCPKSC KGGLVDSLAA AQRFRGCTII EGELKISIRG GDNIIDELEE
     NLGLIEEVGH YVAIVRSYAL VTLDFLRSLK RIRGIQKENG YAFYVLDNRN LEKLFDWDRT
     DITIDEGKLF FHFNPKLCRH VILTMVDKVG LPEHAITDTD ISTLTNGDQA QCSFSRLEIE
     EINTSKDMII LRWSEFRPPD PRDLLSYTVS YRETEDQGID EYDGQDACGN TEWKEFDVSP
     TQTAHIITGL KPWTQYALLV KTYTKAGARE GSGAKSDIVY ARTDADKPTH PQDVVVYSNS
     SNTLIITWKP PNRPNGNVTH YIVKYKRQQE DVAEMEQREY CKGGLKPHRP TQGLEDIVNN
     EEEPNNSTIG DGTCCECPKS EDEIRIEEEE AAFQQEFENF LHNNVYHKRE NETRAGRRRR
     ELPVTARPFY SNQTVNVTLP STNRTVPPTP TPNPNPQLET TVWNEHMVVL TGLRHFSEYI
     IEVIACNADA AVGCSGSAVE LARTQADDSA DNIPGNITVV EIKEDMAKLY WPKPDSPNSM
     VVHYNIEYKK LGSDFNYEQQ EPKCVENFKF LQSQGYTISN LVAGNYSVRF RATSFAGNGS
     WSNYVTFYVE EEDTSPDPQD PQQQVPVSLM IGMGVGFSLL LILAVIFGIW YCTKKRFGDK
     QMPNGVLYAS VNPEYMSSDD VYVPDEWEVP REKITLIREL GQGSFGMVYE GEAKDVVKDE
     PMVSVAVKTV NESASIRERI EFLNEASVMK TFNCHHVVKL MGVVSKGQPT LVVMELMALG
     DLKNYLRRHR PEEDVGLSDS PASNEAKNSP FAENDNDLPP TFKDIIQMAG VIADGMSYLA
     AKKFVHRDLA CRNCMVAQDR TVKIGDFGMT RDIYETDYYR KGGKGLLPVR WMSPESLKVG
     VFTSQSDVWS YGVVLWEMAT LASQPYQGKS NEEVLKFVID GGMLEKPEGC PNKLYDLMKL
     CWQYRQSMRP TFLEIVEILS PELQAHFNEV SFYHSLDNHG REPLEMDDVA LDSGADTETE
     MYPSGSEFSS TPSPPSETPY SHMNGSHPQN GSMNLRIPKS TLC
//
ID   INSR_AEDAE              Reviewed;        1393 AA.
AC   Q93105; Q17IL5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   07-SEP-2016, entry version 131.
DE   RecName: Full=Insulin-like receptor;
DE            Short=MIR;
DE            EC=2.7.10.1;
DE   Contains:
DE     RecName: Full=Insulin-like receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like receptor beta chain;
DE   Flags: Precursor;
GN   Name=InR; ORFNames=AAEL002317;
OS   Aedes aegypti (Yellowfever mosquito) (Culex aegypti).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea;
OC   Culicidae; Culicinae; Aedini; Aedes; Stegomyia.
OX   NCBI_TaxID=7159;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=UGAL; TISSUE=Ovary;
RX   PubMed=9099579; DOI=10.1111/j.1365-2583.1997.tb00083.x;
RA   Graf R., Neuenschwander S., Brown M.R., Ackermann U.;
RT   "Insulin-mediated secretion of ecdysteroids from mosquito ovaries and
RT   molecular cloning of the insulin receptor homologue from ovaries of
RT   bloodfed Aedes aegypti.";
RL   Insect Mol. Biol. 6:151-163(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=LVPib12;
RX   PubMed=17510324; DOI=10.1126/science.1138878;
RA   Nene V., Wortman J.R., Lawson D., Haas B.J., Kodira C.D., Tu Z.J.,
RA   Loftus B.J., Xi Z., Megy K., Grabherr M., Ren Q., Zdobnov E.M.,
RA   Lobo N.F., Campbell K.S., Brown S.E., Bonaldo M.F., Zhu J.,
RA   Sinkins S.P., Hogenkamp D.G., Amedeo P., Arensburger P.,
RA   Atkinson P.W., Bidwell S.L., Biedler J., Birney E., Bruggner R.V.,
RA   Costas J., Coy M.R., Crabtree J., Crawford M., DeBruyn B.,
RA   DeCaprio D., Eiglmeier K., Eisenstadt E., El-Dorry H., Gelbart W.M.,
RA   Gomes S.L., Hammond M., Hannick L.I., Hogan J.R., Holmes M.H.,
RA   Jaffe D., Johnston S.J., Kennedy R.C., Koo H., Kravitz S.,
RA   Kriventseva E.V., Kulp D., Labutti K., Lee E., Li S., Lovin D.D.,
RA   Mao C., Mauceli E., Menck C.F., Miller J.R., Montgomery P., Mori A.,
RA   Nascimento A.L., Naveira H.F., Nusbaum C., O'Leary S.B., Orvis J.,
RA   Pertea M., Quesneville H., Reidenbach K.R., Rogers Y.-H.C., Roth C.W.,
RA   Schneider J.R., Schatz M., Shumway M., Stanke M., Stinson E.O.,
RA   Tubio J.M.C., Vanzee J.P., Verjovski-Almeida S., Werner D.,
RA   White O.R., Wyder S., Zeng Q., Zhao Q., Zhao Y., Hill C.A.,
RA   Raikhel A.S., Soares M.B., Knudson D.L., Lee N.H., Galagan J.,
RA   Salzberg S.L., Paulsen I.T., Dimopoulos G., Collins F.H., Bruce B.,
RA   Fraser-Liggett C.M., Severson D.W.;
RT   "Genome sequence of Aedes aegypti, a major arbovirus vector.";
RL   Science 316:1718-1723(2007).
CC   -!- FUNCTION: This receptor probably binds an insulin related protein
CC       and has a tyrosine-protein kinase activity. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chains carry the kinase domain (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain and ovary.
CC       {ECO:0000269|PubMed:9099579}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 FU (furin-like) repeat. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=EAT46545.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U72939; AAB17094.1; -; mRNA.
DR   EMBL; CH477238; EAT46545.1; ALT_SEQ; Genomic_DNA.
DR   PIR; T30346; T30346.
DR   RefSeq; XP_001661260.1; XM_001661210.1.
DR   UniGene; Aae.5739; -.
DR   ProteinModelPortal; Q93105; -.
DR   DIP; DIP-29908N; -.
DR   STRING; 7159.AAEL002317-PA; -.
DR   GeneID; 5574210; -.
DR   KEGG; aag:AaeL_AAEL002317; -.
DR   VectorBase; AAEL002317-RA; AAEL002317-PA; AAEL002317.
DR   CTD; 5574210; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000038045; -.
DR   InParanoid; Q93105; -.
DR   KO; K04527; -.
DR   OrthoDB; EOG091G00GE; -.
DR   BRENDA; 2.7.10.1; 149.
DR   Proteomes; UP000008820; Unassembled WGS sequence.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043559; F:insulin binding; ISS:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cleavage on pair of basic residues; Complete proteome;
KW   Disulfide bond; Glycoprotein; Kinase; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    753       Insulin-like receptor alpha chain.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000016719.
FT   CHAIN       758   1393       Insulin-like receptor beta chain.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000016721.
FT   TOPO_DOM    758    966       Extracellular. {ECO:0000255}.
FT   TRANSMEM    967    987       Helical. {ECO:0000255}.
FT   TOPO_DOM    988   1393       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      240    287       FU.
FT   DOMAIN      507    623       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      624    729       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      860    961       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1025   1302       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1031   1039       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1163   1163       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1059   1059       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1189   1189       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1193   1193       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1194   1194       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     76     76       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    257    257       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    439    439       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    457    457       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    553    553       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    765    765       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    772    772       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    793    793       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    796    796       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    871    871       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    919    919       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    933    933       N-linked (GlcNAc...). {ECO:0000255}.
FT   CONFLICT     38     38       S -> T (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT    110    111       IR -> YP (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT    331    331       L -> V (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       L -> P (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT    474    474       C -> W (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT   1126   1132       NGEDPSP -> MRRSIR (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT   1151   1153       MAY -> IGV (in Ref. 1; AAB17094).
FT                                {ECO:0000305}.
FT   CONFLICT   1380   1393       GPMATIRSPHSPLR -> ARWPRSVRHTRH (in Ref.
FT                                1; AAB17094). {ECO:0000305}.
SQ   SEQUENCE   1393 AA;  156728 MW;  BD75381D755CEC60 CRC64;
     MVSLLLFSIL VVPVAVVQGD EMKAGQVGPV PKGGVCGSVD VRNSPAHLDR LKDCVVVEGF
     VHILLIDKYI DSSFENYSFP LLTEITEYLL LFRVNGLKSL RRLFPNLAVI RGDALVGDYA
     MVIYELMHIE EIGLISLMDI TRGGVRIEKN PKLCFANTID WKAMTVPGTN NYIKDNQKDN
     VCPICPAEST AVMLPNGSKQ KCPAAPVRGG NKDHKRTLCW NANHCQTICP PECPKACSKT
     GVCCDAESCL GGCNLPNTSS CSVCRHLSID PAGKRQCVAK CPPNTFKYHT RCVTRDECYA
     MKKPISLDSN PDLPDQPFIP HNGSCLMECP LDHELITELN KTRWCRKCSG TCPKRCEGSN
     IDNIQSAQLL KGCEIIDGSL EIQLRSRGGE NIVKELENFL SSITEIKGYL KVVRSYPLLS
     LGFLKKLKII HGKGNKVSNS SLYVVENQNL QELFDHNVTI GEGKLFFFNN PMLCTDRIKA
     VKKYNPGIEI ENESQLESNN GDRAACSITE LETSLKSIGS ETAIIQWAPF TELSDARMLL
     GYVIYYIEAP YANVTFFDGR DACNTEGWRL DDISDFNMDK ETTKILTQLK PYTQYAYYVK
     TYTLGSEGLG GQSKIKYFTT APGTPSVVRD VEVSVNKNML TVKWLPPLKM NGRLKEYEVF
     IELNADDNEQ LMLRDYCEDD KLRDIVPETP TSAPPPKTSI CTADQCRNYC KAPTSGGSTG
     TIDVTDKENQ ITFEDQLHNY VYIKNPLLRD KTTRRKRSTN LLFPNNTENK KNDTTDRRTE
     KVKDEPYYQY IFNATNETSI TFPLSYFNHY SLYVFKIRAC RHPGDPPAPS VRLVDVELAC
     GNEVFENFRT PKKEGADDIP PESILIEEQS NNTQRQIRVQ WKEPSKPNGP IVKFVVKYQR
     VDLESVSSTD ICIRYSSFNQ TRGALLTKLE PGNYSIRVMA TTIAGDGAPS AARYVLIAKD
     DSMGTTLIWL GTLIVIFLCS VGFVAFYWYK YRYMSKQIRM YPEVNPDYAG VQYKVDDWEV
     ERNHIIQLEE LGQGSFGMVY KGILTQLRGE KCNQPCAIKT VNESATAREK DSFLLEASVM
     KQFNTHHVVR LLGVVSQGDP TLVIMELMAN GDLKSYLRRH RPDYENGEDP SPQPPTLRQI
     IQMAIEIADG MAYLSAKKFV HRDLAARNCM VADDMTVKIG DFGMTRDIYE TDYYRKGTKG
     FLPVRWMAPE SLKDGIFSSS SDVFSYGVVL WEMATLASQP YQGLTNDQVL RYVIDGGVME
     RPENCPDNLY NLMRRCWQHR PTARPTFMEI ISELLPDASP HFQDVAFYNS QDALDMLRGQ
     HQTVIIDEAT TPLRPGDDHD EEPGEDDDLV GHGEGHIGDV GTDDEFSMEM TNSHLVRNNG
     PMATIRSPHS PLR
//
ID   MIPR_LYMST              Reviewed;        1607 AA.
AC   Q25410;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 110.
DE   RecName: Full=Putative molluscan insulin-related peptide(s) receptor;
DE            EC=2.7.10.1;
DE   Contains:
DE     RecName: Full=Putative molluscan insulin-related peptide(s) receptor alpha chain;
DE   Contains:
DE     RecName: Full=Putative molluscan insulin-related peptide(s) receptor beta chain;
DE   Flags: Precursor;
OS   Lymnaea stagnalis (Great pond snail) (Helix stagnalis).
OC   Eukaryota; Metazoa; Lophotrochozoa; Mollusca; Gastropoda;
OC   Heterobranchia; Euthyneura; Panpulmonata; Hygrophila; Lymnaeoidea;
OC   Lymnaeidae; Lymnaea.
OX   NCBI_TaxID=6523;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=CNS;
RX   PubMed=7557427; DOI=10.1016/0378-1119(95)00323-X;
RA   Roovers E., Vincent M., van Kesteren E., Geraerts W.P.M., Planta R.J.,
RA   Vreugdenhil E., van Heerikhuizen H.;
RT   "Characterization of a putative molluscan insulin-related peptide
RT   receptor.";
RL   Gene 162:181-188(1995).
CC   -!- FUNCTION: This receptor probably binds to the four different
CC       molluscan insulin-related peptides and has a tyrosine-protein
CC       kinase activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by
CC       disulfide bonds. The alpha chains contribute to the formation of
CC       the ligand-binding domain, while the beta chains carry the kinase
CC       domain (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X84994; CAA59353.1; -; mRNA.
DR   PIR; T43212; T43212.
DR   ProteinModelPortal; Q25410; -.
DR   SMR; Q25410; 1018-1320.
DR   PRIDE; Q25410; -.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cleavage on pair of basic residues; Disulfide bond;
KW   Glycoprotein; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     35       {ECO:0000255}.
FT   CHAIN        36    694       Putative molluscan insulin-related
FT                                peptide(s) receptor alpha chain.
FT                                /FTId=PRO_0000016708.
FT   CHAIN       698   1607       Putative molluscan insulin-related
FT                                peptide(s) receptor beta chain.
FT                                /FTId=PRO_0000016710.
FT   TOPO_DOM    698    975       Extracellular. {ECO:0000255}.
FT   TRANSMEM    976    996       Helical. {ECO:0000255}.
FT   TOPO_DOM    997   1607       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      517    632       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      636    726       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      756    861       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      870    967       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1037   1308       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1043   1051       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1173   1173       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1072   1072       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1199   1199       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     82     82       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    245    245       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    275    275       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    332    332       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    343    343       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    495    495       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    663    663       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    710    710       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    778    778       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    796    796       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    802    802       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    868    868       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    879    879       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    940    940       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    953    953       N-linked (GlcNAc...). {ECO:0000255}.
SQ   SEQUENCE   1607 AA;  181821 MW;  F9CD1AEB25D2EBD6 CRC64;
     MHPGSISFNM IINKCIPICL FILFIMMMEF TVSKADSKND IVSESHPSLQ KLGCGGSQSP
     TNGVCGSVDI RSSMDNFKLL ENCTVIEGSL RISLFELKAL DFRHLSFPDL REITDYLLMY
     RVYGLETLSK LFPNLAIIRG RELFNSYAIV MYEMRDLQDL GLVNLRTISR GGVRLTKNFK
     LCYIETINWT QIGVSDPEAR RFINNKEQCP NSCKDECQSK RCWTYSDCQK GLNCQCKENT
     YCMENGSCCH DYCLGGCKVP MNPDECFSCK EVQFNNTCRP QCPPGTYKFL NRRCLTDKEC
     LALTNDPDGN TPKLLDGEKG EPSLCLYTCP QNYSVGDSKD NKNLSQCVKC RQLCPKECHG
     LEINNIQDAH KLKECSKISG PLKIQIMSGS NVAQELEKSL GNIREVTETI HIKRSYALVT
     LHFFKNLQII GSKVPSSETQ EGQSFSLFLM DNTNLQELFP EEQMKKMKIL NGGIYVHDNG
     QLCPHTIKEF LSHLNLSEAQ SSISSISNGH QRPCEKHDLN VTVEKIAHNA AILAWNKYKA
     DERQLLTYIL NYKEIKDESN DINIFQGRDL CSHDLWMTRE YAPKEGPEAD QIGMLYDLKP
     FTTYAVYIQA YTVSTATHAA MTNILTFTTY PFHPSEPTDL VAISEDPHEL RVSWKPPKYP
     NGNITHYKIV YHKLELNEKS YEQRNYCRDP LVHQKKKEKV KIEEEGKKIN NSANSNCCKC
     PKSKEEMDTE SRKREIEMYF EDYLHKHIYC KRYDKLPDEV DLNFDGMNLP QLVEMNYNSS
     ETSDRIEVFP NYVIENTSDL ANLTEIVKEV VVYGTTEVTL PNLEHFSEYS IEVLACQDYN
     EKVLSKLCSI RAITFERTKD SYAADMINET TVDTEIETNF TGNVFIKWES PTSPNGLILK
     YLLWYKKANQ ENLVPQTICI TRQEYLKNLG YKLTRLEPGN WTFKISAISL AENSSFTLER
     FFIVPRPPDP ESSNTLLIVA IVLAFFGVLT VSLIVACVYY KQKIRSDDMT VISRNMNYVP
     SEILYISDEW EVDRDKIKLI KELGQGSFGM VYEGVAKGIR DDPNEEIPVA VKTVNDRASF
     SDRREFLKEA TTMKEFHCHH VVKLLGVVST GQPALVIMEL MALGDLKNYL RGHRPDEDHP
     GVMPPHLLDI LQMAGEIADG MAYLADKKFV HRDLAARNCM VSEERTVKIG DFGMTRDIYE
     TDYYRKGGKG MLPVRWMAPE SLKDGVFTSL SDVWSYGVVM WEMVTLAAQP YQGLSNEEVV
     KFISDGYIME LPENCPNEMA YLMQHCWAKK PNQRPTFKAI IEYLLPKLKP SFEKVSYFFT
     SGGGHTDGAG EGTLAEPEGS DDSSSINSLS CEGAAAPRQS LTPCGGGQFK SSTHFNGGSH
     TLYDEGVDRE TILNGVDDGD EDEAAGRYSL SEFGEDLDDS SRPFMSDDFI PPVMTRQPLL
     SHQSNGNDSN VRNSGLIELK PLINKDKRPG LSSPRLNARS NPFSSEYIGH YPPTLTTELE
     TLNGNQSSHN NNSFELMTPD PLKSGPASES SNGVSSSSWR PKPILKLPTL NQARVGDSVG
     CLCLTLGTRI NIVKPIETVR PETNTIRYLK PPHPMLIWST LKMVLVL
//
ID   INSR_DROME              Reviewed;        2144 AA.
AC   P09208; B7Z0N6; Q24023; Q24089; Q9VD94;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   29-MAR-2005, sequence version 3.
DT   07-SEP-2016, entry version 195.
DE   RecName: Full=Insulin-like receptor;
DE            Short=dIR;
DE            Short=dInr;
DE            EC=2.7.10.1;
DE   AltName: Full=dIRH;
DE   Contains:
DE     RecName: Full=Insulin-like receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin-like receptor subunit beta 1;
DE   Contains:
DE     RecName: Full=Insulin-like receptor subunit beta 2;
DE   Flags: Precursor;
GN   Name=InR; Synonyms=dinr, Dir-a, Inr-a; ORFNames=CG18402;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=7628438;
RA   Fernandez R., Tabarini D., Azpiazu N., Frasch M., Schlessinger J.;
RT   "The Drosophila insulin receptor homolog: a gene essential for
RT   embryonic development encodes two receptor isoforms with different
RT   signaling potential.";
RL   EMBO J. 14:3373-3384(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7876183; DOI=10.1074/jbc.270.9.4236;
RA   Ruan Y., Chen C., Cao Y., Garofalo R.S.;
RT   "The Drosophila insulin receptor contains a novel carboxyl-terminal
RT   extension likely to play an important role in signal transduction.";
RL   J. Biol. Chem. 270:4236-4243(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 652-1851.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=3099787; DOI=10.1016/S0006-291X(86)80197-8;
RA   Nishida Y., Hata M., Nishizuka Y., Rutter W.J., Ebina Y.;
RT   "Cloning of a Drosophila cDNA encoding a polypeptide similar to the
RT   human insulin receptor precursor.";
RL   Biochem. Biophys. Res. Commun. 141:474-481(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1300-1598, DEVELOPMENTAL STAGE,
RP   AND AUTOPHOSPHORYLATION.
RX   PubMed=3014506; DOI=10.1073/pnas.83.13.4710;
RA   Petruzzelli L., Herrera R., Arenas-Garcia R., Fernandez R.,
RA   Birnbaum M.J., Rosen O.M.;
RT   "Isolation of a Drosophila genomic sequence homologous to the kinase
RT   domain of the human insulin receptor and detection of the
RT   phosphorylated Drosophila receptor with an anti-peptide antibody.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:4710-4714(1986).
RN   [7]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=2454394;
RA   Garofalo R.S., Rosen O.M.;
RT   "Tissue localization of Drosophila melanogaster insulin receptor
RT   transcripts during development.";
RL   Mol. Cell. Biol. 8:1638-1647(1988).
RN   [8]
RP   FUNCTION, AND AUTOPHOSPHORYLATION.
RX   PubMed=8603594; DOI=10.1210/en.137.3.846;
RA   Chen C., Jack J., Garofalo R.S.;
RT   "The Drosophila insulin receptor is required for normal growth.";
RL   Endocrinology 137:846-856(1996).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH CHICO.
RX   PubMed=10455177; DOI=10.1074/jbc.274.35.24987;
RA   Marin-Hincapie M., Garofalo R.S.;
RT   "The carboxyl terminal extension of the Drosophila insulin receptor
RT   homologue binds IRS-1 and influences cell survival.";
RL   J. Biol. Chem. 274:24987-24994(1999).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF ARG-1467; GLY-1539 AND GLY-1599.
RX   PubMed=11250149; DOI=10.1016/S0960-9822(01)00068-9;
RA   Brogiolo W., Stocker H., Ikeya T., Rintelen F., Fernandez R.,
RA   Hafen E.;
RT   "An evolutionarily conserved function of the Drosophila insulin
RT   receptor and insulin-like peptides in growth control.";
RL   Curr. Biol. 11:213-221(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=11292875; DOI=10.1126/science.1057987;
RA   Tatar M., Kopelman A., Epstein D., Tu M.P., Yin C.M., Garofalo R.S.;
RT   "A mutant Drosophila insulin receptor homolog that extends life-span
RT   and impairs neuroendocrine function.";
RL   Science 292:107-110(2001).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH DOCK.
RX   PubMed=12702880; DOI=10.1126/science.1081203;
RA   Song J., Wu L., Chen Z., Kohanski R.A., Pick L.;
RT   "Axons guided by insulin receptor in Drosophila visual system.";
RL   Science 300:502-505(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1816, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Embryo;
RX   PubMed=18327897; DOI=10.1021/pr700696a;
RA   Zhai B., Villen J., Beausoleil S.A., Mintseris J., Gygi S.P.;
RT   "Phosphoproteome analysis of Drosophila melanogaster embryos.";
RL   J. Proteome Res. 7:1675-1682(2008).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-824; ASN-839; ASN-864;
RP   ASN-898; ASN-1147; ASN-1218 AND ASN-1219, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
CC   -!- FUNCTION: Has a ligand-stimulated tyrosine-protein kinase
CC       activity. Required for cell survival. Regulates body size and
CC       organ size by altering cell number and cell size in a cell-
CC       autonomous manner. Involved in the development of the embryonic
CC       nervous system, and is necessary for axon guidance and targeting
CC       in the visual system. Also plays a role in life-span
CC       determination. {ECO:0000269|PubMed:10455177,
CC       ECO:0000269|PubMed:11250149, ECO:0000269|PubMed:11292875,
CC       ECO:0000269|PubMed:12702880, ECO:0000269|PubMed:7628438,
CC       ECO:0000269|PubMed:8603594}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chains carry the kinase domain.
CC       When autophosphorylated, the beta-subunit binds the SH2 and SH3
CC       domains of the adapter protein Dock. The beta subunit also binds
CC       and tyrosine phosphorylates the insulin receptor substrate Chico.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-92063, EBI-92063;
CC       Q9XTN2:chico; NbExp=3; IntAct=EBI-92063, EBI-176370;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Widely distributed throughout the embryo.
CC       Expressed at high levels in the embryonic nervous system. Larval
CC       expression is limited to the nervous system and all imaginal
CC       disks. Expressed at high levels in the adult nervous system and
CC       ovaries. {ECO:0000269|PubMed:2454394, ECO:0000269|PubMed:7628438}.
CC   -!- DEVELOPMENTAL STAGE: Expressed throughout development. Embryonic
CC       expression is most prominent 8 to 12 hours after egg laying.
CC       {ECO:0000269|PubMed:2454394, ECO:0000269|PubMed:3014506}.
CC   -!- PTM: The 280 kDa proreceptor is proteolytically processed to form
CC       a 120 kDa alpha subunit and a 170 kDa beta subunit. The beta
CC       subunit undergoes cell-specific cleavage to generate a 90 kDa beta
CC       subunit and a free 60 kDa C-terminal subunit. Both the 90 kDa and
CC       the 170 kDa beta subunits can assemble with the alpha subunits to
CC       form mature receptors. {ECO:0000269|PubMed:7628438}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       exogenous insulin. {ECO:0000269|PubMed:18327897}.
CC   -!- PTM: Phosphorylation of Tyr-1354 is required for Chico-binding.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA28644.1; Type=Frameshift; Positions=1753; Evidence={ECO:0000305};
CC       Sequence=AAA68953.1; Type=Frameshift; Positions=864, 877, 2095; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U28136; AAA68953.1; ALT_FRAME; mRNA.
DR   EMBL; U18351; AAC47458.1; -; Genomic_DNA.
DR   EMBL; AE014297; AAF55903.2; -; Genomic_DNA.
DR   EMBL; AE014297; ACL83549.1; -; Genomic_DNA.
DR   EMBL; AE014297; ACL83550.1; -; Genomic_DNA.
DR   EMBL; AE014297; ACL83551.1; -; Genomic_DNA.
DR   EMBL; M14778; AAA28644.1; ALT_FRAME; mRNA.
DR   EMBL; M13568; AAA28645.1; -; Genomic_DNA.
DR   PIR; A56081; A56081.
DR   PIR; S57245; S57245.
DR   RefSeq; NP_001138093.1; NM_001144621.3.
DR   RefSeq; NP_001138094.1; NM_001144622.2.
DR   RefSeq; NP_001138095.1; NM_001144623.2.
DR   RefSeq; NP_524436.2; NM_079712.6.
DR   UniGene; Dm.1271; -.
DR   ProteinModelPortal; P09208; -.
DR   SMR; P09208; 1361-1668.
DR   BioGrid; 67515; 12.
DR   IntAct; P09208; 5.
DR   STRING; 7227.FBpp0288669; -.
DR   iPTMnet; P09208; -.
DR   PaxDb; P09208; -.
DR   EnsemblMetazoa; FBtr0084121; FBpp0083519; FBgn0013984.
DR   EnsemblMetazoa; FBtr0290230; FBpp0288669; FBgn0013984.
DR   EnsemblMetazoa; FBtr0290231; FBpp0288670; FBgn0013984.
DR   EnsemblMetazoa; FBtr0290232; FBpp0288671; FBgn0013984.
DR   GeneID; 42549; -.
DR   KEGG; dme:Dmel_CG18402; -.
DR   CTD; 42549; -.
DR   FlyBase; FBgn0283499; InR.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   InParanoid; P09208; -.
DR   KO; K05087; -.
DR   OMA; PRAFIGF; -.
DR   OrthoDB; EOG091G014Y; -.
DR   PhylomeDB; P09208; -.
DR   BRENDA; 2.7.10.1; 1994.
DR   Reactome; R-DME-77387; Insulin receptor recycling.
DR   SignaLink; P09208; -.
DR   GenomeRNAi; 42549; -.
DR   PRO; PR:P09208; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   Bgee; FBgn0013984; -.
DR   ExpressionAtlas; P09208; differential.
DR   Genevisible; P09208; DM.
DR   GO; GO:0005911; C:cell-cell junction; IDA:FlyBase.
DR   GO; GO:0005899; C:insulin receptor complex; IDA:FlyBase.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; ISS:FlyBase.
DR   GO; GO:0005524; F:ATP binding; IC:FlyBase.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; ISS:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; IDA:FlyBase.
DR   GO; GO:0005520; F:insulin-like growth factor binding; NAS:FlyBase.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IMP:FlyBase.
DR   GO; GO:0007411; P:axon guidance; IMP:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IMP:FlyBase.
DR   GO; GO:0016049; P:cell growth; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:FlyBase.
DR   GO; GO:0007623; P:circadian rhythm; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:UniProtKB.
DR   GO; GO:0048589; P:developmental growth; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; TAS:FlyBase.
DR   GO; GO:0009790; P:embryo development; IEP:UniProtKB.
DR   GO; GO:0001700; P:embryonic development via the syncytial blastoderm; IEP:FlyBase.
DR   GO; GO:0048132; P:female germ-line stem cell asymmetric division; IMP:FlyBase.
DR   GO; GO:0008585; P:female gonad development; IMP:FlyBase.
DR   GO; GO:0060180; P:female mating behavior; IMP:FlyBase.
DR   GO; GO:0007390; P:germ-band shortening; IGI:FlyBase.
DR   GO; GO:0060250; P:germ-line stem-cell niche homeostasis; IMP:FlyBase.
DR   GO; GO:0040007; P:growth; TAS:FlyBase.
DR   GO; GO:0007446; P:imaginal disc growth; IMP:FlyBase.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:FlyBase.
DR   GO; GO:0036335; P:intestinal stem cell homeostasis; IGI:FlyBase.
DR   GO; GO:0006629; P:lipid metabolic process; IMP:FlyBase.
DR   GO; GO:0007626; P:locomotory behavior; IMP:FlyBase.
DR   GO; GO:0048133; P:male germ-line stem cell asymmetric division; IMP:FlyBase.
DR   GO; GO:0035264; P:multicellular organism growth; IMP:FlyBase.
DR   GO; GO:0007520; P:myoblast fusion; IMP:FlyBase.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:FlyBase.
DR   GO; GO:0042321; P:negative regulation of circadian sleep/wake cycle, sleep; IMP:FlyBase.
DR   GO; GO:2000252; P:negative regulation of feeding behavior; IMP:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0016322; P:neuron remodeling; IMP:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; IMP:FlyBase.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045793; P:positive regulation of cell size; NAS:FlyBase.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:UniProtKB.
DR   GO; GO:0046622; P:positive regulation of organ growth; IMP:UniProtKB.
DR   GO; GO:0007285; P:primary spermatocyte growth; IMP:FlyBase.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0008361; P:regulation of cell size; IMP:FlyBase.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IMP:FlyBase.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:FlyBase.
DR   GO; GO:0034059; P:response to anoxia; IDA:FlyBase.
DR   GO; GO:0042220; P:response to cocaine; IGI:FlyBase.
DR   GO; GO:0007584; P:response to nutrient; TAS:FlyBase.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:FlyBase.
DR   GO; GO:0007525; P:somatic muscle development; IMP:FlyBase.
DR   GO; GO:0060439; P:trachea morphogenesis; IMP:FlyBase.
DR   GO; GO:0007296; P:vitellogenesis; TAS:FlyBase.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 3.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Glycoprotein;
KW   Growth regulation; Kinase; Manganese; Membrane; Metal-binding;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; SH3-binding; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1      ?       {ECO:0000255}.
FT   CHAIN       651   1081       Insulin-like receptor subunit alpha.
FT                                /FTId=PRO_0000016715.
FT   CHAIN      1086   2144       Insulin-like receptor subunit beta 1.
FT                                /FTId=PRO_0000016716.
FT   CHAIN      1086      ?       Insulin-like receptor subunit beta 2.
FT                                /FTId=PRO_0000016717.
FT   CHAIN         ?   2144       Insulin-like receptor.
FT                                /FTId=PRO_0000016718.
FT   TOPO_DOM   1086   1310       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1311   1331       Helical. {ECO:0000255}.
FT   TOPO_DOM   1332   2144       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      825    927       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      928   1026       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1210   1305       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1371   1659       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1377   1385       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION     1351   1354       Chico-binding. {ECO:0000250}.
FT   COMPBIAS    176    252       Gln-rich.
FT   COMPBIAS    177    197       His-rich.
FT   COMPBIAS    521    580       Cys-rich.
FT   ACT_SITE   1519   1519       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1405   1405       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1354   1354       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1545   1545       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1549   1549       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1550   1550       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1816   1816       Phosphoserine.
FT                                {ECO:0000269|PubMed:18327897}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    203    203       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    356    356       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    376    376       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    509    509       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    561    561       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    569    569       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    751    751       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    810    810       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    824    824       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    839    839       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    864    864       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    898    898       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    946    946       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1053   1053       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1147   1147       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD   1218   1218       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD   1219   1219       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD   1265   1265       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    531    539       {ECO:0000250}.
FT   DISULFID    535    545       {ECO:0000250}.
FT   DISULFID    546    554       {ECO:0000250}.
FT   DISULFID    550    564       {ECO:0000250}.
FT   DISULFID    567    576       {ECO:0000250}.
FT   DISULFID    580    591       {ECO:0000250}.
FT   DISULFID    597    618       {ECO:0000250}.
FT   DISULFID    635    638       {ECO:0000250}.
FT   MUTAGEN    1467   1467       R->C: In allele 353; reduction in head
FT                                size. {ECO:0000269|PubMed:11250149}.
FT   MUTAGEN    1539   1539       G->E: In allele 339; strong reduction in
FT                                head size. {ECO:0000269|PubMed:11250149}.
FT   MUTAGEN    1599   1599       G->R: In allele 211; reduction in head
FT                                size. {ECO:0000269|PubMed:11250149}.
FT   CONFLICT     29     29       T -> ATTAK (in Ref. 2; AAC47458).
FT                                {ECO:0000305}.
FT   CONFLICT     89     89       V -> D (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    157    157       Q -> H (in Ref. 1; AAA68953 and 2;
FT                                AAC47458). {ECO:0000305}.
FT   CONFLICT    164    164       F -> C (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    197    197       H -> L (in Ref. 1; AAA68953 and 2;
FT                                AAC47458). {ECO:0000305}.
FT   CONFLICT    319    319       S -> T (in Ref. 1; AAA68953 and 2;
FT                                AAC47458). {ECO:0000305}.
FT   CONFLICT    322    322       T -> P (in Ref. 1; AAA68953 and 2;
FT                                AAC47458). {ECO:0000305}.
FT   CONFLICT    470    470       T -> S (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    485    485       R -> S (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       T -> N (in Ref. 1; AAA68953 and 2;
FT                                AAC47458). {ECO:0000305}.
FT   CONFLICT    653    660       DSLERARE -> PPPPPPPL (in Ref. 5;
FT                                AAA28644). {ECO:0000305}.
FT   CONFLICT    679    681       RES -> GER (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT    723    727       ISGDP -> LAAI (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT    793    793       V -> E (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    822    822       M -> S (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT    864    877       NSTKSSDDPCDDRW -> TQLKAVTIHAMIAG (in Ref.
FT                                5; AAA28644). {ECO:0000305}.
FT   CONFLICT    933    935       Missing (in Ref. 1; AAA68953 and 5;
FT                                AAA28644). {ECO:0000305}.
FT   CONFLICT    954    958       KPYGV -> NLMA (in Ref. 1; AAA68953 and 5;
FT                                AAA28644). {ECO:0000305}.
FT   CONFLICT   1161   1161       Missing (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1187   1192       LCSDYD -> SAAIIH (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1224   1232       VRVRWTPPV -> ATFSLGRHQL (in Ref. 1;
FT                                AAA68953 and 5; AAA28644). {ECO:0000305}.
FT   CONFLICT   1263   1282       DFNQTAGYLIKLNEGLYSFR -> RLQPDCRLFNKAQRGPL
FT                                QLQ (in Ref. 5; AAA28644). {ECO:0000305}.
FT   CONFLICT   1300   1303       IKVE -> LIQQ (in Ref. 2; AAA28645).
FT                                {ECO:0000305}.
FT   CONFLICT   1457   1458       GD -> VE (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1469   1484       EERDEAMMTYLNRIGV -> RSGMRPDDVSLIAWM (in
FT                                Ref. 5; AAA28644). {ECO:0000305}.
FT   CONFLICT   1473   1479       EAMMTYL -> DGHDDVS (in Ref. 2; AAA28645).
FT                                {ECO:0000305}.
FT   CONFLICT   1499   1499       M -> V (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1519   1520       DL -> PF (in Ref. 2; AAA28645).
FT                                {ECO:0000305}.
FT   CONFLICT   1569   1578       RDGVYSSASD -> QAWCLLLVPVT (in Ref. 2;
FT                                AAA28645). {ECO:0000305}.
FT   CONFLICT   1591   1598       TLAAQPYQ -> ILSLWRSP (in Ref. 2;
FT                                AAA28645). {ECO:0000305}.
FT   CONFLICT   1682   1682       N -> H (in Ref. 2; AAC47458 and 5;
FT                                AAA28644). {ECO:0000305}.
FT   CONFLICT   1706   1706       T -> S (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1715   1715       Q -> E (in Ref. 2; AAC47458).
FT                                {ECO:0000305}.
FT   CONFLICT   1792   1799       IYDPSPKC -> STIPVRNG (in Ref. 5;
FT                                AAA28644). {ECO:0000305}.
FT   CONFLICT   1828   1828       Q -> K (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1850   1851       TA -> GI (in Ref. 5; AAA28644).
FT                                {ECO:0000305}.
FT   CONFLICT   1852   1854       SAG -> FTT (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
FT   CONFLICT   1854   1854       G -> A (in Ref. 2; AAC47458).
FT                                {ECO:0000305}.
FT   CONFLICT   1887   1887       F -> Y (in Ref. 1; AAA68953).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2144 AA;  239776 MW;  C4A8ECB08C70523A CRC64;
     MFNMPRGVTK SKSKRGKIKM ENDMAAAATT TACTLGHICV LCRQEMLLDT CCCRQAVEAV
     DSPASSEEAY SSSNSSSCQA SSEISAEEVW FLSHDDIVLC RRPKFDEVET TGKKRDVKCS
     GHQCSNECDD GSTKNNRQQR ENFNIFSNCH NILRTLQSLL LLMFNCGIFN KRRRRQHQQQ
     HHHHYQHHHQ QHHQQHHQRQ QANVSYTKFL LLLQTLAAAT TRLSLSPKNY KQQQQLQHNQ
     QLPRATPQQK QQEKDRHKCF HYKHNYSYSP GISLLLFILL ANTLAIQAVV LPAHQQHLLH
     NDIADGLDKT ALSVSGTQSR WTRSESNPTM RLSQNVKPCK SMDIRNMVSH FNQLENCTVI
     EGFLLIDLIN DASPLNRSFP KLTEVTDYII IYRVTGLHSL SKIFPNLSVI RGNKLFDGYA
     LVVYSNFDLM DLGLHKLRSI TRGGVRIEKN HKLCYDRTID WLEILAENET QLVVLTENGK
     EKECRLSKCP GEIRIEEGHD TTAIEGELNA SCQLHNNRRL CWNSKLCQTK CPEKCRNNCI
     DEHTCCSQDC LGGCVIDKNG NESCISCRNV SFNNICMDSC PKGYYQFDSR CVTANECITL
     TKFETNSVYS GIPYNGQCIT HCPTGYQKSE NKRMCEPCPG GKCDKECSSG LIDSLERARE
     FHGCTIITGT EPLTISIKRE SGAHVMDELK YGLAAVHKIQ SSLMVHLTYG LKSLKFFQSL
     TEISGDPPMD ADKYALYVLD NRDLDELWGP NQTVFIRKGG VFFHFNPKLC VSTINQLLPM
     LASKPKFFEK SDVGADSNGN RGSCGTAVLN VTLQSVGANS AMLNVTTKVE IGEPQKPSNA
     TIVFKDPRAF IGFVFYHMID PYGNSTKSSD DPCDDRWKVS SPEKSGVMVL SNLIPYTNYS
     YYVRTMAISS ELTNAESDVK NFRTNPGRPS KVTEVVATAI SDSKINVTWS YLDKPYGVLT
     RYFIKAKLIN RPTRNNNRDY CTEPLVKAME NDLPATTPTK KISDPLAGDC KCVEGSKKTS
     SQEYDDRKVQ AGMEFENALQ NFIFVPNIRK SKNGSSDKSD GAEGAALDSN AIPNGGATNP
     SRRRRDVALE PELDDVEGSV LLRHVRSITD DTDAFFEKDD ENTYKDEEDL SSNKQFYEVF
     AKELPPNQTH FVFEKLRHFT RYAIFVVACR EEIPSEKLRD TSFKKSLCSD YDTVFQTTKR
     KKFADIVMDL KVDLEHANNT ESPVRVRWTP PVDPNGEIVT YEVAYKLQKP DQVEEKKCIP
     AADFNQTAGY LIKLNEGLYS FRVRANSIAG YGDFTEVEHI KVEPPPSYAK VFFWLLGIGL
     AFLIVSLFGY VCYLHKRKVP SNDLHMNTEV NPFYASMQYI PDDWEVLREN IIQLAPLGQG
     SFGMVYEGIL KSFPPNGVDR ECAIKTVNEN ATDRERTNFL SEASVMKEFD TYHVVRLLGV
     CSRGQPALVV MELMKKGDLK SYLRAHRPEE RDEAMMTYLN RIGVTGNVQP PTYGRIYQMA
     IEIADGMAYL AAKKFVHRDL AARNCMVADD LTVKIGDFGM TRDIYETDYY RKGTKGLLPV
     RWMPPESLRD GVYSSASDVF SFGVVLWEMA TLAAQPYQGL SNEQVLRYVI DGGVMERPEN
     CPDFLHKLMQ RCWHHRSSAR PSFLDIIAYL EPQCPNSQFK EVSFYHSEAG LQHREKERKE
     RNQLDAFAAV PLDQDLQDRE QQEDATTPLR MGDYQQNSSL DQPPESPIAM VDDQGSHLPF
     SLPSGFIASS TPDGQTVMAT AFQNIPAAQG DISATYVVPD ADALDGDRGY EIYDPSPKCA
     ELPTSRSGST GGGKLSGEQH LLPRKGRQPT IMSSSMPDDV IGGSSLQPST ASAGSSNASS
     HTGRPSLKKT VADSVRNKAN FINRHLFNHK RTGSNASHKS NASNAPSTSS NTNLTSHPVA
     MGNLGTIESG GSGSAGSYTG TPRFYTPSAT PGGGSGMAIS DNPNYRLLDE SIASEQATIL
     TTSSPNPNYE MMHPPTSLVS TNPNYMPMNE TPVQMAGVTI SHNPNYQPMQ APLNARQSQS
     SSDEDNEQEE DDEDEDDDVD DEHVEHIKME RMPLSRPRQR ALPSKTQPPR SRSVSQTRKS
     PTNPNSGIGA TGAGNRSNLL KENWLRPAST PRPPPPNGFI GREA
//
ID   HTK7_HYDVU              Reviewed;        1477 AA.
AC   Q25197;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   11-MAY-2016, entry version 108.
DE   RecName: Full=Putative insulin-like peptide receptor;
DE            EC=2.7.10.1;
DE   Flags: Precursor;
GN   Name=HTK7;
OS   Hydra vulgaris (Hydra) (Hydra attenuata).
OC   Eukaryota; Metazoa; Cnidaria; Hydrozoa; Hydroidolina; Anthoathecata;
OC   Aplanulata; Hydridae; Hydra.
OX   NCBI_TaxID=6087;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Steele R.E., Mai N.H., Lieu P., Shenk M.A.;
RL   Submitted (APR-1991) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: This receptor probably binds an insulin related protein
CC       and has a tyrosine-protein kinase activity. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in dividing epithelial cells.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64612; AAA68205.1; -; mRNA.
DR   PIR; T18534; T18534.
DR   RefSeq; NP_001296700.1; NM_001309771.1.
DR   ProteinModelPortal; Q25197; -.
DR   SMR; Q25197; 1022-1329.
DR   GeneID; 100214733; -.
DR   KEGG; hmg:100214733; -.
DR   KO; K05087; -.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:InterPro.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Glycoprotein; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1477       Putative insulin-like peptide receptor.
FT                                /FTId=PRO_0000016714.
FT   TOPO_DOM     25    980       Extracellular. {ECO:0000255}.
FT   TRANSMEM    981   1001       Helical. {ECO:0000255}.
FT   TOPO_DOM   1002   1477       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      652    750       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      780    869       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      880    971       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1044   1315       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1050   1058       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1175   1175       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1077   1077       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1201   1201       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     55     55       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    255    255       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    457    457       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    491    491       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    549    549       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    644    644       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    732    732       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    791    791       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    874    874       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    895    895       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    957    957       N-linked (GlcNAc...). {ECO:0000255}.
SQ   SEQUENCE   1477 AA;  168278 MW;  74ACDBA7C6DE1D41 CRC64;
     MMRNVQSFYF LFLLIVLNFH VVLSAVCIGQ RATTTIWLNQ NGDCQDVGFC QYLQNCTCWH
     GNLVVKSTKY YDEENFKPYF PKLREITGYL LISLCTLKFF HLFPGLTVIR GGDLILNYAL
     VIYYNEIKEV YFPSLTAILN GGVHIGRNHR LCYVNTIRWK SIIKDIHQTG QYGIYLESNK
     LNCDLGCLKG HCHPAPGHDG DPKAQYCWGP GPKKQQNKAQ CQRFCNTQCG PEGCLDGSDH
     ICCHHECLGG CSAINSTNTC HACRKYRIKS TGQCVSKCPR KQYLVDKFLC QESCPYWSIN
     STEYHHYLWQ GECVTKCPVN YISNNQTKKC EKCKSGMKCN TVCKYQDVMA DGTLYNGALI
     RVPSDISKKG LVGCSVFEGS LTFQLQEGTG KAEDSLNELK SLKVLKGHLK IQKSSLKSLN
     FLSSLEVIET PQNALLHNKY VMAVYENSQL SELWPGNESI IVSDGGIFFQ YNPRLCPLHI
     RNLQDRIHYK NGSKVTGEVS LQNNGHKVLC DTQMLVMHVE EFIPPDLNME TDMTAIECNS
     FKCVKVTWNF TMTSAYNNIL FYAIYFKELQ SNQEAVVQLD NECQNNDDWN VITVDIPKIE
     SLEQSLFLQS KIISKLTPYT RYAFYIKEIV SKGEERSSHI HYINISQDLP SEPLGVEASF
     LSENKILLKW RAPSKPNGII TAFKIYYNKP DYSFWEEQKV LDWCSRDASR DKNAKDVAGY
     PVNKENYNQY CNISCVCDEE KENSKAIKAD REAHNFNVEF QTELMRVLFT KNKFSYRNKN
     KSPPKIDFSK NISLILSNKI LTSTSTTVTQ AKIEIIEEPK VTVNGNIFSY VISGLDYFED
     YELKVCGCTV VGCRRPSSTI NLDCGIVQAR TGVNLTADNL DSKMVRVQVQ LDSYNISWIA
     PHKPNAVILK YEISIRYALD KDALVICRPG YLPTYIIRKS RFGNYVAKIR AISPAGNGSW
     TEEIHFKVAE LSVTKNNNQL IIGIISAVSA VIVALLVFIL LYMFLHRKLE KDVQGVLYAS
     VNPEYMNSKE VYIPDEWELN REKIELIREL GQGSFGMVFE GIAHGIGDHA ELRVAVKTTN
     ENASIHDRIQ ILQEASIMKA FNCNHVVKLI GVVSQGQPTF VVMELMGRGD LKSYLKERRP
     DDGGIPLMRQ EIYQMVAEIA DGMAYLAARK FVHCDLAARN CMVASDFTVK IGDFGMARDI
     YERNYYRKDG KSLLPIRWMA PESLKDGIFS TASDVWSFGV VLWEICTLAS QPYQGKTNEQ
     VLNFVLSNGH LDYPEGCDYQ LREFMSLCWH RDPKMRPSFL EIVHVLENEV DDDFVMVSFY
     HEMKRKALED IYMKSESYIK SDAYTMSDGY TKGDGNMQNM LSRSQNRKSA IEKSKERLSI
     SSLDSGTYVE KYDANDTPEE IPKKKKRPRS KRNSAVDSNA CETKPMLRVE SLYDNHDAFS
     ENMQYGDTPV GKSDLMHPET NRELRLSEIF YGKPIPV
//
ID   INSR_CAEEL              Reviewed;        1846 AA.
AC   Q968Y9; B5QS63; O16131;
DT   03-NOV-2009, integrated into UniProtKB/Swiss-Prot.
DT   03-NOV-2009, sequence version 2.
DT   07-SEP-2016, entry version 131.
DE   RecName: Full=Insulin-like receptor {ECO:0000250|UniProtKB:P06213};
DE            Short=IR {ECO:0000250|UniProtKB:P06213};
DE            EC=2.7.10.1;
DE   AltName: Full=Abnormal dauer formation protein 2 {ECO:0000303|PubMed:9252323};
DE   Contains:
DE     RecName: Full=Insulin-like receptor subunit alpha {ECO:0000250|UniProtKB:P06213};
DE   Contains:
DE     RecName: Full=Insulin-like receptor subunit beta {ECO:0000250|UniProtKB:P06213};
DE   Flags: Precursor;
GN   Name=daf-2; ORFNames=Y55D5A.5;
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC   Rhabditoidea; Rhabditidae; Peloderinae; Caenorhabditis.
OX   NCBI_TaxID=6239;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC47715.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, DISRUPTION
RP   PHENOTYPE, AND MUTAGENESIS OF CYS-401; CYS-469; PRO-470; SER-573;
RP   ASP-648; ASP-1374; PRO-1434 AND PRO-1465.
RC   STRAIN=Bristol N2 {ECO:0000312|EMBL:AAC47715.1};
RX   PubMed=9252323; DOI=10.1126/science.277.5328.942;
RA   Kimura K.D., Tissenbaum H.A., Liu Y., Ruvkun G.;
RT   "daf-2, an insulin receptor-like gene that regulates longevity and
RT   diapause in Caenorhabditis elegans.";
RL   Science 277:942-946(1997).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING.
RC   STRAIN=Bristol N2;
RX   PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for
RT   investigating biology.";
RL   Science 282:2012-2018(1998).
RN   [3] {ECO:0000305}
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF PRO-1465.
RX   PubMed=9790527; DOI=10.1016/S0092-8674(00)81751-1;
RA   Apfeld J., Kenyon C.;
RT   "Cell nonautonomy of C. elegans daf-2 function in the regulation of
RT   diapause and life span.";
RL   Cell 95:199-210(1998).
RN   [4] {ECO:0000305}
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF ALA-580 AND
RP   PRO-1465.
RX   PubMed=11274053; DOI=10.1101/gad.867301;
RA   Pierce S.B., Costa M., Wisotzkey R., Devadhar S., Homburger S.A.,
RA   Buchman A.R., Ferguson K.C., Heller J., Platt D.M., Pasquinelli A.A.,
RA   Liu L.X., Doberstein S.K., Ruvkun G.;
RT   "Regulation of DAF-2 receptor signaling by human insulin and ins-1, a
RT   member of the unusually large and diverse C. elegans insulin gene
RT   family.";
RL   Genes Dev. 15:672-686(2001).
RN   [5] {ECO:0000305}
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-364; ASN-453; ASN-696;
RP   ASN-1017 AND ASN-1078, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Bristol N2;
RX   PubMed=17761667; DOI=10.1074/mcp.M600392-MCP200;
RA   Kaji H., Kamiie J., Kawakami H., Kido K., Yamauchi Y., Shinkawa T.,
RA   Taoka M., Takahashi N., Isobe T.;
RT   "Proteomics reveals N-linked glycoprotein diversity in Caenorhabditis
RT   elegans and suggests an atypical translocation mechanism for integral
RT   membrane proteins.";
RL   Mol. Cell. Proteomics 6:2100-2109(2007).
RN   [6] {ECO:0000305}
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF PRO-1465.
RX   PubMed=18782349; DOI=10.1111/j.1474-9726.2008.00435.x;
RA   Evans E.A., Chen W.C., Tan M.-W.;
RT   "The DAF-2 insulin-like signaling pathway independently regulates
RT   aging and immunity in C. elegans.";
RL   Aging Cell 7:879-893(2008).
RN   [7]
RP   ENZYME REGULATION, AND INTERACTION WITH SHC-1.
RX   PubMed=18832074; DOI=10.1101/gad.478408;
RA   Neumann-Haefelin E., Qi W., Finkbeiner E., Walz G., Baumeister R.,
RA   Hertweck M.;
RT   "SHC-1/p52Shc targets the insulin/IGF-1 and JNK signaling pathways to
RT   modulate life span and stress response in C. elegans.";
RL   Genes Dev. 22:2721-2735(2008).
RN   [8]
RP   DISRUPTION PHENOTYPE, AND MUTAGENESIS OF CYS-146 AND PRO-1465.
RX   PubMed=18245374; DOI=10.1534/genetics.107.070813;
RA   Patel D.S., Garza-Garcia A., Nanji M., McElwee J.J., Ackerman D.,
RA   Driscoll P.C., Gems D.;
RT   "Clustering of genetically defined allele classes in the
RT   Caenorhabditis elegans DAF-2 insulin/IGF-1 receptor.";
RL   Genetics 178:931-946(2008).
RN   [9]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=22560223; DOI=10.1016/j.cmet.2012.04.007;
RA   Robida-Stubbs S., Glover-Cutter K., Lamming D.W., Mizunuma M.,
RA   Narasimhan S.D., Neumann-Haefelin E., Sabatini D.M., Blackwell T.K.;
RT   "TOR signaling and rapamycin influence longevity by regulating SKN-
RT   1/Nrf and DAF-16/FoxO.";
RL   Cell Metab. 15:713-724(2012).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF PRO-1465.
RX   PubMed=22278922; DOI=10.1242/dev.074047;
RA   Korta D.Z., Tuck S., Hubbard E.J.;
RT   "S6K links cell fate, cell cycle and nutrient response in C. elegans
RT   germline stem/progenitor cells.";
RL   Development 139:859-870(2012).
RN   [11]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF PRO-1434 AND
RP   PRO-1465.
RX   PubMed=24332851; DOI=10.1016/j.celrep.2013.11.018;
RA   Chen D., Li P.W., Goldstein B.A., Cai W., Thomas E.L., Chen F.,
RA   Hubbard A.E., Melov S., Kapahi P.;
RT   "Germline signaling mediates the synergistically prolonged longevity
RT   produced by double mutations in daf-2 and rsks-1 in C. elegans.";
RL   Cell Rep. 5:1600-1610(2013).
CC   -!- FUNCTION: Insulin receptor-like tyrosine kinase which regulates
CC       metabolism, controls longevity and prevents developmental arrest
CC       at the dauer stage (PubMed:9252323, PubMed:9790527,
CC       PubMed:24332851). Binding of INS family members may either
CC       stimulate, or antagonize, association of the receptor with
CC       downstream mediators such as pdk-1 and age-1 (PubMed:11274053).
CC       Required for germline progenitor proliferation during larval
CC       development (PubMed:22278922). Required for the response to
CC       environmental stimuli such as food, pheromone, and temperature.
CC       Negatively regulates resistance to UV and oxidative stress
CC       (PubMed:24332851). Role in immune function and pathogen resistance
CC       (PubMed:18782349). Negatively regulates autophagy
CC       (PubMed:22560223). {ECO:0000269|PubMed:11274053,
CC       ECO:0000269|PubMed:18782349, ECO:0000269|PubMed:22278922,
CC       ECO:0000269|PubMed:22560223, ECO:0000269|PubMed:24332851,
CC       ECO:0000269|PubMed:9252323, ECO:0000269|PubMed:9790527}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000250|UniProtKB:P06213,
CC       ECO:0000255|PROSITE-ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity (By similarity). Interaction with shc-1 may inhibits its
CC       activity (PubMed:18832074). {ECO:0000250|UniProtKB:P06213,
CC       ECO:0000269|PubMed:18832074}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chains carry the kinase domain (By
CC       similarity). Interacts (via cytoplasmic domain) with shc-1 (PID
CC       domain) (PubMed:18832074). {ECO:0000250|UniProtKB:P06213,
CC       ECO:0000269|PubMed:18832074}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250|UniProtKB:P06213};
CC       Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P06213}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=a {ECO:0000269|PubMed:9252323, ECO:0000269|PubMed:9851916};
CC         IsoId=Q968Y9-1; Sequence=Displayed;
CC       Name=b {ECO:0000269|PubMed:9851916};
CC         IsoId=Q968Y9-2; Sequence=VSP_053157, VSP_053158;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC   -!- DISRUPTION PHENOTYPE: Accumulation of fat, pigmented intestine,
CC       increased lifespan, increased dauer formation and increased
CC       resistance to pathogens. Severe loss of function mutants display
CC       recessive early embryonic lethality (PubMed:9252323,
CC       PubMed:9790527, PubMed:11274053, PubMed:18782349,
CC       PubMed:18245374). RNAi-mediated knockdown in germline, hypodermis,
CC       intestine or in muscles causes increased lifespan
CC       (PubMed:24332851). RNAi-mediated knockdown in adults causes an
CC       increase in lgg-1 positive autophagic vesicles (PubMed:22560223).
CC       {ECO:0000269|PubMed:11274053, ECO:0000269|PubMed:18245374,
CC       ECO:0000269|PubMed:18782349, ECO:0000269|PubMed:22560223,
CC       ECO:0000269|PubMed:24332851, ECO:0000269|PubMed:9252323,
CC       ECO:0000269|PubMed:9790527}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF012437; AAC47715.1; -; mRNA.
DR   EMBL; FO081525; CCD72201.2; -; Genomic_DNA.
DR   EMBL; FO081525; CCD72203.2; -; Genomic_DNA.
DR   PIR; T42047; T42047.
DR   RefSeq; NP_497650.4; NM_065249.4. [Q968Y9-1]
DR   UniGene; Cel.8775; -.
DR   ProteinModelPortal; Q968Y9; -.
DR   SMR; Q968Y9; 180-917, 1026-1596.
DR   BioGrid; 40655; 164.
DR   STRING; 6239.Y55D5A.5a; -.
DR   EPD; Q968Y9; -.
DR   PaxDb; Q968Y9; -.
DR   EnsemblMetazoa; Y55D5A.5a; Y55D5A.5a; WBGene00000898. [Q968Y9-1]
DR   GeneID; 175410; -.
DR   KEGG; cel:CELE_Y55D5A.5; -.
DR   CTD; 175410; -.
DR   WormBase; Y55D5A.5a; CE46852; WBGene00000898; daf-2.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000151241; -.
DR   InParanoid; Q968Y9; -.
DR   KO; K04527; -.
DR   OMA; ASCESHT; -.
DR   OrthoDB; EOG091G014Y; -.
DR   PhylomeDB; Q968Y9; -.
DR   Reactome; R-CEL-77387; Insulin receptor recycling.
DR   SignaLink; Q968Y9; -.
DR   PRO; PR:Q968Y9; -.
DR   Proteomes; UP000001940; Chromosome III.
DR   Bgee; WBGene00000898; -.
DR   ExpressionAtlas; Q968Y9; baseline.
DR   GO; GO:0030424; C:axon; IDA:WormBase.
DR   GO; GO:0005737; C:cytoplasm; IDA:WormBase.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:WormBase.
DR   GO; GO:0043025; C:neuronal cell body; IDA:WormBase.
DR   GO; GO:0031513; C:nonmotile primary cilium; IDA:WormBase.
DR   GO; GO:0044214; C:spanning component of plasma membrane; IDA:WormBase.
DR   GO; GO:0005524; F:ATP binding; ISS:WormBase.
DR   GO; GO:0005009; F:insulin-activated receptor activity; ISS:WormBase.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017046; F:peptide hormone binding; ISS:WormBase.
DR   GO; GO:0019901; F:protein kinase binding; IPI:WormBase.
DR   GO; GO:0051425; F:PTB domain binding; IPI:WormBase.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:WormBase.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0043053; P:dauer entry; IGI:UniProtKB.
DR   GO; GO:0043054; P:dauer exit; IMP:WormBase.
DR   GO; GO:0040024; P:dauer larval development; IMP:WormBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:WormBase.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:WormBase.
DR   GO; GO:0030536; P:larval feeding behavior; IMP:UniProtKB.
DR   GO; GO:0042992; P:negative regulation of transcription factor import into nucleus; IMP:WormBase.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:WormBase.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:WormBase.
DR   GO; GO:2000785; P:regulation of autophagosome assembly; IMP:BHF-UCL.
DR   GO; GO:0061065; P:regulation of dauer larval development; IMP:UniProtKB.
DR   GO; GO:0040034; P:regulation of development, heterochronic; IGI:WormBase.
DR   GO; GO:1903998; P:regulation of eating behavior; IMP:UniProtKB.
DR   GO; GO:1901031; P:regulation of response to reactive oxygen species; IMP:WormBase.
DR   GO; GO:0000003; P:reproduction; IMP:WormBase.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 3.
DR   SUPFAM; SSF52058; SSF52058; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Carbohydrate metabolism;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Disulfide bond; Glycoprotein; Immunity;
KW   Innate immunity; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1      ?       {ECO:0000255}.
FT   CHAIN         ?    966       Insulin-like receptor subunit alpha.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000386619.
FT   CHAIN       970   1846       Insulin-like receptor subunit beta.
FT                                {ECO:0000255}.
FT                                /FTId=PRO_0000386620.
FT   TOPO_DOM    970   1183       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1184   1204       Helical. {ECO:0000255}.
FT   TOPO_DOM   1205   1846       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      775    869       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      969   1067       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1077   1179       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1246   1528       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1252   1260       ATP. {ECO:0000250|UniProtKB:P28523,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE   1388   1388       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:P28523,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10028}.
FT   BINDING    1282   1282       ATP. {ECO:0000250|UniProtKB:P28523,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   CARBOHYD    113    113       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    180    180       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    364    364       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17761667}.
FT   CARBOHYD    453    453       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17761667}.
FT   CARBOHYD    518    518       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    652    652       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    671    671       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    696    696       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17761667}.
FT   CARBOHYD   1017   1017       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17761667}.
FT   CARBOHYD   1047   1047       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1078   1078       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17761667}.
FT   CARBOHYD   1087   1087       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1093   1093       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    371    386       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    393    401       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    397    410       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    413    422       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    426    438       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    469    483       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    486    490       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    615    646       {ECO:0000250|UniProtKB:P06213}.
FT   DISULFID    706    706       Interchain.
FT                                {ECO:0000250|UniProtKB:P06213}.
FT   VAR_SEQ     925   1020       DTMRVRRSIEDANRVSEELEKAENLGKAPKTLGGKKPLIHI
FT                                SKKKPSSSSTTSTPAPTIASMYALTRKPTTVPGTRIRLYEI
FT                                YEPLPGSWAINVSA -> CDIKNDPVGCAMLLLPPEIDDSD
FT                                VGDDDEEPGGGSEQQQRILRNSEILKRQKRQILGRSLGGIH
FT                                GIRSIGRKEYEQFADMILYGNLHDLMMSVMHD (in
FT                                isoform b). {ECO:0000303|PubMed:9851916}.
FT                                /FTId=VSP_053157.
FT   VAR_SEQ    1021   1846       Missing (in isoform b).
FT                                {ECO:0000303|PubMed:9851916}.
FT                                /FTId=VSP_053158.
FT   MUTAGEN     146    146       C->Y: Embronically lethal.
FT                                {ECO:0000269|PubMed:18245374}.
FT   MUTAGEN     401    401       C->Y: Dauer formation; when associated
FT                                with L-470. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN     469    469       C->S: Dauer formation above 20 degrees
FT                                Celsius. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN     470    470       P->L: Dauer formation; when associated
FT                                with Y-401. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN     573    573       S->L: Dauer formation above 25 degrees
FT                                Celsius. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN     580    580       A->T: Dauer formation above 26 degrees
FT                                Celsius. {ECO:0000269|PubMed:11274053}.
FT   MUTAGEN     648    648       D->N: Dauer formation above 25 degrees
FT                                Celsius. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN    1374   1374       D->N: Dauer formation above 20 degrees
FT                                Celsius. {ECO:0000269|PubMed:9252323}.
FT   MUTAGEN    1434   1434       P->L: In e1391; dauer formation above 20
FT                                degrees Celsius and increased lifespan.
FT                                {ECO:0000269|PubMed:24332851,
FT                                ECO:0000269|PubMed:9252323}.
FT   MUTAGEN    1465   1465       P->S: In e1370; extended lifespan.
FT                                Accumulates fat and undergoes dauer
FT                                formation above 25 degrees Celsius.
FT                                Pigmented intestine and increased
FT                                resistance to bacterial pathogens, UV,
FT                                high temperature and paraquat treatment.
FT                                Reduced number of germline progenitors
FT                                during larval development.
FT                                {ECO:0000269|PubMed:11274053,
FT                                ECO:0000269|PubMed:18245374,
FT                                ECO:0000269|PubMed:18782349,
FT                                ECO:0000269|PubMed:22278922,
FT                                ECO:0000269|PubMed:24332851,
FT                                ECO:0000269|PubMed:9252323,
FT                                ECO:0000269|PubMed:9790527}.
FT   CONFLICT    838    838       H -> R (in Ref. 1; AAC47715).
FT                                {ECO:0000305}.
FT   CONFLICT   1313   1313       K -> Q (in Ref. 1; AAC47715).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1846 AA;  207124 MW;  230B28322FF0F126 CRC64;
     MTRMNIVRCR RRHKILENLE EENLGPSCSS TTSTTAATEA LGTTTEDMRL KQQRSSSRAT
     EHDIVDGNHH DDEHITMRRL RLVKNSRTRR RTTPDSSMDC YEENPPSQKT SINYSWISKK
     SSMTSLMLLL LFAFVQPCAS IVEKRCGPID IRNRPWDIKP QWSKLGDPNE KDLAGQRMVN
     CTVVEGSLTI SFVLKHKTKA QEEMHRSLQP RYSQDEFITF PHLREITGTL LVFETEGLVD
     LRKIFPNLRV IGGRSLIQHY ALIIYRNPDL EIGLDKLSVI RNGGVRIIDN RKLCYTKTID
     WKHLITSSIN DVVVDNAAEY AVTETGLMCP RGACEEDKGE SKCHYLEEKN QEQGVERVQS
     CWSNTTCQKS CAYDRLLPTK EIGPGCDANG DRCHDQCVGG CERVNDATAC HACKNVYHKG
     KCIEKCDAHL YLLLQRRCVT REQCLQLNPV LSNKTVPIKA TAGLCSDKCP DGYQINPDDH
     RECRKCVGKC EIVCEINHVI DTFPKAQAIR LCNIIDGNLT IEIRGKQDSG MASELKDIFA
     NIHTITGYLL VRQSSPFISL NMFRNLRRIE AKSLFRNLYA ITVFENPNLK KLFDSTTDLT
     LDRGTVSIAN NKMLCFKYIK QLMSKLNIPL DPIDQSEGTN GEKAICEDMA INVSITAVNA
     DSVFFSWPSF NITDIDQRKF LGYELFFKEV PRIDENMTIE EDRSACVDSW QSVFKQYYET
     SNGEPTPDIF MDIGPRERIR PNTLYAYYVA TQMVLHAGAK NGVSKIGFVR TSYYTPDPPT
     LALAQVDSDA IHITWEAPLQ PNGDLTHYTI MWRENEVSPY EEAEKFCTDA STPANRQHTK
     DPKETIVADK PVDIPSSRTV APTLLTMMGH EDQQKTCAAT PGCCSCSAIE ESSEQNKKKR
     PDPMSAIESS AFENKLLDEV LMPRDTMRVR RSIEDANRVS EELEKAENLG KAPKTLGGKK
     PLIHISKKKP SSSSTTSTPA PTIASMYALT RKPTTVPGTR IRLYEIYEPL PGSWAINVSA
     LALDNSYVIR NLKHYTLYAI SLSACQNMTV PGASCSISHR AGALKRTKHI TDIDKVLNET
     IEWRFMNNSQ QVNVTWDPPT EVNGGIFGYV VKLKSKVDGS IVMTRCVGAK RGYSTRNQGV
     LFQNLADGRY FVSVTATSVH GAGPEAESSD PIVVMTPGFF TVEIILGMLL VFLILMSIAG
     CIIYYYIQVR YGKKVKALSD FMQLNPEYCV DNKYNADDWE LRQDDVVLGQ QCGEGSFGKV
     YLGTGNNVVS LMGDRFGPCA IKINVDDPAS TENLNYLMEA NIMKNFKTNF IVKLYGVIST
     VQPAMVVMEM MDLGNLRDYL RSKREDEVFN ETDCNFFDII PRDKFHEWAA QICDGMAYLE
     SLKFCHRDLA ARNCMINRDE TVKIGDFGMA RDLFYHDYYK PSGKRMMPVR WMSPESLKDG
     KFDSKSDVWS FGVVLYEMVT LGAQPYIGLS NDEVLNYIGM ARKVIKKPEC CENYWYKVMK
     MCWRYSPRDR PTFLQLVHLL AAEASPEFRD LSFVLTDNQM ILDDSEALDL DDIDDTDMND
     QVVEVAPDVE NVEVQSDSER RNTDSIPLKQ FKTIPPINAT TSHSTISIDE TPMKAKQREG
     SLDEEYALMN HSGGPSDAEV RTYAGDGDYV ERDVRENDVP TRRNTGASTS SYTGGGPYCL
     TNRGGSNERG AGFGEAVRLT DGVGSGHLND DDYVEKEISS MDTRRSTGAS SSSYGVPQTN
     WSGNRGATYY TSKAQQAATA AAAAAAALQQ QQNGGRGDRL TQLPGTGHLQ STRGGQDGDY
     IETEPKNYRN NGSPSRNGNS RDIFNGRSAF GENEHLIEDN EHHPLV
//
